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1. Head and neck cancer 
 
1.1  Epidemiology and etiology 
The predominant histological type among malignant tumors of the head and neck consists 
of squamous cell carcinomas. These tumors arise from the mucosa of the upper 
aerodigestive tract, and account for more than 90% of all malignant head and neck tumors. 
In general, and also in this thesis, when speaking of head and neck cancer, squamous cell 
carcinoma of the mucosa of the head and neck area is meant. Other malignancies in the 
head and neck area include primary skin tumors (squamous cell carcinomas, basal cell 
carcinomas, melanomas, and Merkel cell carcinomas), lymphomas, and malignant tumors 
of the salivary glands, soft tissues, and bones. Furthermore, metastases from tumors from 
elsewhere in the body may reveal in the head and neck area.  
Squamous cell carcinomas of the head and neck account for ~5% of all malignant 
tumors in Europe and the United States. Every year, more than half a million new cases of 
head and neck cancer of the oral cavity, pharynx, or larynx are diagnosed worldwide (1,2). 
In the Netherlands, in 2006 a total of 2629 patients developed malignancies in the head and 
neck area (1778 males and 851 females), and 817 patients died from this disease (3). Early 
stages (stage I/II) of head and neck cancer generally have a good prognosis after surgery or 
radiotherapy. Unfortunately, prognosis is much worse for advanced stage disease (stage 
III/IV), which is diagnosed in about two-thirds of all head and neck cancer patients.  
While also genetic predisposition is an important factor for developing head and 
neck cancer, the combination of heavy alcohol use with tobacco use accounts for the 
majority of head and neck cancers. Carcinomas caused by alcohol and tobacco use can 
affect the whole upper aerodigestive tract, including oral cavity, oropharynx, hypopharynx, 
and larynx.  
Recent insights show evidence of the human papillomavirus (HPV) playing a role 
in the pathogenesis of a subgroup of squamous cell carcinomas located in the oropharynx 
(4-6), that are, comparable to female cervical cancers, virtually all caused by an infection 
with HPV (7). The majority of HPV-positive squamous cell carcinomas of the head and 
neck is positive for the high risk HPV type 16, but other HPV types (for example HPV18) 
also have been detected (8). There is no evidence of synergy between exposure to HPV and 
alcohol and tobacco use for developing head and neck cancer. Among young patients, 
widespread use of oral sexual practices and a trend toward multiple sexual partners may 
have contributed to an increased incidence of HPV-related head and neck cancers, 
particularly tonsillar and base of the tongue cancers (9-11). Since HPV-positive and HPV-
negative tumors have different risk profiles, and result from different molecular changes 
(6), these tumors should be considered to be distinct cancers (4,5). Current research shows 
that HPV-positive cancer might be better curable then HPV-negative cancers and have a 
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better prognosis. HPV-positive tumors have a lower number of chromosomal alterations 
and amplifications, and possibly the immune system can recognize HPV induced cellular 
changes. Genetic signatures of HPV-related and HPV-unrelated head and neck cancer are 
different and most likely underlie differences in tumor development and progression (12). 
Clinical trials are now being developed that might improve cancer therapy by selectively 
treating sub-types of head and neck cancer through immunotherapy (13). 
Since HPV-vaccination might become an important strategy to prevent cervical 
cancer (9), it would seem logical that HPV-vaccination will also have an effect on the 
incidence of HPV-induced head and neck cancer. 
 
1.2 Challenges in the treatment of head and neck cancer 
During the last decades, enormous improvements in locoregional treatment modalities have 
been made. Unfortunately, the rate of locoregional recurrence is still close to 40%. 
Furthermore, ~25% of the initially adequately treated patients develop distant metastases. 
Autopsy studies have shown incidences of distant metastases in up to 57% of the treated 
patients (14-17). It is plausible that many advanced stage head and neck cancer patients 
harbor residual tumor cells after surgery and radiotherapy. Another problem is the 
occurrence of second primary tumors. Carcinogenesis, the process of progression from a 
normal cell to a cancer cell (figure 1), is thought to be a multistep process, resulted from an 
accumulation of multiple genetic alterations in the squamous epithelium (18,19). Once 
large areas of the epithelium have been subjected to the toxic effects of alcohol and tobacco 
use (field cancerization), second primary tumors may develop simultaneously, or even 
years after effective treatment of a primary tumor (20). Second primary tumors develop at a 
rate of 2% to 3% per annum (21). 
 The most important prognostic factors for head and neck cancer are regional 
lymph node involvement, vascular or lymphatic invasion, positive surgical margins, and 
extracapsular spread of tumor cells from involved lymph nodes into soft tissue of the neck 
(22-24).  
The local treatment of recurrences and second primary tumors is still challenging, 
especially when the site has already been subjected to extensive surgery before, or when 
radiotherapy is no longer an option because of previous treatments. Important outcomes 
after treatment of head and neck cancer are problems caused by loss of function 
(swallowing and speech) and cosmetic disfigurement. The restrictions caused by earlier 
treatments and the need for function-sparing therapy have motivated the development of 
new techniques for the local treatment of head and neck cancer. Previous treatments should 
not preclude application of these therapies, and repeated treatments should be possible 
when needed. When patients are at risk for the development of second primary tumors, 
local treatments that spare surrounding tissues are needed. Radiotherapy or surgery can then 
be reserved for salvage therapy in the event of a recurrence or second primary. In patients 
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suffering from tumors for which either no curative treatment options are available, or only 
extensive mutilating surgery remains, or in patients with disseminated disease, highly 
selective local therapies can be an option to keep an optimal quality of life in a palliative 
setting. 
Adjuvant therapies are of high importance to improve long-term survival. The 
majority of the present adjuvant therapies, existing of chemotherapeutical approaches, 
suffers from poor selectivity, thus limiting dose escalation (i.e., the doses of drug which are 
required to kill tumor cells cause unacceptable toxicities to normal tissues). Furthermore, 
these anticancer drugs might even accumulate preferentially in normal tissues rather than in 
tumors, due to the high interstitial pressure of solid tumors, and possibly due to the 
impaired vasculature. The use of more aggressive cytotoxic therapies may increase local 
control and survival, but is usually associated with more severe acute and late toxicities. It 
is of high importance that new technologies (so called ‘selective targeting treatment 
modalities’ or ‘targeted therapies’) are being developed, targeting mainly malignant tissue 
while sparing normal tissues. 
  
1.3 Recent advances in the treatment of head and neck cancer 
Traditionally, four different approaches for the treatment of head and neck cancer are 
available: surgery, radiotherapy, chemotherapy, and targeted therapies (including 
immunological and biological agents). In all four approaches, enormous progress has been 
made over the last decade.  
First, surgical techniques are still evolving. Reconstructions are further improving 
by introduction of pedicled myocutaneous flaps and free-tissue-transfer techniques (25-27). 
These developments are resulting in better functional and esthetic outcomes. Furthermore, 
there is greater focus on minimally invasive procedures, like with the development of 
transoral robotic surgery (28). 
Second, radiotherapy, both as a single therapy or combined with surgery or 
chemotherapy, remains one of the most important approaches for curative therapy for 
pharyngeal and laryngeal cancer. Recently, altered fractionation schedules (instead of once-
daily schedules) have been developed, for instance accelerated fractionation or 
hyperfractionated radiotherapy. Furthermore, radiation delivery techniques have been 
developed, such as 3-dimensional conformal radiotherapy and intensity-modulated 
radiation therapy. By using these techniques, a better tumor dose coverage and reduction of 
side effects can be achieved, resulting in therapy as effective as conventional radiotherapy 
with regard to local control, but with reduction of late toxicities (29). 
Third, the role of chemotherapy for the systemic treatment of head and neck 
cancer has been limited for decades. In 1977, cisplatin was established in the first-line 
treatment of recurrent and/or metastatic head and neck cancer (30), leading to a survival 
benefit of around ten weeks (31), but causing dose-limiting hematological, neurological and 
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nephrological toxicities (32). Since that date, no single chemotherapeutical agents has led to 
an improvement of survival. Recently, concurrent radiotherapy with platinum-based 
chemotherapy was developed, and this ‘chemoradiation’ has today become a valuable 
alternative treatment option for surgery in the treatment of locoregional advanced head and 
neck cancer, and an integral part of the treatment of head and neck cancer (33-36). 
Induction chemotherapy has been studied for more than three decades and has been 
repeatedly associated with significant tumor shrinkage and a decreased risk of occurrence 
of distant metastasis (37). Taxane-based induction chemotherapy prior to chemoradiation is 
now under investigation, and shows promising results (38). Postoperative concurrent 
chemoradiotherapy can be considered when high-risk features are present, defined as the 
histological presence of a positive margin, extracapsular spread outside the lymph nodes, 
lymphovascular invasion, perineural invasion, and multiple positive lymph nodes (39,40). 
Despite all these progresses, the development of highly selective and less toxic, adjuvant 
systemic treatment is a major challenge to improve local tumor control and survival, by 
eliminating residual tumor cells. This is important, since two years after treatment, 
approximately 20% of patients with locally advanced disease who have been treated with 
concurrent chemoradiotherapy have distant metastases, and their disease is classified as 
incurable. The median survival of patients with recurrent or metastatic head and neck 
cancer is 6-9 months, and the 1-year survival is only 20-40% (41). Unfortunately, because 
of dose limiting toxicities of current chemotherapeutics, not all patients are healthy enough 
to receive all chemotherapy cycles. 
Finally, targeted agents, selectively targeting cancer cells or critical mechanisms of 
cancer growth, are still evolving in disease-specific therapy during the last decades. Several 
targeted treatments for locoregional cancer treatment (for instance photodynamic therapy 
and chemo-electroporation therapy) as well as for systemic treatment have become 
available. Ideal systemic targeting strategies should be applied as an adjuvant approach to 
the surgical, radiotherapeutical and/or chemotherapeutical treatment of solid tumors, and 
should improve tumor response, overall survival, and disease-free interval, without increase 
of toxicity, and thus leading to a better quality of life. Examples of systemic targeted 
treatments are the use of monoclonal antibodies (mAbs) and small molecules like tyrosine 
kinase inhibitors. These agents are aimed to selectively target tumor cells, for selective 
delivery of toxic payloads or for complete neutralization/blockage of critical tumor 
associated targets and pathways. Nowadays, selective and efficient tumor targeting of 
mAbs and small molecules can easily be confirmed by positron emission tomography 
(PET) imaging, and this enables a more rationalized and individualized use of these 
expensive therapeutic agents (42,43). Normal tissues, that are not expressing the specific 
target, will not be affected by the targeting agents. The identification of tumor-specific 
molecular signatures and the understanding of mechanisms of tumor progression may 
facilitate the identification of new predictive and prognostic markers and new therapeutic 
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targets for the treatment of head and neck cancer. Immunohistochemistry, imaging and 
biodistribution data provide information about the selectivity of the anticancer drugs at 
several stages of the drug development process, and allow a rational optimization of the 
most promising selective agents. 
There are different targeting strategies available. First, targeting of specific tumor-
associated antigens is an option. Antigens that are abundantly expressed in for instance 
squamous cell carcinoma of the head and neck, can be accessible to biological agents. A 
second option is the targeting of growth factors or growth factor receptors, the key drivers 
of tumor growth and survival. This strategy is more widely applicable, in head and neck 
cancer as well as in other solid malignancies. Instead of targeting the tumor cells 
themselves, another application can be the selective blockage of tumor vasculature or tumor 
angiogenesis, resulting in prevention of (out)growth of solid tumors. This strategy can also 
be used in other tumors than head and neck cancer.  
Targeted agents, used as single agents or in combination with other anti-tumor 
agents and/or radiotherapy, might become a valuable addition to the traditional treatment 
armament. In 2006, Bonner et al. showed an improvement of locoregional control and 
reduction of mortality without increase of the common toxic effects of radiotherapy in 
patients treated for locoregionally advanced head and neck cancer with concomitant 
radiotherapy plus the anti-epithelial growth factor receptor (EGFR) mAb cetuximab (44). 
Furthermore, Vermorken et al. showed an improved overall survival of cetuximab plus 
platinum-fluorouracil chemotherapy compared with platinum-fluorouracil chemotherapy 
alone, when given as first-line treatment in patients with recurrent or metastatic head and 
neck cancer. This combination of chemotherapy and systemic targeted therapy using a mAb 
is the first systemic treatment in more than thirty years to show an overall survival benefit 
in this patient group. There was no negative influence on patients’ quality of life (33). 
Recent studies have demonstrated the feasibility of combining cetuximab to concurrent 
chemoradiation with cisplatin. Promising results were shown in a phase II study (45), a 
phase III study is still ongoing. Furthermore, there is interest in induction therapy using 
cetuximab plus cisplatin, 5-fluorouracil and docetaxel prior to radiotherapy (46) or 
chemoradiation (47). Early survival results are promising. 
Until the development of the combination therapy consisting of cetuximab plus 
platinum-fluorouracil chemotherapy, the median survival time of patients with recurrent 
and/or metastatic head and neck cancer had not been improved during the last thirty years. 
Selective targeting of head and neck cancer using these targeted approaches might 
contribute to more efficacious and better tolerated anti-cancer drugs, leading to the 
improvement of loco-regional tumor control, to a more effective treatment of advanced 
stage disease and to an improvement of overall survival. 
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Figure 1: Models of genetic instability and progression in head and neck cancer. Reprinted from Haddad 
RI and Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-1154.  
Head and neck cancer is considered to progress through a multistep process from normal histologic 
features to hyperplasia, mild dysplasia, moderate dysplasia, severe dysplasia, carcinoma in situ, invasive 
carcinoma, and metastasis. Underlying genetic instabilities including the loss of heterozygocity (LOH) of 
certain chromosomes (3p14, 9p21, 17p13, 8p, 11q, 13q, 14q, 6p, 4q27, and 10q23) and amplification or 
deletion or up-regulation or down-regulation of certain oncogenes or tumor-suppressor genes, including 
epidermal growth factor receptor (EGFR), p53, Rb, p65, cyclooxygenase 2 (COX-2), p16, cyclin D1, and 
phosphatase and tensin homolog (PTEN) have been identified as genetic alterations in each of the 
pathological stages of this disease. Several genes — including those encoding E-cadherin (CDH1), 
chemokine (C-X-C motif) receptor–stromal-cell–derived factor (CXCR4–SDF-1), vascular endothelial 
growth factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), 
transforming growth factor α and β (TGF-α and TGF-β), interleukin-8, and the respective receptors, along 
with matrix metalloproteinase (MMP) — are involved mainly in the progression of metastasis and in early 
stages of tumor progression. 
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2. Selective targeting in head and neck cancer: new perspectives 
 
2.1 Locoregional selective targeting 
There is an urgent need for highly selective therapies for the local and locoregional 
treatment of head and neck cancer. Ideal local therapies only target malignant tissues, while 
sparing healthy tissues. Especially in the treatment of head and neck cancer, tissue 
preservation is of high importance, because of the necessity for optimal functional and 
esthetic outcomes. Until recently, there were no highly selective locoregional therapies 
available for those cases surgery or radiotherapy is not an option (see paragraph 1.2). In 
surgical treatment, always ample margins should be taken to prevent local recurrences. 
With the development of photodynamic therapy (PDT), a locoregional targeting strategy 
became available, that selectively destroys tissues that have been subjected to light. Several 
days after intravenous injection of a photosensitizer, which will accumulate in the tumor 
although not selectively, the tumor and surrounding tissue-margins are exposed to a laser 
light with appropriate wavelength (for example 652 nm in case of mTHPC, the most 
commonly used photosensitizer) (48). The whole body has become sensitive for light, but 
only tissue exposed to the laser light several days after the injection will be destructed. 
Photodynamic therapy aims the preservation of the organ function, local tumor destruction, 
relief of symptoms and avoidance of disease-related complications. Photodynamic therapy 
seems to be a suitable treatment for a small group of strictly selected tumors, but the need 
for other, more widely applicable treatment techniques still persists. Only a few tumor types 
are sensitive to PDT. Furthermore, there is a risk of burning wounds on the skin, and the 
therapy is in principle only suitable for superficial tumors, due to the limited tissue 
penetration of laser light. Introduction of interstitial illumination techniques might partly 
solve these shortcomings. 
 Another approach for locoregional selective tumor targeting is chemo-
electroporation therapy (49). When tissues are exposed to direct electrical pulses, 
‘electroporation’ of cell membranes can occur (50). Voltage pulses delivered to the tumor 
by an applicator induces transmembrane potential changes that causes the cell membranes 
in the area to become temporarily hyperpermeable (‘poration’), enabling an accelerated 
penetration of chemotherapeutic agents (for instance bleomycin) into the cells (51). 
Through these permeation structures, larger molecules and hydrophilic molecules that 
normally are nonpermeant, can freely enter the cell by diffusion (52,53). Using 
electroporation therapy, chemotherapy can be administered locally, preventing systemic 
side-effects. As for photodynamic therapy, previous treatments usually do not preclude 
application of this therapy, and it can be repeated if needed. Both approaches are still under 
investigation, and preliminary results are promising in terms of locoregional tumor control 
and patients’ quality of life. When using long-needle applicators, electroporation therapy 
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can also be applied for treatment of “deeper” tumors, and therefore it is more widely 
applicable than PDT. 
 
2.2. Systemic selective targeting 
 
2.2.1 Potential targets for systemic therapy in head and neck cancer 
As mentioned earlier, systemic chemotherapeutical agents suffer from poor selectivity, 
possibly causing unacceptable toxicities to normal tissues. In contrast, ideal systemic 
selective targeting agents are directed against targets of signaling pathways that are 
essential for tumor growth and survival (tumor addiction), and are directed against targets 
with high and preferably homogeneous expression in the tumor tissue, but a low or absent 
expression in normal tissues. Furthermore, to be effective, the tumor target needs to be 
accessible to the targeting ligand, and preferably not be shed into the circulation. 
Different targeting strategies are available for selective treatments in head and 
neck cancer. First, targeting of antigens associated with tissue differentiation is an option. 
In head and neck cancer these are ‘squamous associated antigens’. Antigens that are 
abundantly expressed in squamous cell carcinoma of the head and neck, like E48/Ly-6D 
and CD44v6, can be used for systemic targeted therapy. Care should be taken in case of 
cross-reactivity, i.e. normal tissues that also show expression of the antigen, and thus are at 
risk of being targeted by the therapeutic agents. In case of the E48/Ly-6D and CD44v6 
antigens, cross-reactivity with normal tissues should be anticipated, because both antigens 
are present in the great majority of normal squamous cells, for instance in oral mucosa and 
skin keratinocytes (54).  
Recent research developments have placed the role of CD44v6 in oncogenesis in a 
new perspective. The cancer stem cell theory has been hypothesized, which suggests that a 
tumor can be viewed as an aberrant organ that is sustained by a stem cell that drives 
tumorigenesis (55). Only a small subpopulation of cells, the ‘cancer stem cells’, has the 
ability to form new tumors (56,57). Only the cancer stem cell can self-renew and proliferate 
extensively to form new tumors (58,59). Tumors often respond to chemotherapy initially, 
but frequently recur. The residual stem cells remaining after therapy must be responsible 
for the tumor regeneration. The recurrences might behave more aggressive and resistant to 
chemotherapy. Targeted therapies against these cancer stem cells are highly needed, to 
prevent recurrences of cancer and dissemination of tumor cells. CD44v6 has also been 
proposed to be a suitable stem cell marker (55). 
Second, antigens involved in tumor growth regulation can be targeted. Among 
others, EGFR has emerged as a prominent growth driver and survival factor in head and 
neck cancer, and also in other solid tumors, like ovarian cancer, and non-small cell lung 
cancer. EGFR is a transmembrane cell surface receptor found primarily on cells of 
epithelial origin, and is a member of the ErbB family, consisting of the epidermal growth 
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factor receptor (EGFR/erbB-1/HER1), HER2 (neu/erbB-2), HER3 (erbB-3), and HER4 
(erbB-4). The members of this receptor class have a common structural architecture: an 
ecto-domain that is binding to the different ligands, a transmembrane region, an 
intracellular domain containing the receptor tyrosine kinase (RTK) and different tyrosine 
residues that are phosphorylated upon receptor activation (60,61). The ErbB receptors can 
be stimulated by more than 20 different ligands of which EGF en TGFα are binding to 
EGFR. Binding of the ligand induces receptor homo- or heterodimerization (dimerization 
of two receptors of the same or different type) resulting in allosteric activation of the 
intracellular tyrosine kinase and signaling leading to cell proliferation. Exceptions to this 
common theme are ErbB2 (HER2/neu) that does not bind to any known ligand and ErbB3 
that contains an inactive tyrosine kinase. Heterodimerization is therefore essential for the 
functioning of these two receptors, which is not without consequence: overexpression of 
these ErbB members, in particular ErbB2, and transactivation by heterologous signaling 
networks can result in increased tumor growth. The ligand identity as well as the dimer 
partner determine which tyrosines are phosphorylated, and hence which proteins are 
recruited and which (tumor-promoting) processes are affected (e.g. proliferation, migration, 
metastasis, angiogenesis etc). As these processes are the hallmarks of cancer, ErbB 
receptors are considered to be the tumor Achilles heels for therapeutic approaches, with 
EGFR being the most broadly exploited target in head and neck cancer.  
Several approaches are currently being undertaken to inhibit ErbB signaling: 1) 
blocking of ligand binding to EGFR by (antagonistic) mAbs; 2) blocking of EGFR and 
ErbB2 heterodimerization by mAbs, 3) kinase inhibition by small molecule drugs; and 4) 
modulation of EGFR expression, either by inhibition of EGFR synthesis by siRNA or by 
stimulation of EGFR degradation. EGFR has been shown to be essential for the 
upregulation of tumor cell proliferation, differentiation, and survival, and is associated with 
worse outcome in terms of loco-regional tumor control, overall survival and resistance to 
therapy (62-65). In addition, the level of EGFR expression has been shown to be inversely 
related to the effectiveness of radiation therapy to control cancer cell growth (66). 
Inhibition of EGFR results in radiosensitization (62,67). Blocking of EGFR may interfere 
with signal transduction pathways and can result in disease stabilization and increased 
survival for patients with head and neck cancer. 
A third possibility of targeting is the eradication of tumor vasculature. 
Angiogenesis is required for tumor progression and metastasis, and inhibiting this process 
has become an intensive focus of clinical investigation (68,69). The potential of this 
approach is best exemplified by studies aiming at the neutralization of vascular endothelial 
growth factor (VEGF) activity, either by capturing the growth factor itself or by blockage 
of its receptors (VEGFRs) (68,70). VEGF expression is up-regulated in many tumors, 
favoring tumor vascularization and growth, and has been demonstrated to be highly 
correlated with worse prognosis in patients with head and neck cancer (71). 
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Another appealing anti-angiogenesis approach is the targeted destruction of 
established tumor vasculature, e.g. by mAbs directed against markers of angiogenesis 
(68,70). This approach might be especially attractive since these markers are expressed by a 
diversity of tumor types, and are well accessible for systemic therapies. Among others, 
extra domain B (ED-B) of fibronectin is an appealing target for such approach. Fibronectin 
is an extracellular matrix component that is widely expressed in a variety of normal tissues 
and body fluids. Different fibronectin isoforms can be generated by alternative splicing, a 
process modulated by cytokines and extracellular pH (72). The ED-B-containing isoform of 
fibronectin is immunohistochemically undetectable in normal adult tissue, with the 
exception of tissues undergoing physiological remodeling (for instance endometrium and 
ovary) and during wound healing (72). Furthermore, it has been demonstrated that ED-B is 
a marker of tumor angiogenesis (73). ED-B is highly conserved in different species, having 
100% homology in all mammalians thus far studied (human, rat, mouse).  
 
2.2.2 Targeting agents: monoclonal antibodies and small molecules 
The concept of the ‘magic bullet’ was proposed by Ehrlich at the beginning of the 20th 
century (74). He described a chemical with the ability to specifically target 
microorganisms, and this concept was expanded thereafter to include cancer treatments. 
These chemicals include mAbs as well as small molecules for the use of disease-specific 
therapies (75,76). mAbs are part of the immune system in both humans and animals. mAbs 
can be used either as therapeutic agents, or as carrier agents to deliver other toxic agents to 
the tumor cells or tumor tissue (for instance radioactive agents or cytotoxic drugs). The 
introduction of the hybridoma technology for the production of mAbs by Kohler and 
Milstein in the mid 1970s turned the magic bullet concept of Ehrlich into a realistic option. 
With the hybridoma technology an unlimited range of mAbs could be developed against 
any particular cellular antigen. Presently, the US Food and Drug Administration (FDA) has 
approved twenty-two therapeutic mAbs, mostly for the systemic treatment of cancer (77). 
Well known mAbs with intrinsic anti-tumor activity for treatment of solid tumors are 
cetuximab (Erbitux® directed to EGFR, HER1), trastuzumab (Herceptin® directed to 
HER2) and bevacizumab (Avastin® directed to VEGF) (78-80). These mAbs are aimed to 
completely neutralize/block growth factors or growth factor receptors, the key drivers of 
tumor growth and survival, for a prolonged period of time.  
Despite clinical enthusiasm, however, it is fair to state that efficacy of current 
mAbs is still quite limited, with benefit for just a portion of patients, while costs of 
antibody therapy are excessive (81). All mAbs except three that have been approved till 
now are intact antibodies (82). This is remarkable, since these large-sized molecules (~150 
kDa) are considered to have limited capacity for tumor penetration (83). For this reason, 
much effort has been put in the evaluation of antibody fragments, but without convincing 
therapeutic success to date (84). While production of such fragments is not always 
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straightforward and can result in diminished affinity, the main in vivo limitation of antibody 
fragments is their rapid blood clearance and the associated low tumor uptake. Especially 
molecules smaller than 60-70 kDa are generally filtered out by the kidneys very rapidly, 
and are therefore not well qualified for long term blockage of the growth factor receptor. 
During the last two decades, also so called ‘small molecule inhibitors’ have been 
developed. These light-weight (~500 Da) chemical agents can be inhibitors of crucial 
mediators in signaling pathways of cell proliferation, differentiation, migration, 
angiogenesis, and cell-cycle regulation (85-87). Well known examples of small-molecule 
inhibitors are EGFR tyrosine kinase inhibitors, that bind intracellularly within the kinase 
domain and inhibit kinase activity, thus modulating transcription, cell-cycle progression, 
cell survival, and motility, all of which facilitate invasiveness and metastasis (88). 
Recently, three anti-EGFR tyrosine kinase inhibitors have been approved by the FDA for 
use in oncology: erlotinib (Tarceva®), gefitinib (Iressa®) and lapatinib (Tykerb®) for 
inhibition of the signaling pathways (89). 
There are several differences between mAbs and mAb fragments on one hand, and 
small molecule inhibitors on the other hand. These differences can result in arguments to 
focus on the development of either mAbs or small molecule inhibitors. mAbs are in general 
more specific and selective than small molecule inhibitors. The antigens for antibody 
binding are located extracellularly, whereas the binding domains of small molecules are 
mostly intracellularly located. Furthermore, the half-lives of both agents are different, being 
3.1-7.8 days for antibodies (allowing for weekly or bi-weekly dosing) versus less than 36 
hours for small molecule inhibitors (allowing for daily dosing). For mAbs, an intravenous 
administration is necessary, small molecule inhibitors can often be administrated orally. 
Therefore, plasma concentrations are more constant in antibody therapies, even more 
because the degradation system for small molecule inhibitors may vary between 
individuals. Small molecule inhibitors have one mechanism of toxicity (e.g. tyrosine kinase 
inhibition), whereas antibody-based mechanisms can be classified into two categories. The 
first category is the direct action, being blockage of a receptor, induction of apoptosis or a 
targeting function. With respect to the latter, mAbs can be used as a vehicle for selective 
delivery of toxic payloads, such as toxins or radioisotopes. The second category is the 
indirect action, mediated by the immune system. Herein, the elimination of tumor cells 
depends on immunoglobulin-mediated mechanisms, including complement-dependent 
cytotoxicity (CDC) and antibody-dependent cellular toxicity (ADCC) (76). Synergistic 
effects with other anti-cancer treatments, like radiotherapy and/or chemotherapy, have been 
more often found in antibody therapy, rather than in small molecule inhibitors therapy. A 
well known example is the radiosensitization of the antibody cetuximab (90). Because of 
the relatively large molecular weight of antibodies, the penetration into solid tumors may be 
impaired, compared to small molecule inhibitors. This might be particularly the case for 
targeting brain tissues, because of the blood-brain barrier (91). The final important 
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difference is the effects on the immune response. Distinct from chemicals (small molecule 
inhibitors), proteins (mAbs) are potential immunogenic. The human body might develop a 
reaction against the non-human proteins. The initially developed murine antibodies were 
rapidly cleared from the human body by human anti-murine antibodies (HAMA’s). With 
the development of chimeric and humanized antibodies, the clearance via human anti-
chimeric antibodies (HACA’s) and  human anti-human antibodies (HAHA’s) in general is 
limited (92,93). 
Although the use of mAbs and small molecules both meet theoretical pros and 
cons, the initial successes of mAbs in the treatment of cancer in general, and in the 
treatment of head and neck cancer in particular, made us decide to focus on mAbs and mAb 
fragments for systemic treatment of head and neck cancer in this thesis. 
     
2.2.3 Targeting of head and neck cancer using monoclonal antibodies: current status 
In the past decade, encouraging progress was obtained with the development of CD44v6-
directed mAbs coupled to radionuclides (‘radioimmunotherapy’ = RIT) in head and neck 
cancer. For this purpose, the chimeric antibody U36 (cmAb U36) and the humanized 
antibody BIWA 4 (bivatuzumab), both directed against CD44v6, have been evaluated 
(94,95). Phase I dose escalation RIT studies with 186Re-labeled-cmAb U36 and 186Re-
labeled-bivatuzumab, showed promising anti-tumor effects with consistent stable disease at 
higher radioactivity dose levels (96-98). An important advantage of RIT compared to 
pharmacological agents, is the capacity to kill tumor cells in the vicinity of the targeted 
cells. For this treatment to be effective, it is not necessary to target every single tumor cell 
with a radionuclide-containing mAb. Toxicities observed in the RIT studies were 
myelotoxicity caused by circulating radioimmunoconjugate and, in some patients, mild oral 
mucositis. In these studies, bivatuzumab seemed to have low immunogenicity. Binding of 
these antibodies to the target antigen resulted in partial internalization of the antibody (99). 
The lack of efficacy with un-armed mAbs, makes these targets less suitable for targeting 
with small molecules. Apparently, these targets are less critical in the malignant behavior of 
squamous tumor cells.  
Head and neck cancer is considered to progress through a multistep and 
complicated process, from normal histological features to hyperplasia, mild dysplasia, 
moderate dysplasia, severe dysplasia, carcinoma in situ, invasive carcinoma, and 
metastasis, resulted from an accumulation of multiple additional genetic alterations in the 
squamous epithelium (18-20). Figure 1 shows this model of genetic instability and 
progression in head and neck cancer. Virtually all cancers must acquire the six capabilities 
of cancer: 1) self-sufficiency in growth signals; 2) insensitivity to anti-growth signals; 3) 
evading apoptosis; 4) limitless replicative potential; 5) sustained angiogenesis; and 6) tissue 
invasion and metastasis (100). These capabilities are also known as the ‘hallmarks of 
cancer’ (figure 2). As indicated before, there are different approaches to selectively inhibit 
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critical growth factors and receptors involved in tumor growth and survival. Without doubt, 
the EGFR signal transduction route belongs to the key drivers in head and neck cancer 
(101), and overexpression of EGFR occurs in up to 90% of head and neck cancers 
(102,103). Despite the clinical success of cetuximab, it is fair to state that the efficacy of 
current mAbs is still quite limited. This conclusion comes with very recent insights that 
several other growth factors and their corresponding receptors are involved in malignant 
growth, also of head and neck cancer. Among others, c-Met and the insulin-like growth 
factor-I receptor (IGF-IR), are currently exploited as targets for treatment of head and neck 
cancer. c-Met, or the ‘hepatocyt growth factor receptor’, is a receptor tyrosine kinase that 
regulates cell cycle progression, migration, angiogenesis, and cell survival. c-Met might 
become an attractive target for molecular-targeted cancer therapy (104,105). Activated c-
Met appears to be a marker of primary gefitinib resistance in non-small cell lung cancer 
patients (106,107), and therefore, a rationale for treatments using combinations of different 
critical anti-growth factor and anti-growth factor receptor targeting approaches in tumors 
manifesting acquired resistance to cetuximab is suggested (108). Signaling through the 
insulin-like growth factor-I receptor leads to cellular proliferation, apoptosis, metastasis, 
and resistance to cytotoxic cancer therapies. Blocking one of these signal transduction 
pathways, or several of these pathways simultaneously, might be a promising strategy to 
improve tumor control (89). 
Agents targeting neovasculature of tumors or agents preventing angiogenesis, are 
bevacizumab, targeting VEGF, mAbs targeting the VEGF receptors, and small 
immunoprotein L19-SIP, targeting the extra domain B of fibronectin, a marker of tumor 
angiogenesis. The neutralizing humanized anti-VEGF mAb bevacizumab (Avastin, 
Genentech) has recently been approved by the FDA for the treatment of advanced 
colorectal, breast, and lung cancer in combination with chemotherapy and for advanced 
renal cell cancer in combination with interferon alpha (109). Also in head and neck cancer, 
the application of antibodies and small molecules for selective blockage of VEGF/VEGFR 
signal transduction is subject of extensive research (110-113). Phase I and II studies with 
bevacizumab in combination with chemoradiation or erlotinib for the treatment of recurrent 
and metastatic head and neck cancer were recently performed (114,115). A potential hurdle 
in approaches aiming the neutralization of only one critical pro-angiogenic factor is that 
other redundant pro-angiogenic factors may compensate for the one which is inhibited. 
In an immunohistochemical study of 82 head and neck tissue biopsy specimens, a 
strong positive staining with the anti-ED-B L19 antibody was observed in 87% of the 
investigated malignant tumors, in only 38% of the benign tumors, and in 20% of the 
nontumoral lesions (116). Therefore, the ED-B of fibronectin is an interesting target for the 
treatment of head and neck cancer. Until recently, clinical studies with L19-SIP have not 
been performed. 
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2.2.4 New perspectives in targeting of head and neck cancer with mAbs 
Based on the promising clinical results of RIT using the CD44v6-directed mAbs in head 
and neck cancer, it might be interesting to investigate the possibilities of coupling a 
nonradioactive cytotoxic drug to an anti-CD44v6 antibody, instead of radionuclides. 
Because the CD44v6 antigen is present on nearly every single head and neck squamous 
cancer cell, all malignant squamous cells in the whole body can be targeted. This might 
result in a promising option for adjuvant therapy in head and neck cancer. From such 
conjugate no bone marrow toxicity has to be expected, and therefore perspectives might 
arise for combined treatment with conventional chemotherapeutics. Moreover, antibody-
drug conjugates might appear to be the ideal format to kill CD44v6 expressing stem cells. 
Omission of radioactivity should solve several issues related to logistics and radiation 
safety. 
As indicated before, several growth factors and growth factor receptors are 
involved in malignant growth in head and neck cancer. As indicated before, selective 
targeting of just one single tumor target (i.e. ‘monotargeting’) might be insufficient for fully 
effective cancer treatment. Targeting different tumor capabilities simultaneously (‘dual-
targeting’ or ‘multi-targeting’) is an interesting new strategy in efficient anticancer therapy 
to eliminate cancer cells and to limit the emerge of drug resistance (76,117). The rationale 
for this approach is that cancer cells have the inherent ability to become addicted to several 
growth factor (receptor) systems for growth advantage and survival (107), and frequently 
there are defects in more than one signaling pathway (100). Therefore, efforts should be 
made to block several critical signal transduction pathways simultaneously. These can be 
multiple approaches combined, or multispecific single molecule formats that inhibit several 
targets simultaneously. 
The FDA might approve bevacizumab for the treatment of recurrent and/or 
metastatic head and neck cancer, if clinical data appear to be decisive. Nevertheless, also 
other strategies are appealing to target angiogenesis. The mAb fragment L19-SIP is an 
interesting agent for targeting neovasculature. The promising immunohistochemical data of 
ED-B expression in head and neck cancer will open new avenues: for the evaluation of in 
vivo uptake of L19-SIP in preclinical biodistribution studies, and for the evaluation of 
targeting angiogenesis in the human body in clinical studies (116). These studies should 
then be clinical dose escalation studies with L19-SIP coupled to the radionuclides or 
cytotoxic drugs.  
Finally, for assessment of the targeting potential of novel mAbs, imaging studies 
might be of great value for confirmation of selective tumor targeting and for quantification 
of biodistribution. The latter might be particular important when the mAb is carrying a 
toxic payload, to predict efficacy and to anticipate toxicity. To this end, studies should 
ideally be performed with antibodies carrying positron emitters, to allow imaging with a 
PET camera (i.e., immuno-PET) (43). 
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Figure 2: Acquired capabilities of cancer. Reprinted from Hanahan D and Weinberg RA. The hallmarks of 
cancer. Cell 2000;100:57-70. It is suggested that most if not all cancers have acquired the same set of 
functional capabilities during their development, albeit through various mechanistic strategies. 
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3. Aim and outline of the thesis 
  
For the treatment of head and neck cancer, four different approaches are available: surgery, 
radiotherapy, chemotherapy, and targeted therapies. During the last ten years, enormous 
progress has been made in the development of targeted therapies, selectively targeting 
malignancies while sparing normal tissues. Targeted therapies can become the basis for the 
adjuvant treatment of cancer. As indicated in chapter 1, there will be a future role for 
targeted therapies in the locoregional as well as the systemic treatment of malignancies. 
The major aim of the present study is the development of new strategies for locoregional or 
systemic selective targeting of squamous cell carcinoma of the head and neck (HNSCC), to 
increase the overall survival of patients suffering from this disease. These are strategies to 
improve selective uptake of locally admitted cytotoxic agents, and strategies to improve 
systemic adjuvant therapy by use of antibody technology.  
During the last decades, efforts have been made in the locoregional treatment of 
cancer, focusing on minimal invasive procedures, leading to less damage to the surrounding 
tissues. Tissue preservation and quality of life are key in modern cancer treatment 
strategies. There is an urgent need for locoregional treatment modalities that can be 
repeated when necessary in case of recurrent disease or second primary tumors. These 
tumors often can only be treated palliatively, after initial successful treatment procedures. 
Recently, a few treatment modalities have been developed for the locoregional treatment of 
recurrences, second primary tumors, and metastases that could not be treated by standard 
therapies, because of earlier treatments, or an impaired patient’s performance status. One of 
these modalities is the local injection of the cytotoxic drug bleomycin directly into the 
tumor, followed by the application of electric pulses in and around the tumor. In chapter 2, 
we evaluated the potential of this bleomycin-electroporation therapy as a locoregional 
targeted therapy for the treatment of patients suffering from malignancies in the head and 
neck area. We evaluated this treatment in terms of local tumor control, overall survival, 
tissue preservation and quality of life. 
Besides the need for locoregional selective treatment strategies, there is a need for 
systemic selective strategies to target minimal residual diseases and occult metastases. 
These adjuvant strategies are essential to improve the overall survival after initial heavy 
treatment of head and neck cancer. Monoclonal antibodies (mAbs) or antibody fragments 
are gaining momentum for the use in disease-selective systemic therapy. mAbs are agents 
aimed to selectively target tumor cells, for selective delivery of toxic payloads or for 
complete neutralization/blockage of critical tumor associated targets and pathways. Normal 
tissues, that are not expressing the specific target, will not be affected by mAbs. Selective 
and efficient tumor targeting of mAbs and mAb fragments can easily be confirmed by 
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positron emission tomography (PET) imaging, and this enables a more rationalized 
development and individualized use of these expensive therapeutic agents. 
The humanized mAb bivatuzumab is directed against the CD44v6 antigen that is 
predominantly expressed on squamous cell carcinomas. Using bivatuzumab as a carrier, 
head and neck cancer cells can selectively be targeted by cytotoxic agents coupled to 
bivatuzumab. The selective delivery of radioisotopes to head and neck tumors by 
bivatuzumab, and the therapeutic potential of such approach,  have already been shown in 
previous radioimmunotherapy (RIT) studies. In chapter 3, we assessed the safety, 
pharmacokinetics, maximum tolerated dose and preliminary efficacy of bivatuzumab 
coupled to the super-toxic anti-microtubule drug mertansine in a clinical phase I dose 
escalation study with HNSCC patients. From such conjugate no bone marrow toxicity has 
to be expected, and omission of radioactivity can solve several issues related to logistics 
and radiation safety.  
Another appealing therapeutic strategy is the selective targeting of tumor 
angiogenesis and neovasculature. Angiogenesis is required for tumor progression and 
metastasis, and inhibiting this process as well as the eradication of tumor vasculature has 
become an intensive focus of clinical investigation. The mAb fragment L19-SIP is directed 
against the extra-domain B of fibronectin, a marker of angiogenesis. In chapter 4 we 
evaluated the biodistribution and efficacy of 131I-labeled L19-SIP in preclinical 
radioimmunotherapy studies with HNSCC xenograft bearing nude mice. In addition, 
combination therapy of 131I-L19-SIP with cetuximab was considered because this anti-
EGFR mAb also causes anti-angiogenic effects and has proven clinical value in 
chemoradiation of HNSCC. For assessment of the targeting potential of L19-SIP in clinical 
studies, imaging studies might be of great value for confirmation of selective tumor 
targeting and for quantification of biodistribution. Pretherapy antibody imaging has mostly 
been applied as prelude to RIT, for assessment of dosimetry. In this setting, quantitative 
imaging is particularly attractive, because of the small therapeutic window of RIT with 
bone marrow being the dose limiting organ. In chapter 5, we described the development 
and application of 124I-labeled L19-SIP for immuno-PET imaging of tumor neovasculature, 
and for prediction of biodistribution and dosimetry of 131I-L19-SIP in RIT. In addition, 
GMP-compliant 124I-production procedures were developed. 124I-L19-SIP was evaluated by 
comparison the biodistribution with 131I-L19-SIP upon coinjection in HNSCC xenograft 
bearing nude mice and by imaging with a high-resolution research tomograph (HRRT) PET 
scanner.  
As mentioned before, mAbs appeared to be ideal agents for disease-selective 
systemic therapy, also for treatment of HNSCC as exemplified by the approval of the anti-
EGFR mAb cetuximab. Nevertheless, there are several properties of mAbs that leave room 
for improvement. The costs of development and production of mAbs are excessive, and 
because of the relatively large molecular weight of mAbs, the penetration into solid tumors 
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may be sub-optimal. Therefore, much effort has been put in the evaluation of small-sized 
antibody derivatives, however, their rapid blood clearance make them less suitable for 
therapy of cancer. Moreover, conventional mAbs like cetuximab normally bind to one 
critical tumor target, and it is questionable whether this is sufficient for fully effective 
cancer treatment. In chapter 6 we considered whether nanobodies could deal with the 
aforementioned limitations of conventional mAbs. Nanobodies are derived from a unique 
antibody format that is present in species from the family of Camelidae, including llama, 
camel, and dromedary. These animals contain, next to their conventional antibody 
repertory, an antibody class consisting of heavy chains only. Consequently, the variable 
region of the heavy chain from these “heavy-chain-only” antibodies represents the complete 
binding unit of the antibody. The development and production of these nanobodies is much 
easier and less expensive than the development and production of intact mAbs, while tumor 
penetration might be better. Particular attractive is the flexibility of drug formatting 
whereby it is straightforward to generate multivalent and/or multispecific single–molecule 
formats. In chapter 6, we explored nanobody technology for efficient EGFR targeting, as a 
first step to the use of nanobodies in multi-target therapy. 
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Abstract 
 
Bleomycin-electroporation therapy is a therapeutic tumor ablation modality for the 
treatment of solid tumors. Details of the technique for locoregional treatment of cancer are 
provided in this chapter. The safety, effectiveness, and burden of bleomycin-electroporation 
therapy was determined in patients with head and neck or skin cancer, who could no longer 
be treated by surgery or radiotherapy, or for whom conventional treatment would be very 
extensive and thus declined by the patient. 
Bleomycin-electroporation therapy is an easy to perform treatment that causes 
little burden to the patient and is potentially effective in patients with a head and neck or 
skin tumor. Based on the outcome of patients treated at our site, bleomycin-electroporation 
therapy has the potential to become a valuable addition to the treatment options for patients 
with head and neck or skin tumors. 
Five patients with head and neck cancer and nine patients with cutaneous cancer 
with a total of 24 tumors were treated using bleomycin-electroporation therapy. The 
procedure was well-tolerated by the patients in all cases. Two patients with mucosal head 
and neck tumors reported complaints about pain, but could easily be treated with oral pain 
medication. The nine patients with cutaneous cancer reported no pain. Twenty-three tumors 
have responded to treatment, one tumor could not be evaluated because the patient died of 
other disease shortly after treatment. Local tumor control during more than two years was 
obtained for 10 of the 24 tumors. In all cases functions were preserved successfully and the 
treatment provided good cosmetic results. Prolonged wound healing can be expected and 
therefore care should be taken in regions that already have been subjected to extensive 
radiotherapy. 
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Introduction 
 
Early stage head and neck cancer has a favorable prognosis and is usually treated with 
surgery or radiotherapy. Approximately two-thirds of the patients present with advanced 
stage disease and are generally treated with a combination of surgery and radiotherapy or 
concomitant radiotherapy and chemotherapy. Nevertheless, 10% to 30% of these patients 
will develop a local recurrence, 10 to 20% a regional recurrence, and also second primary 
tumors frequently develop in these patients at a rate of 2% to 3% per annum. Treatment of 
these second primary tumors is challenging, especially when the site has already been 
subjected to extensive surgery, or when radiotherapy is no longer an option because of 
previous treatment. Furthermore, primary cutaneous malignancies, and infrequently 
occurring cutaneous metastases, may be particularly troublesome to the patient. Surgical 
resection may lead to functional and esthetical problems, and if radiotherapy is no longer an 
option, chemotherapy as monotherapy can usually only be used palliatively (1). 
 An important outcome after treatment of head and neck cancer, are problems that 
are caused by loss of function (swallowing and speech) and cosmetic disfigurement. The 
restrictions caused by earlier treatments and the need for function-sparing therapy have 
motivated the development of new techniques to treat head and neck cancer, like 
photodynamic therapy and electroporation therapy. Previous treatments usually do not 
preclude application of these therapies, and they can be repeated if needed. Photodynamic 
therapy seems to be a suitable treatment for a small group of strictly selected tumors. For 
this reason, the need for other, more widely applicable treatment techniques has persisted.  
 We report on a case series of patients treated in our institution with electroporation 
therapy. The bleomycin-electroporation therapy consists of injections of bleomycin directly 
into the tumor under local or general anesthesia, after which the six needle-electrodes of a 
disposable applicator are inserted into the tumor. Following insertion, voltage pulses are 
delivered to the tumor, while the polarity between opposite needles continuously switches. 
This causes the cell membranes in this area to become temporarily hyperpermeable 
(‘poration’), enabling an accelerated penetration of the hydrophilic chemotherapeutic agent 
bleomycin into the cells. After entering the cell, the bleomycin can become effective (2). 
The cytotoxicity of bleomycin is 300- to 700-fold enhanced by the electroporation 
procedure (3). Due to the electroporation, the extracellular concentrations of bleomycin can 
be very low to kill the cell (4). It is important to realize, that the procedure leads to poration 
only in the area encased by the needle-electrodes, therefore it is necessary to treat the tumor 
in overlapping fields to cause poration of the whole tumor (5). 
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Patients and Methods 
 
Subjects 
Fourteen patients with primary, secondary, recurrent or metastatic tumors of mucosa or skin 
for which either no curative treatment options were available, or only extensive mutilating 
surgery remained were included in this open-label study. Prerequisite for inclusion was 
sufficient accessibility of the entire tumor for the applicator with electrode array. 
Histologically confirmed squamous cell carcinomas of the mucosa of the head and neck 
area, malignant tumors of the salivary glands and primary skin tumors or cutaneous 
metastases (squamous cell carcinomas, basal cell carcinomas, melanomas, 
adenocarcinomas, Merkel cell carcinomas, sarcomas, cutaneous lymphomas, skin 
metastases or primary cutaneous tumors) were eligible for treatment (Table 1). The 
maximum diameter of the tumors was 5.0 cm, and the upper limit of volume to be treated 
was 60.0 cm3 for mucosal tumors and 80.0 cm3 for skin tumors. Tumors encasing >50% of 
a major artery and tumors invading bone were excluded. Maximum administration of 
bleomycin during the entire life was 400 IU. The end of study evaluation timepoint was 
defined 2 years after treatment. 
 
 
Table 1. Patient and tumor characteristics 
          
Patient  Age Sex Histologic type  No. of Tumor Tumor site    
no.     (year)             tumors      size (mm)*   
  
1 50 M Primary SCC   9 15 Cutaneous, Scalp and Chest 
2 71 M Recurrent SCC  1 25 Cutaneous, Auricle  
3 26 M Metastatic Sarcoma  1 50 Cutaneous, Scalp  
4 50 F Second primary SCC  1 25 Mucosal, Oral Cavity  
5 60 M Recurrent Melanoma  1 10 Mucosal, Nasal Vestibule 
6 82 F Metastatic Merkel cell carcinoma  3 50 Cutaneous, Chest  
7 59 F Primary SCC   1 10 Mucosal, Oral Cavity  
8 78 M Primary SCC   1 30 Cutaneous, Auricle  
9 66 F Second primary SCC  1 30 Mucosal,  Oropharynx  
10 59 M Recurrent SCC  1 40 Cutaneous, Occipital  
11 56 F Second primary SCC  1 20 Mucosal, Hypopharynx 
12 82 F Recurrent Melanoma  1 30 Cutaneous, Retroauricular 
13 71 M Metastatic SCC  1 50 Cutaneous, Submental  
14 51 M Recurrent SCC  1 30 Mucosal, Oral Cavity  
         
SCC, Squamous cell carcinoma. 
*, Largest tumor diameter. 
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Bleomycin-electroporation therapy method 
The treatment volume of the tumor was determined clinically and/or radiologically, taking 
extra margins of 0.5 cm all around (figure 1a). With the use of general or local anesthesia, 1 
IU bleomycin in 0.25 ml water/cm3 of tissue with a maximum of 60 IU for mucosal tumors 
and 80 IU for skin tumors was administered through several injections into the tumor and 
its margins, so that the entire area was infiltrated as thoroughly as possible (figure 1b). 
After 8-10 min, electroporation therapy was started using a dedicated pulse generator 
(MedPulser, Genetronics Inc., figure 2), connected to a disposable applicator, which 
consists of a hand piece with, in hexagonal arrays located, 6-needle array electrodes. 
Different designs are available to facilitate treatment of many different tumors, with 
diameters ranging from 0.5 to 1.0 cm, electrode lengths ranging from 1.0 to 3.0 cm and 
some types with adjustable lengths and angle heads. After connecting the applicator, the 
needle array was inserted in the tumor and the first electroporation cycle was started (figure 
1c) using a foot pedal to deliver the pulses. The treatment consisted of the administration of 
a number of short pulses. Shortly after, the needles were removed from the tumor and a 
new cycle was initiated. The duration of one cycle was ~10 s. The positioning of the 
electrode array during the subsequent cycle was performed in overlapping fields with the 
previous treated site, until the entire tumor had been treated. For a tumor of 2.0 by 1.0 cm, 
~20 cycles were executed. Muscles in the vicinity of the treated area occasionally 
contracted during the treatment as a result of stimulation by the administered pulses. This 
can be burdensome to the patient and therefore was reason for treating under general 
anesthesia. Within a few days after the treatment, crusting occurred at the tumor site, under 
which necrosis of the tumor took place. In general, the crust disappeared after 10-14 weeks, 
and the tumor was replaced by scar tissue. Tumors in the mucous membranes of the mouth 
healed faster than skin, and the wound completely closes within 8 weeks (figure 1d). Both 
during and after the treatment, extra pre-cautionary measures were undertaken to protect 
personnel from contact with bleomycin. Patients were cared for 3 days in a private room. 
Outpatient follow-up exams took place on a regular base. In cases where tumor response 
was clinically hard to evaluate, biopsies were taken after 1 and 2 months. 
 
Ethics 
The study was approved by the Institutional Review Board/Ethics Committee before the 
start of patient enrolment. Written informed consent was obtained from all participants 
according to national and institutional guidelines after the patients had received a thorough 
explanation of the study and sufficient time to decide on participation. 
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Figure 1. Patient no. 7: Squamous cell carcinoma of the oral cavity, located at the right upper buccogingival 
fold. Location of the tumor (a). Injection of bleomycin directly into the tumor (b). Insertion of the needle 
array into the tumor (c). Complete remission, only some scar tissue is visible. Photo was taken 4 months 
after bleomycin-electroporation therapy (d). 
 
 
 
 
 
 
 
 
 
 
Figure 2. The electroporation system: pulse generator, foot pedal, disposable applicator and printer.
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Results 
 
The technique was feasible and no technical problems occurred during therapy. Five 
patients were treated for mucosal tumors (patients no. 4, 7, 9, 11, and 14), and nine patients 
for skin tumors (Table 1). A total of 24 different lesions were treated in these patients. Ten 
patients had a squamous cell carcinoma (three oral cavity, one oropharyngeal, one 
hypopharyngeal, two auricle, one patient with multiple primary skin tumors on the scalp 
and thorax, one skin lesion occipitally and one skin lesion submentally). Two patients had a 
melanoma (one located in the nasal vestibule, and one located retroauricular). One patient 
had a sarcoma (a cutaneous metastasis of a malignant peripheral nerve sheath tumor), and 
one patient had a metastasized Merkel cell carcinoma. 
The procedure was well-tolerated by all patients. Only one of the patients with an 
oral cavity carcinoma and the patient with the oropharyngeal carcinoma reported mild pain 
complaints. These complaints were adequately controlled with oral pain medication. 
Antibiotics (metronidazole 500 mg three times daily) were prophylacticly administered in 
the five patients with the mucosal tumors in order to reduce the odor produced by the 
necrotic tumor tissue. However, no infections were detected clinically. Patient no. 5 was 
found to suffer from mild hair loss, which is normally only a side-effect of systemic 
administration of bleomycin. In patient no. 7, slight nausea was reported that lasted for two 
days following the treatment. In patient no. 11, a bleeding occurred a few days after 
treatment, because of necrosis of surrounding tissue. This area had been treated by 
radiotherapy some years earlier.  
Twenty-three of 24 tumors responded to therapy. One tumor was not evaluable, 
because patient died of other disease. Local tumor control for at least 2 years was reached 
in 10 of the 24 (41.7%) tumors, as was determined by clinical examination, MRI and/or 
biopsy during follow-up (Table 2). 
 A few patients are discussed in detail. Patient no. 1 was suffering from multiple 
primary squamous cell carcinomas of the skin, caused by treatment with 
immunosuppressive drugs for many years after a kidney transplant. This patient developed 
multiple basal cell and squamous cell carcinomas, which were excised on multiple 
occasions. Three small lesions on the scalp could not be removed surgically, since prior 
surgery had left limited possibilities for reconstruction. In this patient, six lesions on the 
chest and three lesions on the scalp were treated. During the follow-up exams no 
recurrences were found on the scalp for more than two years. After two months, a 
recurrence appeared in one of the lesions on the chest, which was successfully treated by 
local resection. 
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Table 2. Results 
         
Patient  no.     Follow-up (months)  Tumor response 
          
  
1¥ 50   8 complete remissions, one local recurrence after 2 months 
2 15   Local recurrence 5 months after EPT*, DOD† 
3 16   Complete remission, DOD† 
4 24   Complete remission, DOD† 
5 24   Local recurrence 2 months after EPT*, DD‡ 
6 2   Local tumor control, DD‡ 
7 17   Local recurrence 8 months after EPT*, DD‡ 
8 2 weeks   Not evaluable, DOD† 
9¥ 36   Local tumor control, surgery for axillary and neck metastases, DOD† 
10¥ 6   Local recurrence after 6 months, retreated with EPT* 
 28   Complete remission for 28 months after 2nd EPT* 
11 12   Local recurrence 9 months after EPT*, DD‡ 
12 6   Local control for 6 months, withdrew further follow up 
13 4   Local recurrence 4 months after EPT*, DD‡ 
14  6  Local recurrence 2 months after EPT*, DD‡ 
         
¥, Patient still alive at end of study timepoint. 
*EPT, Bleomycin-electroporation therapy. 
†DOD, Died of other disease. 
‡DD, Died of disease treated by bleomycin-electroporation therapy. 
 
 
Patient no. 2 presented with a recurrence of a squamous cell carcinoma of 25 mm 
of the auricle after treatment with cryotherapy and radiotherapy. The patient declined 
amputation of the ear, because his life expectancy was probably more importantly 
determined by a primary bronchial carcinoma, for which he was receiving palliative care. 
After 5 months a recurrent squamous cell carcinoma developed on the scalp, at the margin 
of the original treatment site. At the same time, the patient received additional palliative 
radiotherapy because of renewed symptoms related to the bronchial carcinoma. Since the 
small recurrence of the auricle carcinoma did not give the patient any burdensome 
symptoms, further treatment was declined in this case. Patient died of his bronchial 
carcinoma 15 months after treatment.  
Patient no. 4 received bleomycin-electroporation therapy because of a fourth 
primary T2N0 oral cavity carcinoma, located at the right upper buccogingival fold. Her 
history mentioned extensive treatment for an oral cavity carcinoma and two oropharyngeal 
carcinomas on the left and right hand side, 7, 4, and 4 years before, respectively. Surgery 
for the present tumor was no longer an option without significant loss of function and 
disfiguration, and radiotherapy could not be administered another time. One and two 
months after the procedure, the patient underwent an examination under general anesthesia, 
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with taking biopsies. No malignancy could be detected. Two years after bleomycin-
electroporation therapy, she died of a fifth and sixth primary tumor located at the 
oropharyngeal region. The study lesion was still in complete remission at the time of death.  
Patient no. 7 received bleomycin-electroporation therapy because of a T1 primary 
oral cavity squamous cell carcinoma, located at the right upper buccogingival fold. Her 
history mentioned neck dissection and radiotherapy because of a lymph node metastasis 
from an unknown primary tumor three years earlier. She declined surgery for the present 
tumor because of significant loss of function and disfiguration. Biopsies taken after 
treatment showed no residual disease. However, a local recurrence was detected eight 
months after bleomycin-electroporation therapy, for which she underwent 
hemimaxillectomy. She died of a local recurrence nine months after this procedure (figure 
1).  
 Patient no. 9 was treated because of a T2N0 tonsillar carcinoma of 30 mm after 
extensive treatment because of squamous cell carcinoma of the oropharynx and oral cavity, 
10 years and 4 years before, respectively, for which she underwent local surgery, neck 
dissection, and radiotherapy. No curative treatment options were available. Local tumor 
control was reached during 32 months, but she developed a bilateral lymph node metastasis 
located in the axillar region one year after treatment and a neck metastasis in the neck 32 
months after treatment. Local resection of the metastases was performed, leading to 
complete remission for >18 months for the axilla and 4 months for the neck. She died of an 
infection three years after bleomycin-electroporation therapy. 
 Typical in patients who had already been treated with radiotherapy were the 
wound healing problems in areas without a substantial muscular tissue layer. Surrounding 
areas that had been subjected to irradiation appeared to be much more sensitive for 
bleomycin-electroporation therapy than areas that had not underwent irradiation, and 
delayed wound healing was often detected. 
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Discussion 
 
Despite the fact that all patients were heavily pre-treated with conventional therapies, our 
first results using bleomycin-electroporation therapy are encouraging. In all cases functions 
were preserved successfully and the treatment yielded no cosmetic impairments. The 
burden to the patient was not experienced as being severe. A recurrence occurred in one of 
the first tumors with a squamous cell carcinoma of the chest treated with bleomycin-
electroporation therapy, in patient no. 1. Another recurrence occurred in a patient with a 
recurrent carcinoma of the auricle in patient no. 2. Good results have been achieved with 
the treatment of melanomas during prior studies with large series (up to 223 patients), in 
which bleomycin was injected either intralesionally or intravenously (6-8), only one patient 
with melanoma in our study showed a response (patient no. 12), while in the other 
melanoma patient (patient no. 5) malignant cells still could be detected eight weeks after 
treatment. One patient (patient no. 10) developed a recurrence of a squamous cell 
carcinoma of the skin occipitally six months after treatment. A second bleomycin-
electroporation therapy was performed, leading to complete remission for 28 months. The 
last two patients treated in our study developed recurrences two and four months after 
treatment (patients no. 13 and 14, respectively). These patients had already underwent such 
heavy treatments earlier that no treatment with bleomycin-electroporation could be given 
another time due to wound healing problems after first bleomycin-electroporation 
treatment. One patient (patient no. 8), who was also suffering from low grade non-Hodgkin 
lymphoma, died of pulmonary infection two weeks after treatment. 
In the cases where recurrences were detected, the indication for bleomycin-
electroporation can be reason for discussion. In retrospect, the benefits for some patients 
might be marginal. Anyhow, the burden to the patients was minimal. In our opinion, care 
should therefore be taken in regions that already have been subjected to extensive 
radiotherapy, especially if no substantial muscular tissue layer is located between the 
treated lesion and vital structures beneath the treated lesion. 
In vitro electroporation therapy studies have shown bleomycin to be one of the 
most effective anti-tumor agents (9,10). These studies indicate that bleomycin-
electroporation leads to a 300- to 700-fold increase of cell death compared with bleomycin 
alone. Belehradek et al. have also demonstrated the in vivo anti-tumor activity of 
bleomycin-electroporation therapy in tumor-bearing animals (11). Electroporation therapy 
without bleomycin had no effect on tumor tissue. No seeding of tumor cells via needle-
electrodes was detected in these models and the treatment around arteries did not cause any 
problems either. In addition, it was shown that in both laboratory animals and patients, only 
minute amounts of bleomycin entered the bloodstream with this treatment, which means 
that the systemic exposure to the cytostatic drug is minimal (12). The total potential 
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exposure of bleomycin infiltrated intralesionally (max. 80 IU) must not exceed the systemic 
treatment intravenous dose for bleomycin. Furthermore, the dose of 1 IU/cm3 of tissue 
bleomycin 4 IU/ml results in minimal systemic exposure. 
 Bleomycin is a cytostatic drug that causes DNA damage. Once intracellularly 
present, the bleomycin binds with the DNA and causes ruptures in the DNA strings, 
followed by cell death. A cell is most sensitive to bleomycin during the G2- and M- phases 
of the cell cycle. Normal cells (that are normally in the G1- or S- phases of the cell cycle) 
are much less sensitive to bleomycin, so this therapy can be applied with ample margins, 
without damaging surrounding tissues (13). Seminomas, malignant lymphomas, uterine 
cervix carcinomas and squamous cell carcinomas of the head and neck area are the most 
sensitive to bleomycin (6,14). Radiotherapy also leeds to DNA damage, this might be the 
reason for normal tissues to be more sensitive for bleomycin-electroporation therapy after 
extensive radiotherapy (15). 
The clinical strength of bleomycin-electroporation therapy as an additional option 
to existing anti-tumor therapies was first demonstrated by Reintgen et al. (16) and Glass et 
al. (17). Later studies with patients with, for instance, basal cell carcinoma and metastasized 
melanoma have shown the occurrence of a selective tumor effect with this technique, 
sparing healthy tissue (6,13,18-22). In total, 84 patients with head and neck cancer were 
treated in these trials (64 patients in stages III and IV of the disease, and 20 in stages I and 
II), which amounted to the treatment of a total of 99 tumors. Of the patients in advanced 
stages of the disease, 59% responded, while 22% showed complete remission. Patients in 
early stages of the disease showed a response rate of 100%, of whom 84% were in complete 
remission. The most important and most frequently occurring side effect (in 78% of the 
cases) was localized pain at the treatment site. Adverse reactions such as necrosis, edema, 
and erythema were frequently seen (14-47%). Bleeding was a less often occurring side 
effect (10%). A recent phase II study in advanced stage head and neck carcinoma with 54 
patients with 69 tumors showed 25% complete response and 32% partial response. Several 
patients were hospitalized for localized pain at the treatment site. Adverse reactions such as 
cellulitis and infection were reported in 14%. Bleeding was a less often occurring side 
effect (12%) (23).  
In conclusion, bleomycin-electroporation therapy is an easy to perform treatment 
that causes little burden to the patient and is potentially effective in selected patients with 
head and neck or skin tumors. In our opinion, it must be considered as a valuable addition 
to our treatment armamentarium for a highly selected, difficult to treat, patient group. Care 
should be taken when treating regions that already underwent full dose radiotherapy. In our 
institution, electroporation therapy was only used to deliver cytotoxic drugs to the tumor. 
We do not have experience with other indications to use electroporation therapy, for 
instance for the introduction of DNA or other molecules into cells. In the future, this might 
open new avenues for selective targeting of cancer. 
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Abstract 
 
Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary 
efficacy of bivatuzumab mertansine. Bivatuzumab is a humanized monoclonal antibody 
directed against CD44v6, which previously seemed to be safe in phase I 
radioimmunotherapy trials, whereas the conjugated mertansine is a potent maytansine 
derivative.  
Experimental Design: Patients with incurable squamous cell carcinoma of the head 
and neck or esophagus were eligible. Bivatuzumab was given weekly for 3 consecutive 
weeks by i.v. infusion. One patient was planned to be treated at each dose tier as long as 
toxicity did not reach grade 2; otherwise, three patients had to be treated until dose-limiting 
toxicity occurred. Starting dose was 20 mg/m2, and dose was subsequently escalated in 
steps of 20 mg/m2. Patients without disease progression and not experiencing dose-limiting 
toxicity were eligible for repeated courses. Blood serum samples were taken throughout the 
treatment period to determine the pharmacokinetic properties of bivatuzumab mertansine 
and to assess the human anti-bivatuzumab mertansine antibody response.  
Results: Seven patients received a total of 23 weekly doses of bivatuzumab 
mertansine. One patient at the 100 mg/m2 and one at the 120 mg/m2 level experienced stable 
disease during treatment phase, but also developed grade 1 skin toxicity (desquamation). 
One of them received a second treatment course. At the highest dose level achieved in this 
study (140 mg/m2), one patient developed toxic epidermal necrolysis after two infusions 
and died. Massive apoptosis of skin keratinocytes had occurred, while only symptomatic 
therapy for skin toxicity was available. The risk-benefit assessment of all patients treated in 
the total phase I program (4 clinical trials, 70 patients) turned out to be negative after 
consideration of this case of a toxic epidermal necrolysis and the skin-related adverse 
events observed in the other trials. Therefore, development of the conjugate was 
discontinued. Interindividual variability in pharmacokinetic parameters was low and 
exposure to bivatuzumab mertansine increased proportionally with dose. No anti-
bivatuzumab mertansine reactions were observed. 
Conclusion: The main toxicity of bivatuzumab mertansine was directed against the 
skin, most probably due to CD44v6 expression in this tissue. The majority of skin reactions 
was reversible; however, one fatal drug-related adverse event had occurred. Clinical 
development was discontinued before reaching maximum tolerated dose. 
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Introduction 
 
Squamous cell carcinoma, the predominant histologic type among tumors of the head and 
neck, accounts for ~5% of all malignant tumors in Europe and the United States. In 2000, 
an estimated 551,100 new cases of head and neck squamous cell carcinoma of the oral 
cavity, pharynx, or larynx were diagnosed worldwide (1). Early stages (stage I/II) of head 
and neck squamous cell carcinoma generally have a good prognosis after surgery or 
radiotherapy. Unfortunately, prognosis is much worse for advanced stage disease (stage 
III/IV), which is diagnosed in about two-thirds of all head and neck squamous cell 
carcinoma patients. Despite improvements in locoregional treatment modalities, the rate of 
locoregional recurrence is still close to 40%, whereas ~25% of these patients develop 
distant metastases. Autopsy studies have shown incidences of distant metastases in up to 
57% (2-5). It is plausible that many advanced stage head and neck squamous cell carcinoma 
patients harbor residual tumor cells after surgery and radiotherapy. The role of adjuvant 
chemotherapy for this group of patients is limited, and therefore the development of an 
effective adjuvant systemic treatment is a major challenge. 
The incidence of esophageal cancer amounts to 13,000 new cases in the United 
States alone with >12,000 cancer related deaths per year (6). The majority of patients is 
diagnosed with locally advanced disease with median survival rates of 12 to 14 months, or 
with metastatic disease with survival rates of <12 months. Systemic therapy in this disease 
has modest activity, and new treatment modalities are urgently needed in this disease as 
well. 
Selective targeting of head and neck squamous cell carcinoma by use of 
monoclonal antibodies (mAbs) might contribute to a more effective treatment of advanced 
stage disease. Previous efforts of our group focused on the development of 
radioimmunoconjugates for radioimmunotherapy, because head and neck squamous cell 
carcinoma is relatively radiosensitive. In our selection of a suitable target antigen for head 
and neck squamous cell carcinoma, the E48 antigen (7,8) and CD44 splice variants 
containing the v6 domain (CD44v6) seemed to be the most promising thus far.  
In the past decade, encouraging progress was obtained with the development of 
CD44v6-directed radioimmunotherapy in head and neck squamous cell carcinoma. For this 
purpose, the chimeric mAb U36 (cmAb U36) and the humanized mAb BIWA 4 
(bivatuzumab), both directed against CD44v6, have been evaluated (9,10). Although not a 
primary objective, phase I dose escalation radioimmunotherapy studies with 186Re-labeled-
cmAb U36 and 186Re-labeled-bivatuzumab, showed promising antitumor effects with 
consistent stable disease at higher radioactivity dose levels (11-13). The only toxicity 
observed in the radioimmunotherapy studies was myelotoxicity caused by circulating 
radioimmunoconjugate and, in some patients, mild oral mucositis. In these studies, 
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bivatuzumab seemed to have low immunogenicity. Binding of these mAbs to the target 
antigen resulted in internalization of the antibody (14). 
Based on aforementioned promising clinical results, we hypothesized that coupling 
of a nonradioactive cytotoxic drug to bivatuzumab instead of radionuclides might provide 
us with a second promising option for adjuvant therapy in head and neck cancer. From such 
conjugate no bone marrow toxicity has to be expected, and therefore perspectives might 
arise for combined treatment with conventional chemotherapeutics. Besides, omission of 
radioactivity will solve several issues related to logistics and radiation safety. Therefore, we 
decided to start the development and clinical evaluation of bivatuzumab mertansine. 
Bivatuzumab mertansine is a tumor-activated prodrug conjugate, which consists of 
the cytotoxic mertansine covalently linked to bivatuzumab. After binding to CD44v6, the 
complex can be internalized, and the mertansine molecules will be released intracellularly 
by cleavage of the antibody-mertansine disulfide bonds. The origin of mertansine and the 
clinical evaluation of a first mertansine-antibody conjugate have recently been described by 
Tolcher et al. (15) and Helft et al. (16). Mertansine [N2-deacetyl-N2-(3-mercapto-1-
oxopropyl)-maytansineC35H48CIN3O10S] is a derivative of the antimicrotubule agent 
maytansine, and has a 100- to 1,000-fold higher cytotoxic potency than other clinically used 
anticancer drugs such as taxanes or anthracyclines (17,18). On intracellular delivery and 
release, mertansine inhibits tubulin polymerisation, thereby disrupting microtubule 
assembly (19,20); as a result mitotic arrest and tumor cell death occur. A phase I trial with 
cantuzumab mertansine (huC242-DM1), 235 mg/m2 given i.v. once every 3 weeks in 
patients with solid malignancy, showed minor responses in chemotherapy-refractory 
patients without severe toxic effects (15). 
In the phase I trial presented herein, bivatuzumab mertansine was given weekly for 
3 weeks as an i.v. infusion to patients with incurable carcinoma of the head and neck or 
esophagus. The principal objectives of the study were to assess the safety, maximum 
tolerated dose (MTD), and preliminary efficacy and to determine the pharmacokinetics and 
immunogenicity of bivatuzumab mertansine. Patients without disease progression and not 
experiencing dose limiting toxicity (DLT), were eligible for repeated courses. 
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Patients and methods 
 
Patient selection 
This was a phase I study with an accelerated dose titration. The study was approved by the 
Institutional Review Board of the VU University Medical Center (Amsterdam, The 
Netherlands)  and written informed consent was required from all patients.  
Patients with histologically confirmed squamous cell carcinoma of the head and 
neck or esophagus with local and/or regional recurrent disease or distant metastases who 
were refractory to or not amenable to established treatments were eligible for participation 
in this study. Other eligibility criteria included clinically or radiologically (by computed 
tomography, magnetic resonance imaging, or ultrasound) evaluable tumor deposits, age at 
least 18 years, life expectancy of at least 3 months, an Eastern Cooperative Oncology 
Group performance score ≤2, and without prior chemotherapy, radiotherapy, or 
immunotherapy within the past 4 weeks, brain metastases requiring therapy, known 
secondary malignancy requiring therapy, active infectious disease, neuropathy grade ≥2 or 
concomitant non-oncological diseases that could interfere with the evaluation of the safety 
of the trial drug. Expression of CD44v6 was assessed by immunohistochemistry on archival 
tumor samples, but this was not done before patient entry in the study, as >95% of the 
squamous carcinomas of the head and neck and esophagus are known to show 
homogeneous expression of the antigen (10). 
Patients were required to have adequate organ function defined as an absolute 
neutrophil count of at least 1,500/mm3, platelet count of at least 100,000/mm3, bilirubin ≤26 
µmol/l, serum creatinine ≤132 µmol/l, and aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase ≤3 times the upper limit of normal. Pregnant and 
lactating women were excluded from participation in the study, and all patients with 
reproductive potential were required to use an effective contraceptive method if they were 
sexually active.  
 
Bivatuzumab, bivatuzumab mertansine, and CD44v6 
Bivatuzumab (BIWA 4), an immunoglobulin G1 (IgG1) mAb against CD44v6, is the 
humanized version of BIWA 1, and was generated, produced, and characterized by 
Boehringer Ingelheim (Germany) as described previously (13). 
The CD44 protein family consists of isoforms, encoded by standard exons and up 
to nine alternatively spliced variant exons (v2-v10), which are expressed in a tissue-specific 
way and involved in physiological functions like signal transduction, growth factor binding, 
cell adhesion, and cell migration. Expression of v6-containing CD44 variants has been 
related to aggressive behavior of various tumor types and was shown to be particularly high 
and homogeneous on the outer cell surface of squamous cell carcinoma of the head and 
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neck, esophagus, lung, cervix, and vulva (21,22). Expression was also found in some 
normal tissues such as skin keratinocytes, squamous epithelium of the cervix, epithelium of 
the cornea, and epithelium of the tonsils. No evidence was found for variability of CD44v6 
expression between skin biopsies of different individuals. Immunohistochemical screening 
of a representative profile of normal human and cynomolgus monkey tissues revealed that 
CD44v6 expression was almost identical in man and monkey (23). Bivatuzumab does not 
cross-react with murine CD44v6. 
On the basis of aforementioned data, before starting the present clinical study with 
bivatuzumab mertansine, toxicity studies had been done with the same conjugate in 
cynomolgus monkeys (unpublished data). In one of the studies, animals (n = 3 per sex per 
group) had been treated by once weekly i.v. administration for 6 weeks followed by a 4-
week recovery period at doses of 0.5, 1.5, and 4 mg/kg. No mortality had occurred and 
none of the animals had to be sacrificed prematurely. Exfoliation of the skin was noted for 
males and females in all dose groups from day 8 of study. In the mid dose, exfoliation was 
predominantly located at the femoral region. In the high dose exfoliation progressed to 
scabs and was reported in the femoral regions, legs, arms, and chest. Pigmentation was seen 
at the injection site of all treated animals. Microscopically epidermal necrosis and 
epidermal hyperplasia as well as prominent melanin in the stratum basale, were noted. 
Body weight, food consumption, electrocardiogram, and blood pressure were 
unremarkable. Whereas no differences in hematology were noted between treated animals 
and controls, a lower percentage of neutrophils was detected in the bone marrow. The 
changes had returned to pretreatment values after end of recovery. Increase of aspartate 
aminotransferase and alanine aminotransferase by a factor two in the mid and high doses 
was not considered to be of biological significance. Ophthalmologic examination revealed 
increased pigmentation from week 3 onwards; however, no microscopical changes were 
observed in the eye. At the end of the recovery period, however, the intensity of 
pigmentation had decreased. Based on these findings and the safety assessment of the eye 
findings, the highest nonsevere toxic dose of bivatuzumab mertansine following once 
weekly administration to cynomolgus for 6 weeks was 4 mg/kg. This reflects an AUC0-∞ of 
2410 µg · h/ml and a Cmax of 105 µg/ml (at first dose). 
Treatment of mice bearing established A431 or FaDu human SCC xenografts with 
a single cycle of five daily i.v. doses of bivatuzumab mertansine resulted in dose-dependent 
anti-tumor efficacy with complete, long-lasting tumor regressions observed at well-
tolerated doses (2.1-21 mg/kg/d). The unconjugated antibody given at the highest dose level 
showed no effect on tumor growth. In the FaDu model, an alternative treatment schedule 
(once weekly for 4 weeks) was tested in addition and resulted in comparable antitumor 
efficacy (24). 
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Starting clinical studies was considered to be justified because toxicities were 
expected to be completely reversible, and the potential benefit of immunotherapy with 
bivatuzumab mertansine was anticipated to outweigh these risks. 
 
Study design 
Bivatuzumab mertansine was administered i.v. in 30 minutes as a weekly infusion for 3 
weeks at 7-day interval. The dose of bivatuzumab mertansine was fixed within one course 
of three infusions, starting at 20 mg/m2 body surface area (expressed as dose of 
immunoconjugate protein). Body surface area was calculated according to Du Bois and Du 
Bois (25). Doses were escalated in increments of 20 mg/m2. Patients were observed for 4 
weeks after first infusion to evaluate experiences of toxicities. The National Cancer 
Institute Common Toxicity Criteria, version 2, was used to grade toxicity. DLT was defined 
as drug-related grade 3 or 4 nonhematological toxicity (excluding nausea and/or vomiting) 
or drug related grade 4 neutropenia for ≥4 days and/or complicated by infection or drug-
related thrombocytopenia < 25,000/mm3. One patient was planned to be treated at each 
dose level as long as any drug-related toxicity did not exceed grade 1 during first course; 
otherwise three patients had to be treated until DLT occurred. When at the ongoing dose 
level one patient experienced DLT, the number of patients treated at that dose level had to 
be increased to a total of six. When no more patient experienced DLT, the dose was to be 
escalated to the next level. When two (or more) of six patients experienced DLT, three 
additional patients would be treated at one dose tier below unless six patients had already 
been treated at that dose tier. MTD was defined as the highest dose at which no more than 
one of six patients experienced DLT. Another 12 patients would be included at the MTD 
dose level after MTD had been established until 18 patients had been treated at MTD. 
Patients without disease progression and not experiencing DLT during the 4 weeks after 
start of treatment were eligible for a second course. This course had to be started at least 3 
weeks after the last infusion of the previous course.  
During the course of this study, another three dose escalation studies were being 
conducted with bivatuzumab mertansine in six other centers. One trial was conducted in 
advanced head and neck carcinoma with single infusion and two trials in metastatic or 
recurrent CD44v6-positive adenocarcinoma of the breast with either single infusion or three 
infusions once weekly.   
Bivatuzumab mertansine was supplied in 20-ml single-use vials by Boehringer 
Ingelheim (Biberach, Germany). Each vial contained protein at a concentration of 2.0 
mg/ml in PBS (pH 6.5) containing 0.02% Tween 20. The manufacturing process was 
designed to give a yield of 3.5 to 4 molecules of mertansine coupled per molecule of 
bivatuzumab on average. Free mertansine was detected at a concentration of 300 ng/mg 
(0.03%). The drug product was not prefiltered on instilling the dose volume into the 
infusion bag and was administered to patients through an inline 1.2-µm filter (B. Braun 
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AG, Melsungen, Germany) within 6 hours of preparation. After 30-minute infusion, the i.v. 
line was flushed with 100 ml of 0.9% NaCl fluid to ensure delivery of the full drug dose.  
 
Pretreatment and follow-up studies 
Before initiation of therapy, all patients had a history and general physical examination 
including ENT examination, vital signs, electrocardiogram and chest X-ray. Preclinical 
toxicity studies in cynomolgus monkeys had revealed a dose- and time-dependent increase 
in exfoliation of the skin. In addition, pigmentation of the skin of the eyelids, and 
pigmentation of sclerae and peripheral cornea was detected. Therefore, in this trial, besides 
a general physical examination, an ophthalmologic examination was done, which included 
slit lamp examination of sclera and cornea in mydriasis, assessment of the eyelids for 
reddening or dermal exfoliation of the skin, conjunctival mucosa ulcerations, blepharitis of 
the lid margins, madarosis of the lashes, visual acuity, intraocular pressure, inspection of 
the crystalline lens, and funduscopy in mydriasis. In addition, pigmentation of sclera and 
cornea was assessed. Several registered drugs cause pigmentation of the cornea without any 
effect on vision. Routine laboratory studies included full blood cell counts,  reticulocyte 
count, chemistries, and International Normalized Ratio/prothrombin time and partial 
thromboplastin time, and urine analysis. 
 Appropriate radiological studies for the evaluation of all measurable and 
evaluable sites of disease were done. Radiological studies for assessment of disease status 
were repeated after 4 weeks. Tumor response was assessed according to the Response 
Evaluation Criteria in Solid Tumors after each course (26). During the 4-week period of 
treatment, patients were observed for 24 hours after the first infusion and for 8 hours after 
second and third infusion. Blood samples for complete blood counts, chemistries, and 
coagulation variables were obtained just before the infusion (on days 1, 8, and 15), 48 hours 
after the infusion (on days 3, 10, and 17) and 1 week after the last infusion (day 22). On 
days 1, 3, 6, 8, 10, 13, 15, 17, 20, 22, and 24 an assessment of the clinical status of the 
patient was done. On day 29, at the end of trial visit, all pretreatment studies were repeated, 
including tumor staging and assessment.  
 
Immunohistochemical staining of tumor tissues 
Expression of CD44v6 in tumor samples was retrospectively assessed by 
immunohistochemistry. To this end, archival tumor biopsies of the patients, obtained at 
earlier presentation of the patient at the clinic, were stained for CD44v6 expression. 
Staining was done using the streptavidin-biotin-immunoperoxidase technique with the 
murine anti-CD44v6 mAb BIWA 1 (also designated VFF18, Bender Med Systems, Vienna, 
Austria) as primary antibody. Staining intensity for CD44v6 was scored positive [with the 
three gradings 1(+), 2(++), 3(+++)] or negative or not evaluable, while in case of positivity 
the percentage of positive cells was estimated. 
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Serum pharmacokinetic sampling and assays 
Serum samples for the determination of bivatuzumab mertansine and anti-CD44v6-IgG 
(which is the sum of intact bivatuzumab mertansine plus any IgG antibody recognizing 
CD44v6) were collected at the following time points: just before the start of each of the 
three infusions, at 35 minutes, 2 hours, 8 hours, 3 days, and 6 days after start of each of the 
three infusions. Additional samples were collected after the third infusion within a course at 
days 22, 24, and 29. In repeated courses a reduced sampling scheme was applied.  
Evaluation of the immunogenicity of the bivatuzumab mertansine conjugate was conducted 
by determination of human anti-bivatuzumab mertansine antibodies in serum samples taken 
before administration of bivatuzumab mertansine (screening visit), at all 3 infusion days 
before start of infusion and at end-of-trial visit (2 weeks after last administration). 
At each sampling time point, 6 ml of blood were drawn to obtain ~3 ml of serum 
for the determination of bivatuzumab mertansine, anti-CD44v6-IgG and human anti-
bivatuzumab mertansine antibodies. Serum concentrations of bivatuzumab mertansine, anti-
CD44v6-IgG, and anti-bivatuzumab mertansine antibodies were determined by fully 
validated ELISAs.  
Bivatuzumab mertansine ELISA. Intact bivatuzumab mertansine was quantified with a 
sandwich-type ELISA with the antigen glutathione S-transferase-CD44v6 immobilized on 
the microtiter plates and a selective, biotinylated, mouse monoclonal anti-mertansine 
detector antibody. Sandwich complexes formed were detected photometrically after 
incubation with streptavidin-peroxidase and a chromogenic substrate. The optimized 
ELISA enabled the accurate and precise measurement of the analyte in the range of 2 to 
100 ng/ml serum. The lower limit of quantification was ~13 pM. All samples were diluted 
by a factor of at least 1:100.  
Anti-CD44v6-IgG ELISA. The analyte, which is the sum of intact bivatuzumab mertansine 
plus any IgG antibody recognizing CD44v6, was quantified with a sandwich type ELISA 
with the antigen glutathione S-transferase-CD44v6 immobilized on the microtiter plates 
and an enzyme-labeled rabbit polyclonal anti-human IgG as detector antibody. Sandwich 
complexes formed were detected photometrically after incubation with a chromogenic 
substrate. The optimised ELISA enabled the accurate and precise measurement of the 
analyte in the range of 100 to 4,000 ng anti-CD44v6-IgG equivalents/ml serum. The lower 
limit of quantification was ~0.67 nM. All samples were diluted by a factor of at least 1:200.  
Deconjugated bivatuzumab mertansine concentrations (bivatuzumab without 
mertansine; however, the linker or parts of the linker might still be present) were calculated 
by subtracting the measured bivatuzumab mertansine concentrations from the respective 
measured anti-CD44v6-IgG concentrations. 
Anti-bivatuzumab mertansine antibody ELISA. The anti-bivatuzumab mertansine antibodies 
were detected using a selective ELISA of the double antigen or bridging type, essentially as 
described before (13). Due to a missing positive human anti-bivatuzumab mertansine 
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serum, which could have been used as standard, the validation of the present assay was 
done with polyclonal rabbit anti-bivatuzumab mertansine IgG antibodies that were purified 
from serum using protein A. This antibody fraction was only available in solutions with a 
concentration for the whole content of rabbit IgG, which was specific as well as unspecific 
for bivatuzumab mertansine. It is not possible to quantify the antibody concentrations 
absolutely in terms of antibody mass per volume. This assay only enabled the relative 
measurement of anti-bivatuzumab mertansine concentration in nanograms of reference 
antibody equivalents per milliliter. The range of measurement was 10 to 500 ng 
equivalents/ml after a 1:5 dilution of serum. The first value was also taken as cut-off value, 
(i.e., all sera ≥10 ng equivalents/ml indicated an anti-bivatuzumab mertansine immune 
response).  
 
Pharmacokinetic analysis 
The pharmacokinetic analysis of bivatuzumab mertansine and deconjugated bivatuzumab 
mertansine was carried out by noncompartmental analysis of the serum concentration-time 
data using the WinNonlin software program (Professional, version 4.1, Pharsight Corp., 
Mountain View, CA). Actual sampling times were used for the pharmacokinetic analysis. 
The following parameters were determined for each of the three administrations for each of 
the two substances: area under the serum concentration-time curve from 0 to 168 hours 
(AUC0-168), the maximum serum concentration (Cmax), the time to reach the maximum 
concentration (tmax), and the terminal half-life (t1/2). As pharmacokinetics of bivatuzumab 
mertansine were at steady state after the third administration, the variables are assigned a 
(ss) denoting steady-state. The parameters AUC0-168/τ,ss, Cmax(ss)  were dose normalized; τ 
stands for the 168-hour dosing interval. Clearance (CLss) and volume of distribution (Vss) at 
steady-state were in addition calculated for bivatuzumab mertansine. And for both 
substances, the accumulation index for AUC (RA,AUC) and Cmax (RA,Cmax) was determined. 
Individual Cmax(ss) and tmax(ss) values were determined directly from the serum concentration-
time profiles of each subject. The apparent terminal half-life was calculated by dividing ln2 
by the terminal rate constant [λz(ss)], which was estimated from a regression of ln(C) versus 
time over the terminal log-linear drug disposition portion of the concentration-time profiles. 
AUC0-168/τ,ss was calculated using the linear up/log down algorithm. The CLss was 
calculated by dividing the dose by AUCτ,ss. Vss was calculated by the product of CLss and 
mean residence time at steady state (MRTss), where MRTss was calculated according to the 
following equation: )5.0(
AUC
AUMC
MRT
,
ss ×−= T
ss
ss
τ
, where AUMCss is the area under the 
first moment curve at steady state and T is the duration of infusion. The accumulation 
indices were calculated by dividing the Cmax and AUC0-168 values after the third 
administration by the respective values after the first administration. 
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Table 1. Patient and tumor characteristics 
 
        
Characteristic    No. patients   
        
No. of patients    7 
Sex 
 Male     6 
 Female    1 
Age (y)  
Median    67 
 Range    50-73  
ECOG performance status 
 0    1 
 1    3 
2    3 
Prior therapy 
 Radiotherapy   1 
 Surgery and radiotherapy  4 
 Chemoradiation   1 
 Surgery and chemoradiation  1 
Tumor type 
 Oral cavity   1 
Larynx    1 
 Hypopharynx   2 
 Esophagus    2 
Nose    1 
        
Abbreviation: ECOG, Eastern Cooperative Oncology Group. 
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Results 
 
All patients were included between October 2003 and November 2004. The characteristics 
of the seven patients enrolled in the study are listed in Table 1, whereas the treatment data 
are shown by Table 2. Patients received a total of 23 weekly infusions of bivatuzumab 
mertansine at doses ranging from 20 to 140 mg/m2. The median number of weekly doses 
administered per patient was 3 (range, 2-6).  
Toxicity. No drug-related toxicity greater than grade 1 was observed during the 
first course of the first six dose levels. One patient in the 60 mg/m2 dose level group 
experienced a nondrug-related grade 2 skin infection due to tumor growth through the skin. 
Two patients experienced a grade 1 desquamation of the skin at the 100 and 120 mg/m2 
dose level group, respectively. In the first patient, desquamation started 6 days after first 
infusion and ended 34 days after third infusion, whereas in the second patient symptoms 
started 6 days after second infusion and ended 16 days after third infusion. Both patients 
with desquamation showed stable disease during treatment phase. After disappearance of 
skin toxicity, another course of three infusions was given to the patient in the 100 mg/m2 
dose level starting 37 days after third infusion in the first course. Again, a grade 1 toxicity 
(desquamation of the skin) was seen during this treatment phase starting  4 days after the 
first infusion of the second course. After one week (4 days after second infusion), this 
toxicity was classified as grade 2 (desquamation of the skin). Toxicity had totally 
disappeared without scars 18 days after the third infusion in the second course. After the 
second course progressive disease occurred. The patient treated in the 120 mg/m2 dose level 
did not receive another course due to treatment of radionecrosis of the mandible. 
 
 
Table 2. Dose levels of bivatuzumab mertansine administered 
           
Dose  No. patients BSA (m2)* Total no. doses          Cumulative  
(mg/m2/week)          administered  dose (mg)  
  
20 1   1.9 3 114 
40 1   1.9 3 228 
60 1   1.8 3 324 
80 1   1.8 3 432 
100 1   2.1 / 2.0† 3 + 3 630 + 600  
120 1   1.6 3 576 
140 1   1.7 2 476 
          
* BSA, Body surface area according to Du Bois and Du Bois. 
† Weight was decreased at start second course; BSA was recalculated. 
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The patient treated at the next dose level, 140 mg/m2, experienced a grade 1 skin 
toxicity (desquamation of the skin) 5 days after the first infusion. Three days after the 
second infusion this patient experienced a DLT: a grade 4 skin toxicity resulting in death 
(figure 1). At autopsy of this patient, gross inspection showed loss of epidermis on large 
parts of the body (back from shoulders to buttocks, groins, back of the right arm, and 
several small loci) and bullae on both malleoli (figure 2). Moreover, the skin of the whole 
body came off on touch (Nikolsky sign). Microscopy of both affected (next to the bullae on 
the ankles) and unaffected skin showed separation of the epidermis from the dermis with 
extensive apoptosis of keratinocytes in the basal and suprabasal layers. The skin toxicity 
observed was a toxic epidermal necrolysis, consisting of a full lysis of epidermis. The 
patient died within 2 days after start of symptoms. No other drugs had been administered 
which could have caused the toxic epidermal necrolysis.  
With respect to peripheral neuropathy and transaminases, no toxicities of 
biological significance as noted in the anti-MUC1-mertansine clinical studies were seen 
(15,16). No other toxicities were seen during the study. No critical ophthalmologic changes 
were detected.  
 
 
 
 
Figure 1. Desquamation of skin between buttocks. Photo was taken at start of symptoms 2 days after second 
injection of bivatuzumab mertansine 140 mg/m2 (patient no. 7).  
 
 
63 
Chapter 3  
 
 
Figure 2. Bulla on the ankle. Photo taken during autopsy, one week after second injection of bivatuzumab 
mertansine 140 mg/m2 (patient no. 7). Apoptosis of cells was observed both in affected and nonaffected skin. 
 
 
 
Figure 3. Individual ( —— ) and geometric mean ( ● ) serum concentration-time profiles of bivatuzumab 
mertansine during a 3-week once weekly infusion regimen, normalized to 1 mg/m². A, linear scale. B, semi-
log scale.  
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Figure 4. Individual (—— ) and geometric mean ( ● ) serum concentration-time profiles of deconjugated 
bivatuzumab mertansine during a 3-week once weekly infusion regimen, normalized to 1 mg/m². A, linear 
scale. B, semi-log scale. 
 
 
Pharmacokinetics. Figures 3 and 4 show the dose-normalized individual and 
geometric mean serum concentration-time profiles of bivatuzumab mertansine and 
deconjugated bivatuzumab mertansine, respectively. Bivatuzumab mertansine serum 
concentration-time profiles are almost superimposable after each of the three infusions, 
whereas the serum concentration-time profiles of deconjugated bivatuzumab mertansine 
after multiple dosing show accumulation. 
Descriptive statistics of (dose-normalized) pharmacokinetic variables for 
bivatuzumab mertansine and deconjugated bivatuzumab mertansine are shown in Tables 3 
and 4. The maximum serum concentrations were mainly reached at the end of infusion. The 
Cmax values indicate that bivatuzumab mertansine distributes initially into the plasma water; 
however, the values for VSS are slightly higher than the volume of the plasma water, 
suggesting later additional distribution into extravascular spaces. Clearance, volume of 
distribution at steady-state, and half-life were 1.51 ml/min, 5.25 l, and 69.1 hours, 
respectively. Individual dose-normalized AUC0-168 values show no dependency on dose.  
No significant accumulation of bivatuzumab mertansine took place during first and third 
administration as shown by the accumulation indices for Cmax and AUC of 0.99 and 1.07. 
Due to the long half-life of deconjugated bivatuzumab mertansine (152-183 hours), 
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accumulation was observed. Accumulation factors of 1.75 (Cmax) and 1.9 (AUC) were 
determined between the first and third injection.  
Interindividual variability in all pharmacokinetic variables of bivatuzumab 
mertansine and deconjugated bivatuzumab mertansine was relatively small. The 
pharmacokinetic variables/profiles of conjugated and deconjugated bivatuzumab 
mertansine of the patient in dose group 140 mg/m2 were similar to the pharmacokinetic 
variables/profiles observed in the other patients. 
CD44v6 expression, human anti-bivatuzumab mertansine response, and antitumor 
activity. From five of seven treated patients, archival tumor biopsies were available for 
immunohistochemical assessment of CD44v6 expression. From two patients no biopsies 
were available, because chemoradiation therapy had been done instead of surgery. All 
tested specimens, and 100% of the cells within the specimen, were strongly positive [+++] 
for CD44v6 expression. In none of the seven patients a human anti-bivatuzumab mertansine 
response was detected. Two patients at 100 and 120 mg/m2, respectively, experienced 
stable disease. The 100 mg/m2 dose group patient was treated because of a supraclavicular 
lymph node metastasis, which was refractory to radiotherapy. Patient had previously 
received surgery and radiotherapy because of a squamous cell carcinoma of the nose (ala 
nasi). After a first course of three infusions, there was stable disease. After another 
treatment of three infusions, tumor size increased. During this period, the patient developed 
grade 2 skin toxicity. The second patient with stable disease was treated because of a lung 
metastasis, which did not enlarge during treatment. Because of radionecrosis of the 
mandible, the patient did not receive an additional course of three infusions. During surgery 
of the mandible a few weeks later, a locoregional recurrence was detected at the primary 
tumor site. 
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Discussion 
 
The objective of the study was to determine the MTD of three weekly doses of 
bivatuzumab mertansine in patients with histologically confirmed squamous cell carcinoma 
of the head and neck or esophagus. A total of seven patients were treated at doses ranging 
from 20 to 140 mg/m2. The MTD could not be properly assessed due to the premature 
termination of this trial.  
   The reason for the premature termination was a fatal case of toxic epidermal 
necrolysis in a patient with squamous cell carcinoma of the esophagus. In view of similar, 
albeit less severe, unpredictable skin toxicities seen in parallel studies, a decision was taken 
to halt the development of this agent, and all studies were terminated. In the patient who 
died of toxicity, there were no signs of a spongiotic dermatitis. Immunofluoresence 
microscopy of the skin revealed no specific pattern. Immunofluoresence at the epidermal-
dermal junction was negative (IgG, IgA, IgM, C1q, C3, κ, λ), ruling out paraneoplastic 
bullous pemphigoid.  
 
 
Table 3. Descriptive statistics of noncompartmental pharmacokinetic variables of bivatuzumab mertansine 
after a 3-week once weekly infusion regimen (n = 7, week 1 and 2; n = 6, week 3) 
 
  AUC0-168* Cmax* tmax† t½ CLss Vss 
week  [(µg·h/ml)/ 
(mg/m2)] 
[(µg/ml)/ 
(mg/m2)] 
[h] [h] [ml/min] [l] 
1 gMean 19.9 0.568 0.75 42.1   
gCV (%) 16.3 13.2 0.75-2.08 4.45   
2 gMean 20.2 0.564 0.783 40.2   
gCV (%) 14.5 16.4 0.667-2.17 26.5   
3‡ gMean 20.4 0.559 0.875 69.1 1.51 5.25 
gCV (%) 18.9 17.8 0.75-2.75 14.7 21.5 15.0 
Abbreviations: gMean, geometric mean; gCV, geometric coefficient of variation 
*Dose normalized. 
†Median and range. 
‡Variables at steady-state (ss). 
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During preclinical toxicity studies in cynomolgus monkeys and during the course 
of this and parallel clinical trials, it became evident that the main toxicity of bivatuzumab 
mertansine was directed against the skin. This can be explained by the expression of 
CD44v6 on skin keratinocytes. Accumulation of administered anti-CD44v6 mAbs in the 
basal layers of the skin had been observed in previous studies (10). The majority of skin 
reactions in the present trial were mild to moderate and fully reversible. In the present 
study, two patients had received a higher total dose of bivatuzumab mertansine during their 
first course than the patient with fatal toxic epidermal necrolysis (Table 2), whereas skin 
toxicity for these patients did not exceed grade 1. In addition, in a parallel study with single 
infusion of bivatuzumab mertansine, head and neck cancer patients had received doses as 
high as 325 mg/m2 (27). Although two patients treated at this dose level experienced DLT, 
with some signs of epidermolysis, toxicity had been totally reversible. The previous dose 
level of 300 mg/m2 had well been tolerated. It is therefore difficult to predict when severe 
skin toxicity would occur and it does not seem to be strictly dose dependent. 
 
 
Table 4. Descriptive statistics of pharmacokinetic variables of deconjugated bivatuzumab mertansine after 
a 3-week once weekly infusion regimen (n = 7, week 1 and 2; n = 6, week 3) 
 
  AUC0-168* Cmax* tmax† t½ 
week  [(µg·h/ml)/ 
(mg/m2)] 
[(µg/ml)/ 
(mg/m2)] 
[h] [h] 
1 gMean 13.3 0.111 48.6 183 
gCV (%) 24.0 23.1 47.3-120 38.5 
2 gMean 20.8 0.166 47.5 166 
gCV (%) 21.2 19.1 6.03-73.3 32.1 
3‡ gMean 23.8 0.187 36 152 
gCV (%) 20.1 19.7 21.7-73.3 10.4 
*Dose normalized. 
†Median and range. 
‡Variables at steady-state (ss). 
 
 
In preclinical toxicity studies in cynomolgus monkeys, nonsevere dose-related 
reversible skin toxicity of bivatuzumab mertansine had been observed following weekly 
administration of 0.5, 1.5, and 4 mg/kg for 6 weeks. The 4 mg/kg dose resulted in a mean 
AUC0-∞ of 2,410 µg · h/ml and a mean Cmax of 105 µg/ml after the first dose. In the patients 
treated with 20 to 140 mg/m2, who received three instead of six administration, the AUC at 
steady state (AUCτ,ss) ranged from  464 to 2,600 µg · h/ml and the Cmax at steady state 
68 
 Phase I study with bivatuzumab mertansine 
(Cmax,ss) ranged from 12.8 to 69.5 µg/ml. According to these data, the starting dose of 20 
mg/m2 and dose escalation steps of 20 mg seem to be cautious also in retrospect. 
According to most recent insights, toxic epidermal necrolysis is considered to be a 
rare disorder characterized by extensive epidermal death, caused by an idiosyncratic drug 
reaction. The estimated annual incidence of toxic epidermal necrolysis is 1 to 2 per million 
population and the mortality rate is high (28). CTLs are involved in this reaction. 
Management of toxic epidermal necrolysis requires intensive care unit admission for 
extensive supportive care and protection of the exposed dermis and mucosal surfaces, 
respiratory care, and appropriate nutritional support with maintenance of strict 
normoglycaemia. All possible triggering drugs should be stopped. No specific treatment 
regimen has been described. Treatment with immunosuppressive drugs can be considered, 
although the risk of developing secondary infection will increase. Use of corticosteroids is 
not recommended. Plasmapheresis may have benefit, but the working mechanism is still 
unclear. Conflicting results with antiapoptotic measures have been reported. Whereas, in 
general, the pathogenesis of toxic epidermal necrolysis is not understood (28), one may 
assume that, in the present study, toxic epidermal necrolysis was caused by direct 
eradication of keratinocytes by mAb-targeted mertansine. A complicating factor in 
bivatuzumab mertansine-induced toxic epidermal necrolysis is the long circulating time of 
the conjugate, which made immediately stopping of the trigger impossible. 
In the present study, no indications were found for toxicity related to free 
mertansine as a result of deconjugation. Neural and gastrointestinal toxicities are the side 
effects of the unconjugated drug, as reported in the phase I and II studies performed in the 
1980s with maytansine in unconjugated form (29-32). Nevertheless, data presented in 
figure 4 suggest a slow but substantial deconjugation of bivatuzumab mertansine in the 
circulation. Substantial deconjugation was also previously observed with the cantuzumab 
mertansine conjugate, for which the same conjugation chemistry had been applied (15). In 
two patients of the latter study, also free mertansine plasma concentrations were measured 
with an ELISA of a protein-free extract of blood. Mertansine was detected in the plasma up 
to 48 hours following treatment, and at all time points the free mertansine represented <1% 
of the total circulating mertansine (antibody-conjugated mertansine plus free mertansine). 
These data indicate rapid elimination of free mertansine from the circulation on 
deconjugation.  
Expression of CD44v6 is probably not selective enough for tumor cells to allow 
safe antibody-based cancer therapy. This conclusion is probably reasonable for approaches 
in which supertoxic drugs like mertansine are used, but may not necessarily be the case for 
other approaches. Phase I dose escalation radioimmunotherapy studies with the anti-
CD44v6 conjugates 186Re-cmAb U36 and 186Re-bivatuzumab showed promising antitumor 
effects with consistent stable disease at the higher radioactivity dose levels (11-13). In one 
of these studies, transplantation of autologous blood progenitor cells was applied (11). This 
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procedure enabled the doubling of the MTD of 186Re-cmAb U36 and resulted in 
stabilization of disease in the majority of patients and in all patients treated at the MTD 
level. No skin toxicity was observed in these radioimmunotherapy studies, whereas just a 
small proportion of patients experienced mucositis. In general, mucositis was less severe 
than experienced by these patients during a previous course of external beam irradiation. 
Among others, two aspects make radioimmunotherapy fundamentally different from 
therapy with mAb-mertansine conjugates. First, radiation deposition with 186Re is relatively 
slow, due to the long half-life of 89 hours of this ß-emitting radionuclide. Second, whereas 
the energy and path length (5 mm) of the ß-emission of 186Re are ideal for irradiation of 
small-sized to medium-sized tumors (0.5-1 cm) (33), toxicity in the skin is just moderate 
due to the fact that a large part of the disintegration energy dissipates outside the 
distribution volume of this tissue (especially the basal cell layer). This explains diminished 
skin toxicity in case of radioimmunotherapy. As a corollary, radiation absorption will also 
be relatively small in small tumor cell clusters, and therefore radioimmunotherapy with 
186Re-labeled anti-CD44v6 mAbs will most probably not be effective as single-modality 
adjuvant. 
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Abstract 
 
The extra domain B of fibronectin (ED-B) is a marker of tumor angiogenesis. The human 
monoclonal antibody (mAb) L19-SIP (~80 kDa; SIP is “small immunoprotein”) has been 
selected for targeting of ED-B. The aim of this study was to evaluate the potential of 
radioimmunotherapy (RIT) with L19-SIP, either alone or in combination with cetuximab, 
for treatment of head and neck squamous cell carcinoma (HNSCC). Combination with 
cetuximab was considered because this anti-EGFR (epidermal growth factor receptor) mAb 
has proven value for th treatment of HNSCC. 
HNSCC xenograft lines FaDu and HNX-OE were evaluated for ED-B and EGFR 
expression. L19-SIP was radiolabeled with two candidate radionuclides for RIT, 177Lu and 
131I (or 125I as substitute). The biodistribution of coinjected 177Lu-L19-SIP and 125I-L19-SIP 
was assessed in FaDu bearing nude mice, while 131I-L19-SIP was evaluated in both 
xenograft lines. After labeling with high dose 131I (623-789 MBq/mg), the maximum 
tolerated dose (MTD) was assessed. The efficacy of RIT with injected 131I-L19-SIP, either 
alone or in combination with unlabeled cetuximab (1 mg two times a week intraperitoneally 
for 4 wk), was evaluated in both xenograft lines. 
Xenograft lines expressed both antigens, with similar EGFR expression and the 
highest ED-B expression in FaDu. Radioiodinated L19-SIP performed better than 177Lu-
L19-SIP and was further exploited. The biodistribution of 131I-L19-SIP was most favorable 
in FaDu-bearing mice with tumor uptake values at 24, 48 and 72 h after injection of 8.6 ± 
1.6, 5.8 ± 0.4 and 3.4 ± 0.2 %ID/g (%ID/g is percentage injected dose per gram of tissue), 
respectively, and ratios of tumor to normal tissues that gradually increased in time such as 
for blood from 4.4 ± 1.8 at 24 h to 21.4 ± 1.7 at 72 h, after injection. RIT at the MTD level 
of 74 MBq caused significant tumor growth delay and improved survival in both lines. 
Although FaDu was most sensitive for RIT, with size reduction of all tumors, HNX-OE 
was most sensitive for treatment with cetuximab. The best survival and cure rates were 
obtained, however, when RIT and cetuximab were combined. 
RIT with 131I-L19-SIP appeared efficacious in HNSCC xenografts. The efficacy of 
RIT was enhanced by combination with cetuximab, without increase of toxicity. 
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Introduction 
 
Angiogenesis is one of the hallmarks of cancer and, therefore, considerable efforts have 
been invested in the discovery of agents that block this process. One approach aims at the 
neutralization of growth factors and other angiogenic mediators involved in endothelial cell 
migration and proliferation. The potential of this approach is best exemplified by studies 
aiming at the neutralization of vascular endothelial growth factor (VEGF) activity, either by 
capturing the growth factor itself or by blockage of its receptor (1,2). The neutralizing 
humanized anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin; Genentech) has 
recently been approved for use in combination with 5-fluorouracil-based chemotherapy as a 
first-line treatment for metastatic colorectal cancer (3). A potential hurdle in approaches 
aiming at the neutralization of one critical proangiogenic factor is that other redundant 
proangiogenic factors may compensate for the one that is inhibited. 
 Another appealing therapeutic approach is the targeted destruction of established 
tumor vasculature – for example, by mAbs directed against markers of angiogenesis (1,2). 
An interesting candidate target for this approach is the extra domain B (ED-B) of 
fibronectin (FN). FN is an extracellular matrix component that is widely expressed in a 
variety of normal tissues and body fluids. Different FN isoforms can be generated by 
alternative splicing, a process modulated by cytokines and extracellular pH (4). The ED-B-
containing isoform of FN is immunohistochemically undetectable in normal adult tissue, 
with the exception of tissues undergoing physiological remodeling (e.g. endometrium and 
ovary) and during wound healing (4). Furthermore, it has been demonstrated that ED-B is a 
marker of tumor angiogenesis (5). ED-B is highly conserved in different species, having 
100% homology in all mammalians thus far studied (human, rat, mouse). 
 Recently a human recombinant scFv fragment directed against ED-B, designated 
L19, has been developed (6). Using its variable regions, several other L19 formats were 
constructed, including dimeric scFv ((scFv)2), a human bivalent “small immunoprotein” 
(SIP), and a complete human IgG1 (7). Biodistribution studies with these constructs in 
tumor-bearing nude mice demonstrated selective tumor targeting, with best performance of 
L19-SIP (7). L19-SIP also appeared to be the most favorable mAb format in preliminary 
radioimmunotherapy (RIT) studies, when labeled with 131I (8). Additional animal studies 
with these MAb constructs confirmed the capacity of L19 for targeting of neovasculature 
and causing tumor infarction (9,10). 
 Radiolabeled L19-(scFv)2 was also evaluated in clinical radioimmunoscintigraphy 
studies (11). The conjugate showed selective localization in tumor lesions in aggressive 
types of colorectal and lung cancer and appeared able to distinguish between quiescent and 
actively growing lesions. Also extensive immunohistochemical evaluation of ED-B 
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expression in head and neck tissue biopsies has shown a relationship with aggressiveness 
(12).  
 Motivated by the promising results, we decided to explore L19-SIP also for RIT of 
squamous cell carcinoma of the head and neck (HNSCC). We had investigated the 
perspectives of RIT for treatment of HNSCC in the past because of the sensitivity of this 
tumor type for radiation. Using the radiolabeled mAb U36 or BIWA4, both directed against 
the target antigen CD44v6, promising antitumor effects had been observed in phase I dose 
escalation RIT trials of patients with inoperable HNSCC (13,14). We hypothesized that 
ED-B might be even a better target for RIT of HNSCC. In comparison with CD44v6, which 
also shows high expression in some normal tissues such as skin and oral mucosa, ED-B 
expression seems much more restricted to tumors. In addition, it can be expected that the 
stromal target ED-B is better accessible for mAbs than the tumor cell target CD44v6, 
especially because of the compact structure of HNSCC.  
As a future outlook for RIT of head and neck cancer, we previously proposed the 
combination with inhibitors of the epidermal growth factor receptor (EGFR). Indeed, the 
efficacy of RIT with radiolabeled mAb U36 in HNSCC xenograft-bearing nude mice was 
strongly enhanced, when treatment was combined with an unlabeled anti-EGFR mAb (15). 
The rationale for such combination is (a) EGFR shows a high expression in 80-100% of the 
head and neck tumors and plays a key role in their malignant behavior (16,17), (b) 
inhibition of EGFR results in radiosensitization (18), and (c) RIT and anti-EGFR therapy 
show complementary toxicity profiles. Because inhibition of EGFR was also shown to 
result in anti-angiogenic effects such as decrease of VEGF synthesis (19), combining L19 
RIT with anti-EGFR therapy might be particularly attractive. 
 In the present study, 2 HNSCC xenograft lines with representative ED-B 
expression were selected for tumortargeting studies with radiolabeled L19-SIP. L19-SIP 
was radiolabeled with 2 candidate radionuclides for RIT, the residualizing radionuclide 
177Lu and the non-residualizing radionuclide 131I (for one experiment 125I was used as a 
substitute). The biodistribution of both conjugates was evaluated and compared in nude 
mice bearing the HNSCC xenograft lines. Finally, the therapeutic efficacy of RIT with 131I-
L19-SIP, either alone or in combination with the anti-EGFR mAb cetuximab, was 
evaluated in the same HNSCC xenograft lines. 
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Materials and methods 
 
mAb, xenograft lines, and radioactivity  
Antibody L19-SIP (0.3-0.5 mg/ml), directed against the ED-B domain of FN, was obtained 
from the Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, 
Zurich, Switzerland. Selection, construction, and production of L19-SIP (∼ 80 kDa) have 
been described previously (6,7). A schematic drawing of its molecular structure was 
provided by Berndorff et al. (8). mAb cetuximab (C225/Erbitux; 2 mg/ml) was obtained 
from Merck. Cetuximab is a mouse-human chimeric anti-EGFR mAb that binds with high 
affinity to the receptor, blocks ligand-induced activation of receptor tyrosine kinase, and 
induces dimerization and downregulation of EGFR (20). The human HNSCC cell lines 
FaDu and HNX-OE have been described earlier (21,22). The HNX-OE line has been 
developed at our own institute (21), whereas the FaDu line was obtained from Karl-Heinz 
Heider (Boehringer Ingelheim Austria). 
131I (7.4 GBq/ml) and 125I (3.7 GBq/ml) were purchased from Amersham 
Biosciences, whereas 177Lu (725 GBq/mg) was obtained from Perkin-Elmer.  
 
Immunohistochemical staining of HNSCC xenografts 
The 2 HNSCC xenograft lines FaDu and HNX-OE were characterized for ED-B and EGFR 
expression by performing immunohistochemistry with L19-SIP and cetuximab, 
respectively. Cryostat sections (5-µm thick) were air dried and fixed in cold aceton for 10 
min at –20°C.  
For immunohistochemical staining of ED-B, biotinylated L19-SIP was used in the 
first step, whereas the Dako ChemMate Detection Kit (streptavidin-alkaline 
phosphatase/red; DakoCytomation) was used for color development. In short, after fixation 
the sections were incubated in Tris buffer (50 mmol/l, pH 7.2) with 2% bovine serum 
albumin (BSA) for blocking for 30 min, followed by incubation with biotinylated antibody 
L19-SIP for 1 h at room temperature (RT). After extensive washing with the Tris buffer, 
sections were incubated with the ChemMate Detection Kit according to instructions 
provided by the supplier. After washing with demineralized water (demiwater), 
hematoxylin Gill III (Merck), 1:3 in water, was used as a counterstain followed by 
mounting in Kaisers glycerol gelatin (Merck). For immunohistochemical staining of EGFR, 
cetuximab was used as the primary antibody followed by horseradish peroxidase (HRP)-
labeled rabbit antihuman IgG (Dako). After fixation in 2% paraformaldehyde, sections were 
blocked with 2% BSA in phosphate-buffered saline (PBS) for 20 min at RT. Sections were 
incubated with cetuximab (10 µg/ml) for 1 h at RT. After extensive washing with PBS, 
sections were incubated with rabbit antihuman IgG HRP (1:100) for 1 h at RT. After 
washing with PBS (3 times for 5 min), sections were incubated for 5 min with 
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diaminobenzidine (1 mg/ml, 1:10) in PBS with 10 µl H2O2 for color development, followed 
by washing with demiwater and mounting in Kaisers glycerol gelatin. Staining intensity 
was evaluated semi-quantitatively. 
 
Radiolabeling for biodistribution experiments 
Preparation of 125I-L19-SIP and 131I-L19-SIP. Iodination of L19-SIP with either 125I or 131I 
was performed essentially as described previously (23). To a 20-ml ß-scintillation glass vial 
coated with 75 µg IODO-GEN (1,3,4,6-tetrachloro-3α,6α-diphenyl-glycouril; Pierce 
Biotechnology), 50 µl Na2HPO4 (0.5 mol/l, pH 7.4), 72-150 µg L19-SIP in 450 µl Na2HPO4 
(0.1 mol/l, pH 6.8) and 6.7-11.1 MBq 125I or 131I were added successively for a reaction of 4 
min. Purification of radiolabeled L19-SIP was performed as described previously (23).  
     Preparation of 177Lu-L19-SIP. Antibody L19-SIP was conjugated under strict metal-free 
conditions with p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (p-SCN-Bz-DOTA; Macrocyclics), essentially as described by Perk et al. (24). For 
conjugation, 125 µl p-SCN-Bz-DOTA (1.6 mg/ml in NaHCO3, 0.1 mol/l; pH 9.0) and 875 
µl (0.438 mg) of L19-SIP were incubated for 30 min at 37oC, pH 9.0. Approximately 1 p-
SCN-Bz-DOTA moiety was coupled per L19-SIP molecule. L19-SIP-p-SCN-Bz-DOTA 
(150 µg) was labeled with 177Lu (18.5 MBq) in a total volume of 700 µl CH3COONH4 (0.25 
mol/l, pH 5.5). Purification of unlabeled and labeled L19-SIP-p-SCN-Bz-DOTA was 
performed as described previously (24).  
 
Radiolabeling for therapy experiments 
Preparation of 131I-L19-SIP for therapy was performed according to the so-called “IODO-
GEN-coated mAb method”, essentially as described previously (23). Three milliliters L19-
SIP (0.9-1.5 mg), 35 µl IODO-GEN/MeCN (1 mg/ml) and 131I (884-1,880 MBq) were used 
for labeling. This method was recommended as it minimizes chemical and radiation 
damage to the mAb, and allows the use of a large reaction volume (required because of the 
low concentration of L19-SIP available, 0.3-0.5 mg/ml). 
 
Analysis 
All conjugates were analyzed by instant thin-layer chromatography (ITLC) for 
radiochemical purity, by high-performance liquid chromatography (HPLC) and sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by phosphor 
imager analysis for integrity, and by an antigen-binding assay for immunoreactivity. ITLC 
analysis of radiolabeled L19-SIP was carried out on silica gel-impregnated glass fiber 
sheets (Gelman Sciences). As the mobile phase, citrate buffer (20 mmol/l, pH 5.0) was used 
for 131I- and 125I-labeled antibody. ITLC samples of 177Lu-labeled L19-SIP were first 
incubated for 5 min in a solution of ethylenediaminetetraacetic acid (50 mmol/l) and 
subsequently spotted on ITLC. As the mobile phase, 0.9% NaCl was used. HPLC analysis 
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of radiolabeled L19-SIP was performed as described previously (24). The integrity of the 
radioimmunoconjugates was monitored by electrophoresis on a Phastgel System 
(Amersham Biosciences) using preformed high-density SDS-PAGE gels under nonreducing 
conditions and analyzed on a phosphor imager. 
In vitro binding characteristics of radiolabeled L19-SIP were determined in an 
immunoreactivity assay essentially as described  previously (25), using ED-B-coated 
Sepharose resin in PBS/1% BSA. Five serial dilutions, ranging from 100 to 6.2 µl resin per 
tube, were prepared in triplicate in PBS/1% BSA. L19-SIP (125 ng) labeled with 125I, 131I or 
177Lu was added to the tubes and the samples were incubated overnight at 4°C for binding. 
Excess unlabeled L19-SIP antibody (10 µg per tube) was added to a second set of tubes 
with the lowest concentration of resin to determine nonspecific binding. Binding data were 
graphically analyzed in a modified Lineweaver-Burk plot, and the immunoreactive fraction 
was determined by linear extrapolation to conditions representing infinite antigen excess. 
 
Biodistribution of L19-SIP 
For the biodistribution experiments, female nude mice (Hsd athymic nu/nu, 25-32 g; Harlan 
CPB) bearing subcutaneously implanted HNSCC xenograft line FaDu or HNX-OE were 
used. All animal experiments were performed according to National Institutes of Health 
principles of laboratory animal care and Dutch national law (“Wet op de dierproeven”, Stb 
1985, 336).  
Three biodistribution studies were performed. Biodistribution of coinjected 125I-
L19-SIP (0.37 MBq) and 177Lu-L19-SIP (0.37 MBq) was assessed in FaDu-bearing nude 
mice (n = 20) in the first experiment. 125I was used instead of 131I, to facilitate dual isotope 
counting with 177Lu. Biodistribution of 131I-L19-SIP (0.37 MBq) in FaDu- and HNX-OE-
bearing nude mice (n = 12 each) was assessed in the second and third experiments, 
respectively. The tumor size at the start of the experiment was 83 ± 29, 73 ± 21, and 157 ± 
95 mm3 in experiment 1, 2, and 3, respectively. Mice received 10-16 µg L19-SIP in a total 
volume of 150 µl intravenously. At 3, 6, 24, 48, 72, and 144 h (experiment 1) or 24, 48, and 
72 h (experiments 2 and 3) after injection, groups of 3 or 4 mice containing 5-8 tumors 
were anaesthetized, bled, killed, and dissected. Blood, tumor, and organs were weighed, 
and the amount of radioactivity was counted in a γ-well counter. In the case of 125I and 
177Lu coinjection, dual-isotope counting was performed. Radioactivity uptake was 
calculated as the percentage of the injected dose per gram of tissue (%ID/g), corrected for 
radioactive decay.  
 
RIT with 131I-L19-SIP  
Three therapy experiments were performed using 131I-L19-SIP. The first therapy study was 
designed to assess the maximum tolerated dose (MTD) in FaDu-bearing nude mice. The 
MTD, corresponding to the highest dose at which weight loss did not exceed 20%, was 
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determined by monitoring the weight of FaDu-bearing nude mice injected intraperitoneally 
with diluent (0.9% NaCl) or increasing doses of 131I-L19-SIP. Injection volume was too 
large to allow intravenous administration. Groups of 5 mice containing 8-10 tumors with a 
mean volume of 148 ± 61 mm3 were treated with 37, 56 or 74 MBq 131I-L19-SIP (134-146 
µg). In the second and third experiments, FaDu- and HNX-OE-bearing nude mice were 
used, respectively, for studying the therapeutic efficacy of RIT alone and RIT in 
combination with cetuximab. Mice bearing 1 or 2 subcutaneous xenografts were treated at 
day 0 with a single intraperitoneal injection of 131I-L19-SIP (74 MBq, 110 µg) or cetuximab 
(1 mg given 2 times a week intraperitoneally for 4 wk, as in our previous study on 
combined RIT with anti-EGFR therapy) (15), or a combination of both. The mean tumor 
volume at the start of the experiment was 143 ± 85 (FaDu) and 172 ± 101 mm3 (HNX-OE). 
Treatment groups consisted 8 mice with a total of 12-16 tumors (FaDu) and 13-15 tumors 
per group (HNX-OE). 
 During treatment tumors were measured twice weekly for a planned period of 
three months and tumor volumes relative to the volume at the start of treatment were 
calculated. This period was extended for HNX-OE-bearing mice to 4 months. Toxicity was 
monitored by measurement of body weight twice weekly. Mice were sacrificed when 1 of 
the tumors exceeded 1,000 mm3. Average tumor volumes of the various groups were 
graphically depicted as long as at least 50% of the mice in a group were still alive.  
 An antitumor effect was also expressed as tumor growth delay. The tumor growth 
delay factor (GDF) was defined as the difference between the median values of the time 
required by tumors of treated and control animals to double their volume, divided by the 
median value of the time required by the tumors of the control mice to double their volume 
(26). Median instead of mean values were used because of the fact that sometimes tumors 
regressed completely. In addition, survival curves were constructed.  
 
Statistical analysis 
Differences in tissue uptake between coinjected conjugates were statistically analyzed for 
each time point with Excel 2000 software (Microsoft) using the Student t-test for paired 
data. Therapy experiments were analyzed using Excel 2000 software and SPSS 11.0 
software (SPSS). Differences in average tumor volume between the various groups were 
statistically analyzed for each time point with the Student t-test for unpaired data. Survival 
was calculated using Kaplan-Meier curves. Two-sided significance levels were calculated, 
and P < 0.05 was considered statistically significant.  
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Results 
 
Immunohistochemistry    
The HNSCC xenograft lines FaDu and HNX-OE both expressed the ED-B domain of FN as 
well as EGFR. ED-B expression was highest in FaDu, whereas EGFR expression was 
similar for both lines (figure 1).  
 
  
  
 
Figure 1. Immunohistochemical staining of the HNSCC xenograft lines FaDu (A and C) and HNX-OE (B 
and D) with biotinylated L19-SIP (A and B) and cetuximab (C and D) for assessment of ED-B (red staining) 
and EGFR (staining of cell membrane) expression, respectively. 
 
 
Radiolabeling  
Labeling of L19-SIP with 125I or 131I for biodistribution and therapy experiments resulted in 
overall labeling yields of > 70%. The radiochemical purity always exceeded 99%. Phosphor 
imager analysis of SDS-PAGE gels as well as HPLC analysis revealed optimal integrity of 
L19-SIP, irrespective of whether the mAb was labeled with a low or a high dose of 131I. The 
immunoreactivity of iodinated L19-SIP was always > 70% at the highest ED-B-resin 
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concentration and > 95% at infinite antigen excess. Labeling of L19-SIP-p-SCN-Bz-DOTA 
with 177Lu resulted in an overall labeling yield of 66%, whereas the results of quality tests 
were comparable with those obtained using iodinated L19-SIP. The specific activities of the 
conjugates prepared for the biodistribution studies were 56-62 MBq/mg for iodinated L19-
SIP and 73 MBq/mg for 177Lu-L19-SIP. The specific activities for the therapy studies with 
131I-L19-SIP studies were 623-789 MBq/mg. 
 
 
Figure 2. Biodistribution of intravenously coinjected 125I-L19-SIP (A) and 177Lu-L19-SIP (B) in FaDu 
xenograft-bearing nude mice at 3, 6, 24, 48, 72, and 144 h after injection. 
 
 
Biodistribution of L19-SIP 
For comparison of the biodistribution of 125I-L19-SIP (nonresidualizing radionuclide) with 
177Lu-L19-SIP (residualizing radionuclide) in tumor-bearing nude mice, both conjugates 
were coinjected. The average uptake in blood, tumor and normal tissues is shown in Figure 
2. Uptake of both radionuclides showed relatively small differences in blood, tumor, and 
most of the normal organs like tongue, sternum, heart, lung, bladder, muscle, colon and 
ileum. Large differences, however, were observed in kidney, liver, and spleen, with much 
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higher uptake of 177Lu than of 125I. On the basis of these results, we concluded that 
nonresidualizing radiolabels are better suited for RIT with L19-SIP than residualizing 
labels. Therefore, we decided to select 131I for RIT experiments with FaDu- and HNX-OE-
bearing nude mice. Before starting these experiments, tumor targeting with 131I-L19-SIP 
was first compared in these 2 xenograft models. Uptake of 131I-L19-SIP in FaDu tumors 
was higher than in HNX-OE tumors, with uptake values at 24, 48 and 72 h after injection of 
8.6 ± 1.6, 5.8 ± 0.4 and 3.4 ± 0.2 %ID/g, respectively, for FaDu and of 4.9 ± 1.1, 3.7 ± 0.7 
and 2.5 ± 0.5 %ID/g, respectively, for HNX-OE (figures 3 and 4). Also tumor-to-nontumor 
ratios were in general higher for the FaDu xenograft line (Table 1). For example, alhough 
the tumor-to-blood ratios gradually increased for the FaDu xenograft line from 4.4 ± 1.8 at 
24 h to 21.4 ± 1.7 at 72 h, for the HNX-OE xenograft line these values were 3.1 ± 1.2 and 
15.1 ± 1.5, respectively.  
 
AAAAA 
 
Figure 3. Biodistribution of intravenously injected 131I-L19-SIP in FaDu xenograft-bearing nude mice at 24, 
48, and 72 h after injection. 
 
 
 
Figure 4. Biodistribution of intravenously injected 131I-L19-SIP in HNX-OE xenograft-bearing nude mice at 
24, 48, and 72 h after injection. 
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Figure 5. Mean body weights of FaDu xenograft-bearing nude mice intraperitoneally injected with diluent 
or increasing doses of 131I-L19-SIP. Values are the mean of 5 mice. SDs have been omitted but were <5%. 
 
 
 
 
 
 
 
Figure 6. Mean tumor volume (A) and survival (B) of FaDu xenograft-bearing nude mice after 
intraperitoneal injection of 131I-L19-SIP (RIT) at day 0, cetuximab (1 mg given 2 times a week 
intraperitoneally for 4 wk), or both. SDs have been omitted for sake of clarity. 
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Figure 7. Mean tumor volume (A) and survival (B) of HNX-OE xenograft-bearing nude mice 
intraperitoneally injected with 131I-L19-SIP (RIT), cetuximab (1 mg given 2 times a week intraperitoneally 
for 4 wk), or both. SDs have been omitted for sake of clarity. 
 
 
Therapy of L19-SIP in FaDu- and HNX-OE-bearing nude mice 
The MTD was determined by monitoring the weight of FaDu-bearing nude mice injected 
with diluent or 37, 56, or 74 MBq of 131I-L19-SIP. A dose dependent weight loss was 
observed and the MTD was established at 74 MBq (figure 5). At this dose level weight 
recovered within 14 d, and no treatment related deaths were observed.  
The therapy experiments were set up to compare the efficacy of RIT with 131I-L19-
SIP in FaDu- and HNX-OE-bearing nude mice, either alone or in combination with twice-
weekly injections of cetuximab for 4 wk.  
FaDu tumors in the control group showed exponential growth with a mean tumor 
volume doubling time of 6 d (figure 6A). Treatment with 74 MBq 131I-L19-SIP caused a 
size reduction of all tumors with a maximum decrease of average tumor volume to 74 ± 
38% at day 18. At day 26, the tumors of this group had regrown to their initial volume. 
Thereafter tumors grew more-or-less exponentially. The combination of RIT (74 MBq) 
with cetuximab showed an enhanced efficacy in comparison to RIT or cetuximab treatment 
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alone, whereas toxicity was not increased (data not shown). Cetuximab treatment alone just 
slightly reduced the growth rate of FaDu tumors. When added to RIT, however, the size 
reduction started earlier (day 5) and the reduction was greater (50 ± 48% at day 26), 
whereas regrowth to the initial volume was later (day 35). The mean relative tumor volume 
in the RIT plus cetuximab treatment group was significantly smaller than in the RIT alone 
group from day 4 to day 42. GDF values for the different treatment groups were as follows: 
RIT, 4.8; cetuximab, 0.2; and RIT plus cetuximab, 7.3. At the end of the observation period 
(day 90), 1 out of 8 mice was still alive in the RIT group, whereas this value was 2 of 8 
mice in the RIT plus cetuximab group (figure 6B). 
RIT with a single injection of 131I-L19-SIP was also evaluated in the second 
xenograft line HNX-OE (figure 7). The mean control tumor volume doubling time of this 
line was 8 d. In comparison with FaDu, the HNX-OE xenograft line was less sensitive for 
RIT (no reduction of the mean tumor size) and more sensitive for cetuximab treatment. 
Also in this xenograft line, combined RIT plus cetuximab treatment showed the best 
therapeutic results without causing increased toxicity. Immediately after the start of 
combination treatment, the size of all tumors decreased, with a maximum decrease to 14% 
± 10% at day 62, whereas at the end of the observation period just 3 of 14 tumors had a size 
larger than their initial volume. Consequently, all mice were still alive at day 90. In 
contrast, cetuximab treatment alone resulted just in a minor reduction of the mean tumor 
size for a short duration, whereas just 50% of the mice were still alive at day 90. GDF 
values for the different treatment groups were as follows: RIT, 2.0; cetuximab, 8.5; and RIT 
plus cetuximab, 12.8. 
Because not all tumors had regrown in the combination treatment group, the 
observation period was extended by 30 d. Survival after 120 d following injection was 3 of 
8 for the group with cetuximab treatment alone and 5 of 8 for the RIT plus cetuximab 
treatment group. 
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Table 1. Tumor-to-tissue ratios (± SD) of intravenously injected 131I-L19-SIP in FaDu and HNX-OE 
xenograft-bearing nude mice at 24, 48, and 72 hours after injection. 
 
Timepoints 24  h 48h 72  h 
Xenograft FaDu HNX-OE FaDu HNX-OE FaDu HNX-OE 
Tumor-to-Tissue Ratios       
   T/Blood 4.4 (1.8) 3.1 (1.2) 7.4 (3.7) 6.3 (1.6) 21.4 (1.7) 15.1 (1.5) 
   T/Tongue 3.4 (1.2) 2.1 (0.6) 4.7 (1.7) 3.6 (1.1) 9.3 (0.9) 5.5 (1.6) 
   T/Sternum 9.1 (3.7) 8.2 (4.5) 9.2 (3.2) 8.3 (1.5) 16.7 (1.3) 14.1 (3.1) 
   T/Heart 8.1 (3.6) 6.0 (2.4) 12.6 (6.7) 11.5 (1.7) 31.0 (3.2) 22.7 (3.7) 
   T/Lung 3.4 (1.7) 2.8 (0.6) 5.0 (1.3) 4.7 (0.9) 10.1 (3.5) 9.9 (2.1) 
   T/Liver 14.9 (6.8) 10.7 (4.5) 20.0 (10.3) 18.1 (4.8) 50.6 (5.6) 38.4 (7.9) 
   T/Spleen 11.3 (5.7) 6.6 (2.0) 14.2 (7.5) 10.8 (1.8) 31.4 (1.2) 22.0 (5.1) 
   T/Kidney 5.6 (2.7) 3.9 (1.2) 7.5 (2.9) 7.2 (0.7) 20.2 (3.3) 14.2 (2.5) 
   T/Bladder 2.3 (1.1) 1.8 (0.2) 1.6 (0.5) 1.8 (0.5) 2.8 (0.5) 2.8 (0.5) 
   T/Muscle 17.9 (6.4) 11.9 (3.7) 23.3 (9.7) 22.4 (3.1) 68.1 (15.5) 47.5 (2.5) 
   T/Colon 4.0 (0.9) 2.6 (0.6) 3.9 (1.2) 2.7 (0.2) 4.4 (0.9) 4.6 (0.3) 
   T/Ileum 4.2 (1.3) 2.9 (0.6) 4.1 (1.2) 3.6 (0.4) 8.5 (5.4) 7.1 (1.8) 
   T/Stomach 2.6 (1.5) 1.7 (1.1) 2.9 (2.2) 3.1 (1.0) 8.8 (1.8) 6.3 (1.7) 
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Discussion 
 
In the present study, the potential of RIT with the anti-ED-B FN antibody L19-SIP was 
evaluated for treatment of HNSCC. To this end, nude mice bearing the HNSCC xenograft 
lines HNX-OE and FaDu were used as the model. Immunohistochemical evaluation of ED-
B expression in these xenograft lines revealed a more intensive staining for the FaDu line 
than for the HNX-OE line, whereas staining patterns were comparable with those 
previously observed for head and neck patient tumors in a study of Birchler et al. (12). 
They stained 53 malignant head and neck tumors, primary tumors as well as lymph node 
metastases, along with 8 benign tumors, 10 nontumoral lesions, and 11 normal tissues. A 
strong positive staining was observed with L19 in 87% of the malignant tumors, with 
abundant expression around the neovasculature and in the stroma. Expression in benign 
tumors and nontumoral lesions was just 38% and 20%, respectively, whereas ED-B was 
totally absent in normal control tissue samples. 
Two radionuclides were evaluated as candidates for RIT with L19-SIP, the 
nonresidualizing radionuclide 131I, and the residualizing radionuclide 177Lu. If a mAb 
becomes internalized after binding to the tumor, the use of residualizing radionuclides for 
RIT might be advantageous because of higher tumor-to-nontumor ratios (24). No evidence 
was found, however, for such an advantage in the case of L19-SIP. The biodistribution of 
coinjected 125I-L19-SIP (125I as substitute for 131I to facilitate counting) and 177Lu-L19-SIP 
in tumor-bearing nude mice showed just minor differences in uptake for tumor, blood, and 
most normal organs. In contrast, much higher uptake of 177Lu than that of 125I was found in 
organs of conjugate catabolism - kidney, liver, and spleen. On the basis of these results we 
decided to pursue using 131I for RIT. Berndorff et al. (8) came to the same conclusion in an 
article that was published while our manuscript was in preparation. They compared the 
biodistribution of 125I-L19-SIP and 111In-L19-SIP in nude mice bearing mouse embryonal 
teratocarcinoma F9 tumors. Though tumor uptake was equal with both radionuclides, 
tumor-to-nontumor ratios were lower for the residualizing 111In label. Dosimetric 
calculation using 125I and 111In as surrogates for the therapeutic radionuclides 131I and 90Y 
revealed the most favorable therapeutic index for 131I-L19-SIP. 
The MTD for single intraperitoneal administration of 131I-L19-SIP was assessed at 
74 MBq in FaDu-bearing mice. In our MTD study, weight loss was used as gross toxicity 
criterion. Berndorff et al. (8) found the same MTD value for 131I-L19-SIP, but they arrived 
at this value by a totally different approach. They performed dosimetric predictions using 
the biodistribution data of low-dose labeled 125I-L19-SIP in F9-bearing nude mice. For 
dosimetry they had to make several assumptions – for example, (a) uniform distribution of 
radioactivity within the organs, (b) organ shapes as spheres, and (c) linear interpolation 
within the organs. The properness of MTD prediction, however, was confirmed by studying 
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bone marrow toxicity after administration of 25-74 MBq 131I-L19-SIP to nontumor-bearing 
nude mice. Berndorff et al. also found a high 131I-L19-SIP uptake in uterus and ovaries (7.3 
± 1.8 and 3.1 ± 0.6 %ID/g at 24 h after injection, respectively; this was not determined in 
our study), which is consistent with known ED-B expression in these organs. Although they 
considered these reproductive organs not to be dose limiting, care should be taken when 
including fertile woman in clinical RIT trials with 131I-L19-SIP. For this purpose, 
performance of a scouting imaging procedure is recommended before 131I-RIT to confirm 
tumor targeting and to estimate radiation dose delivery to both tumor and normal tissues. 
The use of 124I-L19-SIP as the PET scouting agent in such approach might be particularly 
attractive (27). 
 RIT with 131I-L19-SIP caused a significant tumor growth delay and improved 
survival in both HNSCC xenograft lines. However, no cures were observed. Antitumor 
effects were more pronounced for the FaDu line than for the HNX-OE line, which might be 
related to the higher ED-B expression in this xenograft line (figure 1) and the 
accompanying higher tumor uptake of L19-SIP as observed in biodistribution experiments 
(figures 3 and 4). Treatment of FaDu-bearing nude mice with 74 MBq 131I-L19-SIP caused 
a size reduction of all tumors, whereas at day 26 the tumors had regrown to their initial 
volume. Antitumor effects in this human HNSCC xenograft line were more pronounced 
than previously observed for mouse embryonal teratocarcinoma F9 xenografts (8). 
Although tumor uptake values of L19-SIP were almost twice as high in the F9 xenograft 
model as in the FaDu model (i.e., 17.5, 16.7, 15.3, and 12.0 %ID/g at 3, 6, 24, and 48 h 
after injection, respectively), tumor growth was delayed for just about 10 d. Because 
murine F9 teratocarcinoma is a very aggressive tumor, it might be that the potential of 131I-
L19-SIP became underestimated in these previous RIT studies.  
 Several options can be explored to optimize the efficacy of RIT with 131I-L19-SIP, 
such as the application of RIT dose fractionation or repeated injections, or the combination 
with chemotherapy (28-30). Alternatively, RIT with 131I-L19-SIP can be used in 
combination treatment enabling simultaneous targeting of multiple critical tumor pathways. 
In HNSCC, angiogenesis has been linked with tumor progression and worse outcome, and 
it might represent a resistance mechanism to anti-EGFR agents (31,32). In this context it 
was interesting to combine 131I-L19-SIP with cetuximab treatment. Cetuximab was a logical 
anti-EGFR candidate as this mAb had shown improved locoregional control and survival in 
combination with radiotherapy in a phase III study in locally advanced inoperable HNSCC 
(33). Our results showed an enhanced efficacy when RIT with 131I-L19-SIP was combined 
with cetuximab treatment. Though the FaDu xenograft line was relatively sensitive for RIT 
and xenograft line HNX-OE was relatively sensitive for cetuximab, the best growth delay 
and survival rates were observed for both lines when treatment modalities were combined. 
Radiation response improvement by anti-EGFR treatment was also observed in previous 
RIT studies in HNSCC-bearing nude mice (15) as well as in clinical studies of external 
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beam irradiation of head and neck cancer (34). An additional advantage for the combination 
with an anti-EGFR mAb, in comparison with other agents studied in combination with RIT, 
such as cytostatic drugs, is the low toxicity of anti-EGFR mAbs. In the present study, the 
combination of RIT with cetuximab treatment did not result in increased toxicity. Also, in 
patients, an increase of RIT-induced dose-limiting toxicity - which is mainly bone marrow 
toxicity - is not expected, in view of the fact that expression of EGFR is absent in the bone 
marrow.  
                        RIT with 131I-L19-SIP in HNSCC 
Conclusion 
 
RIT with 131I-L19-SIP, a radioimmunoconjugate targeting the marker of tumor 
angiogenesis ED-B FN, caused a significant tumor growth delay and improved survival in 
nude mice bearing the HNSCC xenograft lines FaDu and HNX-OE. Antitumor effects were 
more pronounced for the FaDu line than for the HNX-OE line, which might be related to 
the higher ED-B expression in this xenograft line and the accompanying higher tumor 
uptake of L19-SIP as observed in biodistribution experiments. The efficacy of RIT was 
enhanced by combination with the anti-EGFR mAb cetuximab, without increase of toxicity. 
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Abstract 
 
Purpose: The human monoclonal antibody (mAb) fragment L19-SIP is directed against 
extra domain B (ED-B) of fibronectin, a marker of tumor angiogenesis. A clinical 
radioimmunotherapy (RIT) trial with 131I-L19-SIP was recently started. In the present 
study, after GMP production of 124I and efficient production of 124I-L19-SIP, we aimed to 
demonstrate the suitability of 124I-L19-SIP immuno-PET for imaging of angiogenesis at 
early-stage tumor development and as a scouting procedure prior to clinical 131I-L19-SIP 
RIT. 
Methods: 124I was produced in a GMP-compliant way via 124Te(p,n)124I reaction 
and using a TERIMO™ module for radioiodine separation. L19-SIP was radioiodinated by 
using a modified version of the IODO-GEN method. The biodistribution of coinjected 124I- 
and 131I-L19-SIP was compared in FaDu xenograft-bearing nude mice, while 124I PET 
images were obtained from mice with tumors of <50 to ~700 mm3.  
Results: 124I was produced highly pure with an average yield of 15.4 ± 0.5 
MBq/μAh, while separation yield was ~90% efficient with <0.5% loss of TeO2. Overall 
labeling efficiency, radiochemical purity and immunoreactive fraction were for 124I-L19-
SIP: ~80 , 99.9 and >90%, respectively. Tumor uptake was 7.3 ± 2.1, 10.8 ± 1.5, 7.8 ± 1.4, 
5.3 ± 0.6 and 3.1 ± 0.4 %ID/g at 3, 6, 24, 48 and 72 h p.i., resulting in increased tumor to 
blood ratios ranging from 6.0 at 24 h to 45.9 at 72 h p.i.. Fully concordant labeling and 
biodistributions results were obtained with 124I- and 131I-L19-SIP. Immuno-PET with 124I-
L19-SIP using a high-resolution research tomograph PET scanner revealed clear 
delineation of the tumors as small as 50 mm3, and no adverse uptake in other organs.  
Conclusions: 124I-mAb conjugates for clinical immuno-PET can be efficiently 
produced. Immuno-PET with 124I-L19-SIP appeared qualified for sensitive imaging of 
tumor neovasculature and for predicting 131I-L19-SIP biodistribution. 
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Introduction 
 
Angiogenesis is one of the hallmarks of cancer, and therefore, considerable efforts have 
been made recently to image as well as to eradicate tumor vasculature, preferably in a 
combined fashion (1,2). One of the appealing targets for both approaches is the splice 
variant of fibronectin containing extra domain B (ED-B). ED-B is abundantly expressed 
around the vasculature of a variety of human cancers, primary tumors as well as metastases 
(3-6). Interestingly, ED-B is undetectable in normal tissues, with the exception of tissues 
undergoing physiological modeling (e.g. endometrium and ovary) and during wound 
healing (3). This target is highly conserved in different species, having 100% homology in 
many mammalian species (e.g. human, rat, mouse), and therefore making proof of principle 
studies in tumor-bearing mice of special relevance (7). 
Recently, a human recombinant scFv fragment directed against ED-B, designated 
L19, was developed (8). Using its variable regions, several other L19 formats were 
constructed, including dimeric scFv [(scFv)2], a human bivalent “small immunoprotein” 
(SIP, ~80 kDa) and a complete human IgG1 (9). Radiolabeled L19 constructs have been 
evaluated in tumor bearing nude mice to identify the most appropriate conjugate for 
radioimmunotherapy (RIT) of solid tumors (9-12). To this end, the L19 derivatives were 
labeled with iodine-125 (125I) or indium-111 (111In) (10). The resulting biodistribution data 
were used to perform dosimetry for the corresponding therapeutic counterparts labeled with 
131I and yttrium-90 (90Y), respectively, and to select a conjugate for clinical RIT. The most 
favorable therapeutic index was found for 131I-L19-SIP, while this index was a poor one for 
90Y-labeled derivatives (10). RIT with 131I-L19-SIP at maximum tolerated dose caused 
significant tumor growth delay and improved survival in several animal models (10-12).  
On the basis of the aforementioned bright perspectives, a clinical RIT trial with 
131I-L19-SIP was designed (13). This trial comprises the selection of RIT candidate patients 
on the basis of pretherapy SPECT imaging and dosimetry. Rationales for this approach are 
the variable ED-B expression in tumors, with higher expression in the more aggressive 
ones, and the potential occurrence of ED-B expression in normal tissues.  
We and others recently proposed immuno-PET as a high-resolution quantitative 
imaging procedure before or concomitant with RIT to improve confirmation of tumor 
targeting and to assess radiation dose delivery to both tumors and normal tissues (14-16). 
Important in such approach is the choice of the positron emitting radionuclide to be used for 
radiolabeling. Among others, its physical half-life (t1/2) should be compatible with the time 
needed for a mAb to achieve optimal tumor to nontumor ratios, being >24 h for L19-SIP. In 
addition, when immuno-PET is used for selection of RIT candidates, the 
radioimmunoconjugates used for immuno-PET and RIT should demonstrate a similar 
biodistribution, and therefore, by preference, radionuclides with comparable in vivo 
99 
Chapter 5  
100 
behaviour must be used. The starting positron emitter solution should meet appropriate 
radiopharmaceutical quality standards when used for clinical purposes.  
The halogens 76Br (t1/2 = 16.2 h) and 124I (t1/2 = 4.18 d) are promising candidate 
positron emitters for L19-SIP immuno-PET in combination with 131I-L19-SIP RIT, 
however, availability of GMP-compliant material is a problem for both. Rossin et al. (17) 
recently described 76Br-L19-SIP for imaging of tumor neovasculature in xenograft-bearing 
nude mice. While tumor uptake of 76Br-L19-SIP was high, a disadvantage was the long 
retention of radioactivity in blood and the very slow renal excretion. As a consequence, the 
background activity in nontarget organs was higher than that reported for 125I-labeled-L19-
SIP, and this resulted in lower target to nontarget ratios. 
 Taking aforementioned aspects into account, we hypothesized that 124I-L19-SIP 
might be the most optimal candidate for immuno-PET imaging of tumor neovasculature, 
and for prediction of biodistribution and dosimetry of 131I-L19-SIP in RIT. Although the 
choice for 124I-L19-SIP immuno-PET seems logical, no such studies have been reported as 
yet, and several technical hurdles had to be taken to enable future clinical evaluation. For 
this purpose, and to facilitate the translation to clinical application, we developed the 
production and purification of 124I in a GMP-compliant setting, and its coupling to L19-SIP 
with the aid of IODO-GEN. With respect to the latter, procedures were established for 
efficient coupling of no-carrier-added 124I. 124I-L19-SIP was evaluated by comparison of 
biodistribution with 131I-L19-SIP upon coinjection in xenograft-bearing nude mice and by 
imaging of mice with tumors of < 50 to ~700 mm3 with a high-resolution research 
tomograph (HRRT) PET scanner. 
 Immuno-PET imaging with 124I-L19-SIP 
Materials and methods 
 
Monoclonal antibody, xenograft line, and radioactivity  
Antibody L19-SIP (conc. 1.23 mg/ml), directed against the ED-B domain of fibronectin, 
was obtained from Bayer Schering Pharma, Berlin, Germany. Selection, construction and 
production of L19-SIP (MW = ∼80 kDa) have been described previously (8,9). The mAb 
cetuximab (Erbitux® conc. 2.0 mg/ml) was used as reference for optimization of 124I 
labeling and was purchased from Merck, Darmstadt, Germany.  
The human head and neck squamous cell carcinoma (HNSCC) cell line FaDu has 
been described before (18), was obtained from KH Heider (Boehringer Ingelheim Austria), 
and has been characterized for ED-B expression (11). 
Iodine-131 (131I; 66.4 GBq/ml; specific activity 611 GBq/mg) was purchased from 
Perkin Elmer. 
 
124I Production and quality tests 
124I was produced at BV Cyclotron VU (Amsterdam, The Netherlands) via a 124Te(p,n)124I 
reaction and isolated by use of dry distillation essentially as described by Qaim et al. (19). 
In short, the target consisted of a glassy layer of 124TeO2 (enrichment of 99.8%; Isoflex, San 
Francisco, CA, USA) mixed with 5% (w/w) Al2O3. The physical thickness of the target was 
250 mg/cm2. A platinum (Pt) disc (Ø = 25 mm; thickness = 2 mm) containing a cavity (Ø = 
14 mm; depth = 1 mm) was used as backing. The target was loaded on an in house made 
solid target station installed on a IBA Cyclone 18/9 cyclotron and irradiated with 12.5 MeV 
protons using a beam current of up to 20 µA for 2-10 h. During irradiation, the target was 
cooled in front using helium cooling and at the back using water-cooling. A TERIMO 
module (Elex Commerce, Belgrade, Serbia) was used for radioiodine separation by dry 
distillation. Trapping of 124I was performed in 1 ml 50 mM NaOH. 
 Assessment of the radiochemical purity of the 124I preparations was performed by 
HPLC analysis, using a LiChrospher 100 RP-18 column (125 x 4 mm, 5 µm; Merck). As 
eluent 0.1 mol/l NaCl/0.004 mol/l octylamine (pH 7) + 5% (v/v) MeCN was used at a flow 
rate of 1.5 ml/min. The HPLC retention times were 1.5 min for IO3- and 5.0 min for I- (20). 
For identification and quantification of radionuclidic contaminants a germanium(lithium) 
[Ge(Li)] detector was used coupled to a multichannel analyzer (21). The tellurium content 
was assessed by a spectrophotometric method as described by Qui-e et al. (22). The 
endotoxin levels were assessed by use of an FDA-licensed LAL test system according to 
the instructions provided by the supplier (Endosafe®-PTS, Charles River, Charleston, SC, 
USA). Autoclaving was not performed but can be used as an option to assure sterility. 
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Radiolabeling 
Preparation of 124I-L19-SIP. Three sets of labeling experiments with L19-SIP were 
performed within the following general frame (23): 20 ml ß-scintillation glass vials were 
coated with 25 µg IODO-GEN (Pierce, Rockford, IL, USA) in dichloromethane, dried 
under a stream of N2 gas, resulting in a thin coating of IODO-GEN on the bottom surface of 
the vial. The vials were stored under N2 atmosphere. To a IODO-GEN-coated glass vial, 
successively 50 µl 0.5 M Na2HPO4 (pH 7.4), 450-X-Y µl 0.1 M Na2HPO4 (pH 6.8), X µl 
L19-SIP and Y µl radioiodine solution were added. After gentle shaking for 4 min at room 
temperature, 0.1 ml ascorbic acid (25 mg/ml, pH 5) was added to reduce the IODO-GEN 
and to protect the L19-SIP against radiation damage. After an additional 5 min, the reaction 
mixture was transferred to a syringe connected to a filter (0.22 µm Acrodisc, Gelman 
Sciences, Ann Arbor, MI, USA) followed by 0.4 ml 0.1 M Na2HPO4 (pH 6.8), used for an 
additional rinsing of the reaction vial. This combined solution was filtered and purified on a 
PD-10 column (GE Healthcare Life Sciences, Piscataway, NJ, USA) with 0.9% 
NaCl/ascorbic acid (5 mg/ml, pH 5) as eluent. The first 2.5 ml (1.0 ml sample volume and 
the first 1.5 ml) were discarded and the radiolabeled antibody was collected in the next 1.5 
ml.  
 In the first set, the 124I-labeling efficiency was optimized by varying the amount of 
NaI present during the reaction. In these experiments X was 82 µl (100 µg, 1.33 nmol) L19-
SIP, while Y was 50 µl of a series of pre-equilibrated (5 min) 124I/NaI mixtures, each 
containing 2.4 MBq 124I, and respectively, 6700, 1675, 838, 419, 209, 105, 52, 26 and 0 
pmol NaI. A similar series of labelings was performed with the control mAb cetuximab, for 
which X was 50 µl (100 µg, 0.66 nmol). It is of note that the 2.4 MBq 124I activity used in 
each reaction in the case of carrier-free 124I corresponds with 2.1 pmol iodine.  
In the second set, 124I-L19-SIP and 131I-L19-SIP were synthesized for a 
biodistribution study. The labeling was carried out with X = 163 µl (200 µg, 2.66 nmol) 
L19-SIP; Y was 83 µl 124I solution (14.8 MBq, 266 pmol NaI). For 131I, X was also 163 µl 
L19-SIP solution, and Y was 2 µl of a diluted 131I batch (14.8 MBq). No NaI carrier was 
added to this solution, because 14.8 MBq 131I already corresponds with 190.7 pmol 127I and 
61.4 pmol 131I.  
In the third set, 124I-L19-SIP was synthesized for PET studies. The labeling was 
carried out with X is 142 µl (175 µg, 2.33 nmol) L19-SIP; Y was 90 µl 124I solution (38.5 
MBq, 232 pmol NaI).  
 
Analyses 
All conjugates were analysed by instant thin-layer chromatography (ITLC) and HPLC, by 
SDS-polyacrylamide gel electrophoresis (PAGE) followed by phosphor imager analysis for 
integrity, and by a cell-binding assay for immunoreactivity. 
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HPLC monitoring of the final product was performed on a Jasco HPLC system 
using a Superdex™ 200 10/300 GL size exclusion column (GE Healthcare Life Sciences, 
Piscataway, NJ, USA). As eluent a mixture of 0.05 M sodium phosphate and 0.15 M 
sodium chloride (pH 6.8) was used at a flow rate of 0.5 ml/min. 
ITLC analysis of radiolabeled antibodies was carried out on silica gel-impregnated 
glass fibre sheets (Gelman Sciences, Ann Arbor, MI, USA). As mobile phase, 20 mM 
citrate buffer, pH 5.0 was used. The integrity of the radioimmunoconjugates was monitored 
by electrophoresis on a Phastgel System (Pharmacia Biotech, Piscataway, NJ, USA), using 
preformed high density SDS-PAGE gels under nonreducing conditions. Analysis and 
quantification of the radioactivity in the bands was performed with the use of Phosphor 
Imager screens and subsequent scanning by a Phosphor Imager (B&L-Isogen Service 
Laboratory, Amsterdam, The Netherlands). 
 In vitro binding characteristics of radiolabeled L19-SIP were determined in an 
immunoreactivity assay essentially as described before (11), using ED-B-coated Sepharose 
resin in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA). Five 
serial dilutions, ranging from 100 to 6.2 μl resin per tube, were prepared in triplicate in 
PBS/1% BSA. L19-SIP (125 ng), labeled with 124I or 131I, was added to the tubes and the 
samples were incubated overnight at 4oC for binding. Excess unlabeled L19-SIP antibody 
(10 μg per tube) was added to a second set of tubes with the lowest concentration of resin to 
determine non-specific binding. After incubation, resin was spun down and radioactivity in 
the pellet and supernatant was determined in a gamma counter and the percentage bound 
and free radioactivity was calculated. Binding data were graphically analysed in a modified 
Lineweaver-Burk plot and the immunoreactive fraction was determined by linear 
extrapolation to conditions representing infinite antigen excess.  
 
Biodistribution studies 
For the biodistribution experiments with L19-SIP, nude mice bearing the subcutaneously 
implanted HNSCC xenograft line FaDu were used. No control SIP constructs were included 
in the current evaluations, because previous studies had shown the specificity of L19-SIP 
for targeting of ED-B-expressing tumors in a direct comparison with the control D1.3-SIP 
directed against hen egg white lysosyme (9). Female mice (Hsd athymic nu/nu, 25-32 g; 
Harlan CPB) were 8-10 weeks old at the time of the experiments. Animal experiments were 
performed according to National Institutes of Health principles of laboratory animal care 
and Dutch National Law (Stb 1985, 336).  
At t = 0, FaDu-bearing nude mice (n = 20) received 25 µg of L19-SIP including 
0.37 MBq of 124I-labeled format and 0.37 MBq of 131I labeled format, by i.v. injection in the 
retro-orbital plexus. Two days before the experiments, 0.1% of potassium iodide was added 
to the drinking water to block thyroid uptake of 124I/131I. For assessment of biodistribution, 
four mice containing two tumors each were sacrificed at 3, 6, 24, 48, and 72 h after 
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injection. All animals were anaesthetized, bled, killed and dissected. Besides the tumors, 
the following organs were removed: tongue, sternum, heart, lung, liver, spleen, kidney, 
bladder, muscle, colon, ileum and stomach. Also stomach contents were retained. After 
blood, tumor, normal tissues, and stomach contents were weighed, the amount of 
radioactivity in each was counted in a gamma counter (Wallac LKB-CompuGamma 1282, 
Kabi Pharmacia, Woerden, The Netherlands), using the corresponding window settings for 
124I and 131I (for the 603 keV and 364 keV gamma energy, respectively). In this dual-isotope 
biodistribution study, cross-over corrections from one radionuclide into the alternate 
window were automatically performed using a standard of each radionuclide. Radioactivity 
uptake was calculated as the percentage of the injected dose per gram of tissue (%ID/g), 
corrected for radioactive decay.  
The mean tumor size of eight tumors at dissection was 234 ± 204, 384 ± 192, 273 
± 144, 371 ± 213, 315 ± 201 mm3 for the groups to be dissected at 3, 6, 24, 48 and 72 h 
after injection, respectively. 
 
PET imaging procedures 
Two animal PET studies for imaging of tumor targeting with 124I-L19-SIP were performed 
essentially as described by Verel et al. (21). During scanning mice were placed on a 
temperature controlled animal bed. In the first experiment, but not in the second 
experiment, 0.1% of potassium iodide was added to the drinking water to block thyroid 
uptake of 124I. PET studies were performed using a double crystal layer HRRT PET scanner 
(Siemens/CTI Knoxville, TN, USA), a dedicated small animal and human brain scanner 
(24) with a spatial resolution transaxial between 2.3 and 3.2 full-width at half-maximum 
(FWHM) and in axial direction between 2.5 and 3.4 FWHM. A detailed description of the 
performance of the scanner and the software is given by De Jong et al. (24). Transmission 
scans for attenuation and scatter correction were routinely obtained with each scan in two-
dimensional mode using a single point 137Cs source. Three-dimensional emission scans 
were acquired in 64-bit list mode during 60 min using a 400-650 keV window. The 64-bit 
list mode file was first converted into a single-frame sinogram using a span of 9, and 
subsequently reconstructed using a 3-D ANW-OSEM reconstruction with 2 iterations and 
16 subsets and matrix size 256 x 256 including corrections for normalization, decay and 
dead time. 3-D ANW-OSEM is a 3-D attenuation and normalization weighted ordered 
subset expectation maximalization reconstruction (25).  
 In a first PET imaging study, three FaDu xenograft-bearing nude mice were 
injected i.v. with 3.7 MBq 124I-L19-SIP (25 µg). The mean tumor size at the start of the 
experiment was 266 ± 158 mm3. During scanning at 1 and 2 days p.i., the animals were 
sedated using isoflurane. 
Because of clear tumor visualization in the first experiment, a second PET imaging 
experiment was performed to determine at which stage of tumor development tumors can 
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be readily imaged by 124I-L19-SIP immuno-PET. To this end, at 1, 2 and 3 weeks after 
subcutaneous tumor implantation, six mice were injected i.v. with 3.7 MBq 124I-L19-SIP 
(25 µg) and imaged 48 h after each injection. Before each PET imaging procedure, the size 
of the tumors was measured with callipers. Because of inaccurate measurement of tumor 
smaller than 50 mm3, size of these tumors was indicated to be < 50 mm3.  
 
Statistics 
Differences in tissue uptake between coinjected conjugates were statistically analyzed for 
each time point with Excel 2003 software (Microsoft) using Student’s t-test for paired data. 
Differences in average tumor volume between the various groups were statistically 
analyzed for each time point with Student’s t-test for unpaired data. Two-sided significance 
levels were calculated, and p < 0.01 was considered statistically significant.  
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Results 
 
GMP-compliant production of 124I.  
Production of 124I via 124Te(p,n)124I reaction at incident energy of 12.5 MeV resulted in an 
average target yield (n = 15) of 15.4 ± 0.5 MBq/μAh at the end of bombardment (EOB). 
During typical commercial runs, bombardment durations of 8 h at 18 µA resulted in a yield 
of 2.2 GBq 124I in-target. Subsequent dry distillation resulted in >90% recovery of 
radioiodine from the TeO2 target into the 50 mM NaOH solution, while less than 0.5% 
TeO2 was lost from the target. To allow for GMP-compliant harvesting of 124I, the TERIMO 
module was localized in a hot cell integrated in a clean room meeting GMP conditions 
(GMP grade C). Visual inspection of the final product always revealed a clear, colorless 
solution. The radiochemical purity as assessed by HPLC analysis was >99.6% 
(specification for release >95% as iodide). After storage for 11 days, the radiochemical 
purity was still greater than 99.5%. Three days after production (considered the time of 
application) the radionuclidic purity was 99.6 ± 0.06%, fulfilling the specification for 
release (>99.0%). The main radionuclidic contaminants were 123I (<0.5%) and 125I 
(<0.03%); other radionuclidic impurities, if any, were below detection limit. The tellurium 
content of the 124I-NaOH solution was 6 ± 1.6 ng/ml (specification for release <1 μg/ml). 
The endotoxin levels were <1.5 EU/ml (specification for release <5 EU/ml). 
 
Radiolabeling  
Despite being >99% in the iodide form, the overall labeling yield of L19-SIP with 124I 
produced in house was only at around 50%. This low labeling yield is inherent to the fact 
that 124I is carrier free, and not because the oxidative power of 25 μg vial-coated IODO-
GEN is insufficient (25 μg IODO-GEN = 57 nmol and corresponds to 228 nmol N-Cl 
groups). In the presence of the excessive amount of 6.7 nmol NaI the 124I labeling yield was 
96% upon using the same amount of L19-SIP (100 μg, 1.33 nmol) and the same amount (25 
μg vial-coated) IODO-GEN. For a study on the fine tuning of I/mAb molar ratios, the 
labeling of L19-SIP was evaluated in relation to the amount of NaI present during labeling. 
Figure 1 shows that in the presence of 200 pmol NaI or more, the labeling efficiency was 
85-95%. It is of note that the same data as shown in figure 1 were also obtained when 
cetuximab was used as a model substrate (data not shown). 
For the biodistribution study, the amount of NaI was selected in such a way that 
the I/mAb of the 124I product was the same as that of the 131I product. As a result, the I/mAb 
molar ratio of both resulting conjugates was about 1:10. For the subsequent 124I animal PET 
studies the same I/mAb molar ratio was created. The radiochemical purity of the injected 
products was 99.9% for 124I-L19-SIP as well as for 131I-L19-SIP. Phosphor imager analysis 
of SDS-PAGE gels as well as HPLC analysis revealed optimal integrity of the antibody. 
106 
 Immuno-PET imaging with 124I-L19-SIP 
The immunoreactivity of 124I-L19-SIP was 93.1 ± 4.2% at the highest resin concentration 
and 100% at infinite antigen excess (for 131I-L19-SIP these figures were 89.6 and 100%, 
respectively). 
 
 
 
 
Figure 1. Labeling of L19-SIP with 124I: labeling efficiency in relation to the amount of NaI carrier added. 
Labeling efficiency was assessed by ITLC. 
 
 
Biodistribution in tumor-bearing nude mice.  
For comparison of the biodistribution of 124I- and 131I-L19-SIP in tumor-bearing nude mice, 
both conjugates were coinjected. At 3, 6, 24, 48 and 72 h after injection, the average uptake 
(%ID/g, mean ± SEM) in tumor, blood, normal tissues, and gastrointestinal contents was 
determined, and shown in figure 2 for a selected panel of tissues. Blood values were similar 
for both conjugates at all time points, indicating that (1) radiolabeling had not differentially 
altered the pharmacokinetics of the antibody, and (2) serum stability was comparable for 
both conjugates. There was no significant difference in uptake of 124I and 131I in the 
majority of normal organs (differences indicated by asterisk in figure 2). 
Tumor uptake of 124I was 7.3 ± 2.1, 10.8 ± 1.5, 7.8 ± 1.4, 5.3 ± 0.6 and 3.1 ± 
0.4%ID/g tissue at 3, 6, 24, 48 and 72 h p.i.. In comparison, 131I levels at these time points 
were 7.3 ± 2.0, 10.4 ± 1.4, 7.4 ± 1.2, 5.0 ± 0.5 and 2.7 ± 0.4%ID/g, respectively. From 6 h 
p.i. onwards, 124I-L19-SIP uptake in tumors was higher than in any normal organ or tissue. 
During the same period, blood levels decreased from 14.0 ± 2.7%ID/g at 3 h after injection, 
to 0.08 ± 0.03%ID/g at 72 h after injection. This resulted in very favorable tumor to blood 
ratios at later time points ranging from 6.0 at 24 h p.i. to 45.9 at 72 h p.i. (Table 1). Also 
tumor to normal tissue ratios were relatively high from 24 h after injection onwards, for 
most organs exceeding the value 4 (Table 1). Rapid blood clearance during the first 24 h 
was accompanied by high radioactivity uptake in kidney, stomach, and stomach contents. 
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This is indicative of rapid renal excretion and catabolism of the conjugate with partial 
reabsorption of 124I metabolites, which can accumulate in the stomach and are released from 
the body via intestines and colon.  
 
 
 
 
Figure 2. Biodistribution of coinjected 124I-L19-SIP (0.37 MBq) (a) and 131I-L19-SIP (0.37 MBq) (b) in FaDu 
xenograft-bearing nude mice at 3, 6, 24, 48 and 72 h after intravenous injection. Significant differences in 
uptake of the conjugates are marked with an asterisk. Data are presented as average of four animals and 
standard deviation. 
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Table 1. Tumor to normal tissue ratios of coinjected 124I-L19-SIP and 131I-L19-SIP in FaDu xenograft-
bearing nude mice. 
 
Biodistribution 
time 
  3h   6h   24h   48h   72h 
Tumor to tissue ratios of 124I-L19-SIP        
  Blood  0.49  1.07  6.04  15.00  45.90 
  Tongue  1.11  1.69  4.14  5.84  14.76 
  Sternum  2.20  3.74  9.65  13.19  20.37 
  Heart  1.23  2.43  12.39  28.69  75.36 
  Lung  1.18  1.65  6.72  12.09  25.61 
  Liver  2.07  4.44  18.50  46.73  96.01 
  Spleen  1.80  3.37  11.48  27.95  53.25 
  Kidney  0.69  1.42  6.15  14.26  31.30 
  Bladder  1.80  1.96  1.83  3.72  9.99 
  Muscle  5.49  8.24  22.57  49.97  118.89 
  Colon  2.72  2.99  4.44  3.25  3.92 
  Ileum  1.58  2.71  4.90  5.85  4.80 
  Stomach  1.49  1.84  7.22  7.13  11.62 
  Stomach contents  1.23  1.98  15.83  9.86  24.92 
Tumor to tissue ratios of 131I-L19-SIP        
  Blood  0.48  1.00  5.45  13.54  43.44 
  Tongue  1.09  1.61  4.34  6.13  15.40 
  Sternum  2.12  3.39  9.24  12.54  20.49 
  Heart  1.20  2.23  11.39  27.44  59.17 
  Lung  1.17  1.55  6.31  11.52  22.06 
  Liver  2.08  4.16  16.92  41.59  81.63 
  Spleen  1.84  3.28  11.32  26.23  50.53 
  Kidney  0.68  1.30  5.50  12.06  27.88 
  Bladder  1.73  1.81  1.73  4.23  8.57 
  Muscle  5.26  7.60  21.65  45.77  103.17 
  Colon  2.66  2.78  4.25  3.31  5.27 
  Ileum  1.62  2.73  5.42  6.56  5.47 
  Stomach  1.41  1.73  7.01  7.32  12.67 
  Stomach contents  1.17  1.83  14.50  9.53  22.88 
                
Biodistribution assessed at 3, 6, 24, 48 and 72 h after intravenous injection. Data are presented as average of four 
animals. Data derived from figure 2. 
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PET imaging with 124I-L19-SIP in tumor-bearing nude mice.  
Immuno-PET with 124I-L19-SIP revealed clear delineation of the tumors at 24 h p.i. (figure 
3A). In addition, slight uptake was visible in the stomach region, as was previously 
observed in the biodistribution experiments (figure 2). Prominent uptake of radioactivity 
was also observed in the bladder region, and from this single scan it was not clear whether 
uptake was due to targeting of ED-B-expressing normal tissues by 124I-L19-SIP (e.g. 
endometrium and ovary), or due to excretion of 124I-containing catabolites via the urine. 
Later scans of the same tumor-bearing nude mice at 48 h p.i., however, showed only clear 
retention of 124I-L19-SIP in the tumors (figure 3B). This observation confirms that 
temporarily high levels of 124I in the stomach regions were related to the presence of 
catabolites of 124I-L19-SIP and/or free iodine. 
 
 
 
 
Figure 3. PET images of FaDu xenograft-bearing nude mouse injected with 124I-L19-SIP (3.7 MBq, 25 μg). 
Coronal images were acquired at 24 (a) and 48 h (b) after injection. Image planes have been chosen where 
both tumors were visible. Uptake of 124I in the stomach (arrow) and to some extend in bladder (urine) is 
visible at 24 h p.i., but has disappeared at 48 h p.i.. 
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Figure 4. Serial PET images of FaDu xenograft-bearing nude mouse injected with 124I-L19-SIP (3.7 MBq, 25 
μg). At 1 (a, d), 2 (b, e) and 3 (c, f) weeks after tumor implantation. 124I-L19-SIP was administered, and 48 h 
later coronal images were acquired. Image planes have been chosen where the left tumor (upper panel, a-c) 
or right tumor (lower panel, d-f,) is optimally visible. In contrast to figure 3, the thyroid (arrow) is visible 
because this organ was not blocked by potassium iodide in this experiment. 
 
 
 Since tumor size in the previous imaging experiment was relatively large, 266 ± 
158 mm3 at the time of conjugate injection, we examined how early after transplantation 
FaDu tumors can be visualized. To this end, at 1, 2 and 3 weeks after transplantation of the 
FaDu tumors a freshly produced 124I-L19-SIP sample was injected, and 48 h later an 
imaging procedure was performed. As illustrated by figure 4, tumor delineation was 
possible from 1 week after implantation onwards, when tumor size was still <50 mm3. 
 
Chapter 5  
Discussion 
 
Molecular imaging of tumor angiogenesis, one of the hallmarks of cancer, has clinical 
perspectives for lesion detection, patient stratification, new drug development and 
validation, treatment monitoring, and dose optimisation (26). To date, the application of 
PET for imaging of tumor vasculature has mostly exploited the use of radiolabeled RGD 
peptides for imaging of integrin αvβ3 expression, and radiolabeled peptides and mAbs for 
imaging VEGF/VEGFR expression (26). Most recently the antibody fragment L19-SIP, 
directed against the ED-B domain of fibronectin, was identified as another attractive 
candidate for imaging of tumor vasculature, particularly because of its high and prolonged 
uptake in angiogenic tumor vessels and limited uptake in non-target organs. These targeting 
characteristics make L19-SIP, when armed with toxic payloads, also a promising ligand for 
therapy. Radioimmunotherapy is among the most advanced therapeutic approaches in the 
clinical development of L19-SIP, and for this purpose the antibody fragment is radiolabeled 
with 131I (13). 
 After introduction of 131I- and 99mTc-labeled derivatives of L19 for SPECT 
imaging of tumor angiogenesis (27, 28), in 2007 the first PET imaging derivative of L19-
SIP was described: 76Br-L19-SIP (17). Besides clear tumor targeting, 76Br-L19-SIP also 
showed persistent activity in blood, stomach and several other normal organs, most 
probably due to in vivo debromination. The 76Br-L19-SIP conjugates used in these studies 
were slightly less stable and immunoreactive than corresponding 125I-L19-SIP conjugates, 
and appeared vulnerable for aggregate formation. The formation of free 76Br- due to 
catabolism, and its prolonged retention in blood, was also observed by Lövqvist et al., who 
compared the biodistribution of  the 76Br-38S1 and 125I-38S1 antibody conjugates in tumor-
bearing nude mice (29). The aforementioned studies revealed that 76Br cannot be used as a 
PET radionuclide substitute for iodine radioisotopes. Another limitation of 76Br is its 
limited availability, and the lack of supply of clinical grade 76Br. Limited availability of 
long-lived positron emitters for immuno-PET made us decide a few years ago to put effort 
into the large-scale GMP production of zirconium-89 (to be used for internalizing mAbs) 
and 124I (to be used for non-internalizing mAbs), and on the development of standardized 
and easy-to-use radiolabeling procedures to facilitate the broad scale use of immuno-PET in 
clinical trials (15). 
 In the present study, we aimed at the development of 124I-L19-SIP immuno-PET, 
not only for imaging of tumor angiogenesis, but also as a scouting procedure prior to 
clinical 131I-L19-SIP RIT, to confirm selective tumor targeting and to enable dosimetry. We 
considered 124I to be the most suitable positron emitter for these applications (see 
“Introduction” section), but realized that availability of clinical grade 124I would be a 
problem. The urgent need for this positron emitter also became clear from a survey 
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performed in 2005, in which the expectations of European researchers in terms of 
innovative radionuclides was evaluated (30). A questionnaire was sent to 134 nuclear 
medicine centres in Europe, and the 54 responding centres expressed the strongest interest 
in the availability of 124I. This made us decide to make the production of large batches of 
clinical grade 124I the starting point of the present studies. As demonstrated herein, 
infrastructure and procedures were developed for efficient GMP-compliant production of 
large batches of 124I (>2 GBq) at high radionuclidic (>99.0%) and radiochemical (>95% as 
iodide) purity and low tellurium (<1 μg/ml) and endotoxin (<1.5 EU/ml) content. 
Although labeling with radioiodine isotopes has been a widespread practice for 
decades, in several studies 124I-labeled compounds were damaged and obtained in low 
yields (31-34). Herein, L19-SIP was labeled with 124I according to a direct labeling method 
with the use of a low amount of the mild oxidant IODO-GEN, and taking the I/mAb molar 
ratio and interference of radiolytic processes into account to arrive at optimal quality 124I-
L19-SIP conjugates. As convincingly shown by figure 1, addition of NaI as carrier to the 
reaction mixture during 124I labeling, provides a means to increase the labeling yield with 
this precious isotope. This carrier approach was found to be generally applicable. Of 
course, caution should be taken when applying these procedures for mAbs containing an 
overabundance of tyrosines in the complementarity-determining regions (CDR), so when 
the I/mAb molar ratio may be the prime parameter for immunoreactivity (35). In that case, 
even single iodine incorporation on a tyrosine moiety in CDR might destroy the 
immunoreactivity of the mAb molecule owing to the bulkiness of the ion atom and/or 
change in pKa value of the tyrosine moiety (from 10.00 to 8.51). Therefore, in this study we 
decided to take the I/mAb ratio not higher than strictly necessary for obtaining high 
labeling yields and optimal immunoreactivity. However, when aiming the use of a 124I-mAb 
for scouting of a 131I-mAb conjugate in RIT, the I/mAb molar ratios of the conjugates can 
be easily synchronised, since this provides the best guarantee that the biodistribution of the 
therapeutic agent will be accurately predicted by the scouting agent. As another precaution 
to obtain optimal quality conjugates, immediately after radiolabeling ascorbic acid was 
added to the reaction mixture to reduce the IODO-GEN and to protect the L19-SIP against 
radiation damage. 
L19-SIP labeled with 124I according to the aforementioned procedures 
demonstrated optimal integrity and immunoreactivity, and exhibited the same 
pharmacokinetic behavior as the corresponding 131I conjugate. Moreover, biodistribution 
studies revealed high and selective tumor targeting, resulting in tumor to blood ratios 
ranging from 6.0 at 24 h to 45.9 at 72 h p.i.. Normal tissue accumulation of 124I-L19-SIP 
was significantly lower than previously reported for 76Br-L19-SIP. For example, while 
76Br-L19-SIP showed blood levels of 7.6 ± 1.8 and 8.1 ± 1.7%ID/g at 24 and 48 h p.i., 
respectively, for 124I-L19-SIP these values were 1.37 ± 0.43 and 0.37 ± 0.07, respectively. 
As a result, high tumor to normal tissue ratios were obtained with 124I-L19-SIP, resulting in 
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clear visualization of tumors by PET imaging, even when tumors were small (~50 mm3). 
These achievements will open new possibilities for 124I immuno-PET in general, and for 
PET imaging of tumor angiogenesis with 124I-L19-SIP in particular. 
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Abstract 
 
The ~15-kDa variable domains of camelid heavy-chain-only antibodies (called nanobodies) 
can easily be formatted as multivalent or multispecific single-chain proteins. Because of 
fast excretion, however, they are less suitable for therapy of cancer. In this study, we aimed 
for improved tumor targeting of a bivalent anti-epidermal growth factor receptor (EGFR) 
nanobody (αEGFR-αEGFR) by fusion to a nanobody unit binding to albumin (αAlb). 
Biodistributions of αEGFR-αEGFR, αEGFR-αEGFR-αAlb (~50 kDa), αTNF-αTNF-αAlb 
(control, binding tumor necrosis factor-α) and the ~150-kDa anti-EGFR antibody 
cetuximab were compared in A431 xenograft-bearing mice. The proteins were radiolabeled 
with 177Lu to facilitate quantification.  
 Tumor uptake of 177Lu-αEGFR-αEGFR decreased from 5.0 ± 1.4 to 1.1 ± 0.1 
%ID/g between 6 and 72 h after injection. Due to its rapid blood clearance, tumor-to-blood 
ratios >80 were obtained within 6 h after injection. Blood clearance became dramatically 
slower and tumor uptake became significantly higher by introduction of αAlb. Blood levels 
of αEGFR-αEGFR-αAlb were 21.2 ± 2.5, 11.9 ± 0.6, and 4.0 ± 1.4 and tumor levels were 
19.4 ± 5.5, 35.2 ± 7.5, and 28.0 ± 6.8 %ID/g at 6, 24, and 72 h after injection, respectively. 
Tumor uptake was at least as high as for cetuximab (15.5 ± 3.9, 27.1 ± 7.9, and 25.6 ± 6.1 
%ID/g) and significantly higher than for αTNF-αTNF-αAlb. αEGFR-αEGFR-αAlb showed 
faster and deeper tumor penetration than cetuximab. These data show that simple fusion of 
αEGFR and αAlb building blocks results in a bifunctional nanobody format, which seems 
more favorable for therapy as far as pharmacokinetics and tumor deposition are concerned.  
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Introduction 
 
During the last decade, monoclonal antibodies (mAbs) are gaining momentum in disease-
specific therapy. Presently, the U.S. Food and Drug Administration has approved 21 mAbs 
for therapy, mostly for the systemic treatment of cancer (1). Particularly attractive for 
treatment of solid tumors are cetuximab [Erbitux directed to epidermal growth factor 
receptor (EGFR), HER1], trastuzumab (Herceptin to HER2) and bevacizumab (Avastin to 
vascular endothelial growth factor) (2-4). These mAbs are aimed to completely 
neutralize/block growth factors or growth factor receptors, the key drivers of tumor growth 
and survival, for a prolonged period. Despite clinical enthusiasm, however, it is fair to state 
that efficacy of current mAbs is still quite limited, with benefit for just a portion of patients, 
whereas costs of mAb therapy are excessive (5). This conclusion comes with very recent 
insights that selective targeting of just one single tumor target might be insufficient for fully 
effective cancer treatment, a reason why also mixtures of mAbs are exploited in multitarget 
anticancer therapy (6,7). The rationale for this approach is that cancer cells have the 
inherent ability to use several growth factor (receptor) systems for growth advantage and 
survival (8).  
 All mAbs except one that have been approved until now are intact mAbs. This is 
remarkable, because these large-sized molecules (~150 kDa) are considered to have limited 
capacity for tumor penetration (9). For this reason, much effort has been put in the 
evaluation of mAb fragments, but without convincing therapeutic success to date (10). 
Although production of such fragments is not always straightforward and can result in 
diminished affinity, the main in vivo limitation of antibody fragments is their rapid blood 
clearance and the associated low tumor uptake. Especially molecules smaller than 60 to 70 
kDa are generally filtered out by the kidneys very rapidly, and are therefore not well 
qualified for long-term blockage of the growth factor receptor. 
 In the present study, we considered whether nanobodies could deal with the 
aforementioned limitations of conventional mAbs. Nanobodies are derived from a unique 
antibody format that is present in species from the family of Camelidae, including llama, 
camel, and dromedary. These animals contain, next to their conventional antibody 
repertory, an antibody class consisting of heavy chains only (11). Consequently, the 
variable region of the heavy chain from these “heavy-chain-only” antibodies (VHH) 
represents the complete binding unit of the antibody. Considering the small size of the 
VHH fragments (~15 kDa), this binding unit is also called nanobody. A nanobody is 
smaller than a single-chain Fv fragment, because it lacks both the light chain and the linker, 
whereas it has a similar affinity as variable regions of conventional mAbs. In addition, it 
does not show aggregations problems like single-chain Fv, because of hydrophilic instead 
of hydrophobic patches in the VH and VL domains. Due to their single domain character, 
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standard molecular biology techniques such as PCR allow for easy selection of appropriate 
nanobody candidates from the full antibody repertory of immunized animals (12). 
Nanobodies show a high solubility and a good capacity to refold after denaturation while 
retaining their binding capacity (13,14). Particularly attractive is the flexibility of drug 
formatting whereby it is straightforward to generate multivalent and/or multispecific single-
molecule formats and to produce these formats in bacteria and yeast (13,15). The relatively 
small size of the gene (~360 nucleotides) permits the fusion and expression as separate 
building blocks into proteins as dimers (~35 kDa), trimers (~50 kDa), or multimers. Initial 
biodistribution studies with monospecific bivalent antitumor nanobodies in tumor-bearing 
mice showed, as expected, rapid blood clearance and low tumor uptake (16). Therefore, 
mono-specific nanobodies do not seem qualified for long-term blockage of growth factor 
receptors.  
 Very recently, Dennis et al. showed the possibility of using noncovalent albumin 
association as an elegant means to improve the pharmacokinetic properties of otherwise 
short-lived molecules (17,18). For their studies, they used a F(ab) fragment of Herceptin, to 
which an albumin-binding peptide was fused, for imaging (18). We hypothesized that 
noncovalent interaction with albumin might be particularly attractive in nanobody 
applications to improve their pharmacokinetics and tumor-targeting properties for therapy. 
To test this possibility, a single chain nanobody was constructed consisting of two EGFR-
binding units (αEGFR) and one unit binding to mouse (and human) serum albumin (αAlb). 
In case of full functionality, this bispecific ~50-kDa nanobody should show a prolonged 
half-life in blood as well as efficient tumor targeting. For this purpose, the αEGFR-αEGFR-
αAlb nanobody was evaluated for biodistribution as well as for tumor uptake and 
penetration along with the intact 150-kDa anti-EGFR mAb cetuximab in A431 xenograft-
bearing nude mice. This nanobody, as well as cetuximab, were radiolabeled to facilitate 
accurate quantitative analysis. 
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Materials and methods 
 
Nanobodies, antibody and radioactivity 
Nanobodies were obtained from Ablynx. Procedures for immunization of Llama glama and 
production, selection, and characterization of antagonistic anti-EGFR nanobodies with or 
without αAlb unit have been described in great detail by Roovers et al. (12).  
 Nanobody αEGFR-αEGFR-αAlb consists of two units for specific binding to 
human EGFR and one unit for specific binding to murine and human serum albumin (αAlb, 
designated previously MSA21; see ref. 12). Nanobody αEGFR-αEGFR only consists of the 
EGFR binding units. Nanobody αTNF-αTNF-αAlb comprises two units for specific binding 
to human (and not mouse) tumor necrosis factor-α (TNFα; ref. 19). All nanobody constructs 
contain a COOH-terminal His6 tag and a c-Myc tag. 
 Surface plasmon resonance data sets for the monovalent nanobodies were 
obtained on the BIAcore 3000 instrument (GE Healthcare), essentially as described before 
(20). For this purpose, BIAcore CM5 sensor chips (GE Healthcare) were coated with 
purified EGFR (Sigma) or in house purified (human or mouse) albumin according to the 
manufacturer’s instructions at densities of ~5,000 or 500 relative units, respectively. 
Because no appropriate regeneration conditions for the EGFR coated CM5 chip were 
identified, the affinity of the EGFR-specific nanobody was estimated via kinetic titration 
(21) avoiding successive regeneration steps. Association (ka) and dissociation (kd) rate 
constants as well as affinities (Kd) were calculated using BIAcore BIAevaluation software 
4.1. Kinetics and affinity constants are shown in Table 1.  
 
 
Table 1. Kinetics and affinity constants of monovalent nanobodies and mAb directed against albumin and 
EGFR 
        
Antibody-antigen ka (mol/l-1.s-1) kd (s-1) Kd (nmol/l) 
 
αAlb nanobody-mouse albumin 3.7 x 105 2.8 x10-3 7.5 
αAlb nanobody-human albumin 5.8 x 105 9.8 x10-4 1.7 
αEGFR nanobody-human EGFR 1.0 x 106 3.6 x10-3 3.6 
Erbitux F(ab) fragment-human EGFR 8.5 x 105 1.7x10-3 2.0 
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Cetuximab (Erbitux concentration 2.0 mg/ml) was purchased from Merck. 
Cetuximab is a mouse-human chimeric anti-EGFR mAb that binds with high affinity (Kd = 
0.3 nmol/l) to EGFR (22). 
177Lu (725 GBq/mg) was obtained from PerkinElmer. 125I (3.7 GBq/ml) was 
purchased from Amersham Biosciences. 
 
Radiolabeling 
Radioimmunoconjugates were prepared for three sets of experiments in which 
biodistribution of nanobodies and/or cetuximab was assessed and compared in tumor-
bearing mice. For radiolabeling, the radionuclides 177Lu and 125I were used. 177Lu is a 
residualizing radiometal that shows high retention in tumor cells on internalization and 
catabolism of a 177Lu-labeled mAb and therefore optimally reflects antibody accumulation 
in the tumor. In contrast, 125I is a nonresidualizing radiohalogen, which becomes released 
from the tumor after internalization and catabolism of a 125I-labeled mAb. Combined use of 
both radionuclides gives an indication of the level of in vivo internalization (23). For 
preparation of 177Lu-labeled immunoconjugates, 177Lu was coupled to nanobodies or 
cetuximab via the chelate p-SCN-Bz-DOTA (Macrocyclics), essentially as described 
previously (23). For preparation of 125I-labeled conjugates, 125I was directly coupled to 
nanobodies or cetuximab essentially as described by Visser et al. (24). The following 
conjugates were prepared: 177Lu-cetuximab, 125I-cetuximab, 177Lu-αEGFR-αEGFR-αAlb, 
125I-αEGFR-αEGFR-αAlb, 177Lu-αEGFR-αEGFR, and 177Lu-αTNF-αTNF-αAlb. 
 In short: for preparation of 177Lu-conjugates, all steps were performed under strict 
metal-free conditions. Nanobody or cetuximab was extensively dialyzed against metal-free 
0.1 M NaHCO3 pH 9.0. For conjugation 250 µl p-SCN-Bz-DOTA (0.8 mg/ml) and 250 µl 
(0.5 mg) of nanobody or cetuximab were incubated for 30 min at 37ºC temperature, pH 9.0. 
Nonconjugated chelator was removed using a pre-washed PD-10 column (washed with 0.25 
M ammonium acetate pH 5.5) and the conjugates were eluted with 0.25 M ammonium 
acetate pH 5.5. The p-SCN-Bz-DOTA:nanobody molecular ratio was assessed as described 
previously (23) and was ± 0.3, while the p-SCN-Bz-DOTA:cetuximab molecular ratio was 
± 1.0. 
 Nanobodies or cetuximab premodified with p-SCN-Bz-DOTA were labeled by 
adding 14.8 MBq 177Lu to 0.15 mg of the conjugate in a total volume of  0.75 ml 0.25 mol/l 
ammonium acetate pH 5.5. After labeling for 1 h at 45ºC, 0.05 ml 0.05 mol/l EDTA was 
added to the reaction vial, and the mixture was incubated for a further 5 min. Unbound 
177Lu was removed using a pre-washed PD-10 column (washed with 0.9% NaCl solution) 
and 177Lu-labeled conjugates were eluted with 0.9% NaCl solution.. 
For labeling of nanobody or cetuximab with 125I, 20 ml β-scintillation glass vials 
were coated with 75 µg of IODO-GEN (Pierce Biotechnology, Rockford, IL, USA). To a 
IODO-GEN-coated glass vial, 0.05 ml 0.5 mol/l sodium phosphate (pH 7.4), 0.1 mol/l 
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sodium phosphate (pH 6.8) to reach a total volume of 0.5 ml, 0.25 mg nanobody or 
cetuximab, and 55 MBq 125I in 1 mmol/l NaOH were successively added. After gentle 
shaking for 4 min at room temperature, 0.1 ml ascorbic acid (25 mg/ml, pH 5) was added. 
After an additional 5 min, the reaction mixture was transferred to a syringe connected to a 
filter (0.22 µm Acrodisc, Gelman Sciences Inc, Ann Arbor, MI, USA) followed by 0.4 ml 
0.1 mol/l sodium phosphate (pH 6.8), used for an additional rinsing of the reaction vial. 
This combined solution was filtered, and purified on a PD-10 column with 0.9% 
NaCl/ascorbic acid (5 mg/ml, pH 5) as eluent.  
 
Analyses of radioimmunoconjugates 
All conjugates were analyzed by instant TLC for radiochemical purity, by high-
performance liquid chromatography and SDS-PAGE followed by phosphorimager analysis 
for integrity, and by a cell-binding assay for immunoreactivity as described previously (23).  
No binding assay was available for the 177Lu-αTNF-αTNF-αAlb conjugate. 
 
Biodistribution studies 
For assessment of biodistribution and the tumor-targeting capacity of nanobodies in 
comparison with cetuximab, three sets of experiments were done with nude mice bearing 
s.c. implanted human xenografts of the vulvar tumor line A431 at one or two lateral sides. 
Female mice (Hsd athymic nu/nu, 25-32 g; Harlan) were 8 to 10 weeks old at the time of 
the experiments. All animal experiments were done according to NIH Principles of 
Laboratory Animal Care and Dutch national law (“Wet op de dierproeven”, Stb 1985, 336).  
In a first experiment, the biodistribution of the reference mAb cetuximab was 
assessed using the two different radiolabels. To this end, 14 mice with 24 tumors were 
injected i.p. with 177Lu-cetuximab, 125I-cetuximab, and unlabeled cetuximab up to a total of 
1 mg. This high antibody dose was also chosen in previous therapy experiments in the same 
animal model and is aiming for saturation of EGFR (22, 25). The mean tumor size as 
measured by calipers 1 day before the start of the experiment was 95 ± 34 mm3 and was 
similar for the different groups. At 24 h (n = 3), 48 h (n = 4), 72 h (n = 3), and 120 h (n = 4) 
after injection, the mice were anaesthetized, bled, killed, and dissected. After blood, tumor, 
and normal tissues were weighed, the amount of radioactivity in each was counted in a γ-
counter by using dual isotope counting (23). To correct for radioactive decay, injection 
standards were counted simultaneously. Radioactivity uptake was calculated as %ID/g. 
In a second experiment the biodistribution and intratumoral distribution (tumor 
penetration) of 177Lu-αEGFR-αEGFR-αAlb, 177Lu-αEGFR-αEGFR, 177Lu-αTNF-αTNF-
αAlb, and 177Lu-cetuximab were compared. To this end, 36 mice with 63 tumors were 
injected i.v. with equimolar amounts of these conjugates: 100, 67, 100, and 300 µg, 
respectively. The mean tumor size 1 day before the start of the experiment was 92 ± 31 
mm3 and was similar for the different groups. At 6, 24, and 72 h after injection, 
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biodistribution was assessed as described above. Immediately after radioactivity counting, 
tumors were snap frozen in liquid nitrogen to allow further processing for 
immunohistochemistry. 
In the third experiment, biodistribution of αEGFR-αEGFR-αAlb was evaluated in 
a setting comparable to that of cetuximab in experiment 1. To this end, 12 mice with 24 
tumors were injected i.p. with 177Lu-αEGFR-αEGFR-αAlb,125I-αEGFR-αEGFR-αAlb, and 
unlabeled αEGFR-αEGFR-αAlb up to a total of 1 mg. The mean tumor size 1 day before 
the start of the experiment was 245 ± 100 mm3 and was similar for the different groups. At 
24 h (n = 3), 48 h (n = 4), 72 h (n = 3), and 120 h (n = 4) after injection, biodistribution was 
assessed as described above. In addition, 5 tumor-free mice received the same nanobody 
preparation for detailed assessment of pharmacokinetics. Blood was collected by tail 
laceration into preweighed heparinized tubes at 5, 15, and 30 min, and at 1, 4, 48, 72, 168, 
and 216 h after administration.  
 
Distribution of conjugates throughout A431 xenografts  
Cryosections were made from the frozen A431 xenografts obtained from biodistribution 
experiment 2, and the distribution of the injected nanobodies and cetuximab throughout the 
xenografts was assessed. In short, 5-µm thick sections were cut on a cryotome and mounted 
on glass slides, dried, and fixed in 2% paraformaldehyde in PBS for 10 min. Next, sections 
were washed with PBS. This and all subsequent incubations were performed at room 
temperature. A blocking step consisted of 2% normal swine serum in PBS/1% bovine 
serum albumin, for 30 min. 
For assessment of nanobody distribution, sections were incubated for 1 h with 
rabbit anti-llama VHH (Ablynx) diluted 1:100 in PBS/1% bovine serum albumin, followed 
by 3 washes with PBS, and incubation with horseradish peroxidase-conjugated swine anti-
rabbit IgG-horseradish peroxidase (DakoCytomation) diluted 1:100 in PBS/1% bovine 
serum albumin. For assessment of cetuximab distribution sections were incubated for 1 h 
with horseradish peroxidase-conjugated rabbit anti-human IgG (DakoCytomation) diluted 
1:100 in PBS/1% bovine serum albumin. After incubation with secondary antibody, 
sections were washed 3x with PBS, and incubated with diaminobenzidine diluted in ready-
to-use diaminobenzidine solution buffer (Sigma) until color developed. Sections were 
washed with demiwater and counterstained by nuclear stain with Gill-III hematoxylin 
(Merck). After washing with tap water, coverslips were mounted with Kaiser’s glycerol 
gelatin (Merck).  
 Maximal binding was assessed according to the same protocol (see above), except 
that after blocking, the sections were incubated for 1 h with the particular nanobody or 
cetuximab (10 µg/ml in PBS/1% bovine serum albumin) that also had been used for 
injection. The sections were washed 3x with PBS, followed by the procedures described 
above. Stainings without primary or secondary (rabbit anti-human or anti-llama) antibody 
126 
                  Improved tumor targeting of nanobodies by albumin binding 
 
127 
were used as negative control. Semiquantative visual evaluation of stainings was based on 
homogeneity (0 -100%) and intensity (compared with maximal intensity). 
 
Statistics 
Differences in tissue uptake between conjugates were statistically analyzed for each time 
point with Excel software (Microsoft) using paired or unpaired Student’s t test. Two-sided 
significance levels were calculated, and P < 0.01 was considered statistically significant. 
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Results 
 
Radiolabeling 
Labeling of nanobody-p-SCN-Bz-DOTA and cetuximab-p-SCN-Bz-DOTA with 177Lu 
resulted in overall labeling yields of >75%. The radiochemical purity ranged from 98% to 
99.7%. Phosphorimager analysis of SDS-PAGE gels as well as high-performance liquid 
chromatography analysis revealed optimal integrity of the nanobodies and cetuximab. The 
immunoreactivity of the conjugates was >79% at the highest cell concentration for all 
177Lu-conjugates. In addition, the labeling of nanobody or cetuximab with 125I resulted in 
overall labeling yields of >75%. The radiochemical purity was >99.7%. Conjugates showed 
optimal integrity: single peaks on high-performance liquid chromatography and single 
bands on gel, as has been published previously for radiolabeled nanobodies (26). The 
immunoreactivity of 125I-nanobody and of 125I-cetuximab was 90.7% and 98.0%, 
respectively, at the highest cell concentration. 
 
Biodistribution of 177Lu-cetuximab and 125I-cetuximab 
To assess the effect of abundant conjugate internalization and radionuclide residualization 
on radioactivity distribution, biodistribution studies were first done with the reference anti-
EGFR antibody cetuximab. To this end, 177Lu-cetuximab and 125I-cetuximab were 
coinjected i.p. in A431-bearing mice at a total protein dose of 1 mg. As shown by figure 1, 
radioactivity uptake levels in tumors differed markedly for both conjugates, with much 
higher levels for the residualizing radionuclide 177Lu than for nonresidualizing 125I. For 
example, at 72 h after injection, the mean tumor uptake was 21.9 %ID/g for 177Lu-
cetuximab, compared with 4.5 %ID/g for 125I-cetuximab (P = 0.002). Significant higher 
uptake of 177Lu than that of 125I was also found in organs involved in conjugate catabolism 
like liver, kidney, and spleen. In contrast, uptake values in most other organs and in blood 
were similar for both conjugates, the latter indicating that pharmacokinetics of the antibody 
was not altered as a result of radiolabeling. These results made us decide to use 177Lu 
conjugates for subsequent biodistribution studies with nanobodies. 
 
Biodistribution of anti-EGFR nanobodies with or without αAlb unit 
The tumor-targeting potential of anti-EGFR nanobodies was evaluated in the same model. 
We anticipated that introduction of an albumin-binding unit would result in a prolonged 
blood half-life with accompanying higher tumor uptake levels. To test this possibility, 
biodistribution of the following conjugates was assessed at equimolar doses in parallel: 
177Lu-αEGFR-αEGFR, 177Lu-αEGFR-αEGFR-αAlb, 177Lu-αTNF-αTNF-αAlb, and 177Lu-
cetuximab (reference). Biodistribution at 6, 24, and 72 h after injection is shown by figure 
2, whereas figure 3 shows tumor to normal tissue ratios. The 177Lu-αEGFR-αEGFR 
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nanobody showed very rapid clearance from the blood, with a level of 0.06 ± 0.02 %ID/g at 
6 h after injection (figure 2A). Tissue uptake levels above 1 %ID/g were only found for 
tumor and kidney. Tumor uptake was 5.0 ± 1.4, 3.2 ± 0.6, and 1.1 ± 0.1 at 6, 24, and 72 h 
after injection, respectively. Extremely high kidney uptake was observed at those time 
points (168.4 ± 9.3, 167.8 ± 29.3, and 86.5 ± 30.7, respectively), which is typical for 177Lu-
labeled small proteins that are rapidly cleared via the kidneys (16). 
 
 
 
 
Figure 1. Biodistribution of coinjected 177Lu-cetuximab (A) and 125I-cetuximab (B) in A431 tumor-bearing 
nude mice up to 5 d after injection. Total administered antibody dose: 1 mg. Mean (%ID/g) ± SD at each 
time point after i.p. injection (n = 3 or 4 animals per time point). 
 
 
 Introduction of an albumin-binding unit in the molecule (177Lu-αEGFR-αEGFR-
αAlb) resulted in a dramatic change in the biodistribution pattern (figure 2B). Whereas 
blood clearance became much slower, with levels of 21.2 ± 2.5, 11.9 ± 0.6, and 4.0 ± 1.4 
%ID/g at 6, 24, and 72 h after injection, respectively, tumor uptake at these time points was 
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significantly higher: 19.4 ± 5.5, 35.2 ± 7.5, and 28.0 ± 6.8 %ID/g. These data indicate that 
introduction of an αAlb unit resulted in a 25-fold higher tumor uptake of the anti-EGFR 
nanobody at 72 h after injection. Due to the slower body clearance kidney uptake was 
strongly reduced and did not exceed 11 %ID/g. 
 
 
 
 
Figure 2. Biodistribution of 177Lu-αEGFR-αEGFR (A), 177Lu-αEGFR-αEGFR-αAlb (B), 177Lu-αTNF-αTNF-
αAlb (C), and 177Lu-cetuximab (D) in A431 tumor-bearing nude mice at 6, 24, and 72 h after i.v. injection. 
Conjugates were administered at equimolar doses of 66, 100, 100, and 300 µg, respectively. Mean (%ID/g) ± 
SD at each time point after injection (n = 3 animals per time point). 
 
 
177Lu-αTNF-αTNF-αAlb was included as a control nanobody to evaluate the 
possibility that interaction of αAlb with albumin might have introduced a second targeting 
mechanism and therefore might have contributed to the high tumor uptake of αEGFR-
αEGFR-αAlb (figure 2C). This possibility is realistic because albumin has been pursued 
previously as delivery vehicle for chemotherapy (27). 177Lu-αTNF-αTNF-αAlb showed a 
similar blood clearance as 177Lu-αEGFR-αEGFR-αAlb (except at 6 h after injection), 
indicating that blood clearance of these types of constructs is dominated by the αAlb-
albumin interaction. In contrast, tumor uptake of 177Lu-αTNF-αTNF-αAlb was significantly 
lower than of 177Lu-αEGFR-αEGFR-αAlb, and did not exceed 10.2 ± 1.5 %ID/g (at 24 h 
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after injection). Because tumor uptake was slightly higher than in normal tissues, however, 
some contribution of tumor targeting via albumin (or TNF-α) cannot be excluded. 
 
 
 
 
Figure 3. Tumor-to-normal tissue ratios of 177Lu-αEGFR-αEGFR, 177Lu-αEGFR-αEGFR-αAlb, 177Lu-
αTNF-αTNF-αAlb, and 177Lu-cetuximab in A431 tumor-bearing nude mice at 6, 24, and 72 h after i.v. 
injection. Data are derived from figure 2. 
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Finally, 177Lu-cetuximab was included for comparison (figure 2D). Blood levels as 
well as uptake levels in most normal tissues (except for liver and kidney) were very similar 
to those of 177Lu-αEGFR-αEGFR-αAlb. Tumor levels, however, tended to be slightly lower 
(not significantly) for 177Lu-cetuximab: 15.5 ± 3.9, 27.1 ± 7.9, and 25.6 ± 6.1 %ID/g at 6, 
24, and 72 h after injection, respectively. 
 Tumor-to-normal tissue ratios derived from aforementioned biodistribution studies 
have been summarized in figure 3. While 177Lu-αEGFR-αEGFR-αAlb showed superior 
tumor uptake levels, which is important for anti-EGFR therapy, 177Lu-αEGFR-αEGFR 
showed superior tumor-to-normal tissue ratios (except for kidneys). For example, tumor-to-
blood ratios increased for the latter construct from 86.9 ± 32.0 at 6 h after injection to 369.0 
± 139.0 at 72 h after injection, respectively. On the other hand, tumor-to-blood ratios of 
177Lu-αEGFR-αEGFR-αAlb tended to be higher than those of 177Lu-cetuximab (significant 
at 24 and 72 h after injection): 1.0 ± 0.1 versus  0.8 ± 0.1, 3.0 ± 0.3 versus 2.2 ± 0.6, and 7.9 
± 2.5 versus 3.5 ± 0.1 at 6, 24, and 72 h after injection, respectively. 
 
Distribution of anti-EGFR nanobodies and cetuximab throughout tumors 
Tumors derived from aforementioned biodistribution studies were used for 
immunohistochemical analysis of nanobody and cetuximab distribution throughout the 
tumor. Staining of αEGFR-αEGFR-αAlb showed an intense and mostly homogeneous 
staining pattern at all three time points, 6, 24, and 72 h after injection, with 80% to 100% of 
the tumor cells stained. Figure 4A shows a typical staining pattern for αEGFR-αEGFR-
αAlb at 6 h after injection. Preincubation of sections with αEGFR-αEGFR-αAlb to assess 
maximum staining, did not further increase staining intensity (figure 4B). Staining was 
confined to the cell membranes of tumor cells, whereas very weak staining was observed in 
the stromal compartment (figure 4C). In contrast, staining of cetuximab was much more 
heterogeneous at all time points and did not exceed 60% of the cells. Staining was intense 
at 6 h (see figure 4D) and 24 h after injection, and became weaker at 72 h after injection 
(data not shown). Preincubation of tumor sections with cetuximab to assess maximum 
staining resulted in a homogeneous staining pattern (figure 4E). Staining of αEGFR-
αEGFR was homogeneous but weak, while staining of αTNF-αTNF-αAlb was very weak 
without clear delineation of tumor cells nests (data not shown). No staining was observed in 
the absence of either αEGFR-αEGFR-αAlb or cetuximab (figure 4F). 
 
Biodistribution of 177Lu-αEGFR-αEGFR-αAlb and 125I-αEGFR-αEGFR-αAlb 
More extensive studies were done with αEGFR-αEGFR-αAlb to obtain detailed 
information on pharmacokinetics, biodistribution, tumor targeting, and in vivo 
internalization under EGFR saturating conditions as previously described for cetuximab 
(figure 1). To this end, 177Lu-αEGFR-αEGFR-αAlb and 125I-αEGFR-αEGFR-αAlb at a total 
dose of 1 mg were i.p. administered to tumor-free and A431-bearing mice.  
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 Pharmacokinetics were assessed by repeated sampling of five tumor-free mice, and 
showed a similar pattern for both conjugates (figure 5), as was previously the case for 
cetuximab (figure 1). Interindividual differences were very small, especially at later time 
points, and congruent for both conjugates. Nanobody blood levels at 48 h after injection 
were ~50% of the maximum levels observed at 4 h after injection. 
 
 
 
 
Figure 4. In vivo targeting of A431 tumors by 177Lu-αEGFR-αEGFR-αAlb and 177Lu-cetuximab. Following 
in vivo tumor targeting as described in figure 3, tumors were excised at 6 h after injection, and processed 
for immunohistochemical detection of αEGFR-αEGFR-αAlb (A-C) or cetuximab (D and E). Sections B and 
E have been incubated with the same conjugate as injected in vivo and represent maximal binding. C, an 
enlargement, showing that staining is confined to the cell membranes of tumor cells, with minimal staining 
of the stromal compartment. F, a negative control staining in the absence of primary antibody (either 
αEGFR-αEGFR-αAlb or cetuximab). 
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Figure 5. Blood concentrations of coinjected 177Lu-αEGFR-αEGFR-αAlb and 125I-αEGFR-αEGFR-αAlb in 
tumor-free nude mice (n = 5) up to 9 d after i.p. injection. Total administered antibody dose: 1 mg. 
 
 
 177Lu-αEGFR-αEGFR-αAlb and 125I-αEGFR-αEGFR-αAlb were also coinjected to 
assess biodistribution in A431 tumor-bearing mice. As shown by figure 6, radioactivity 
uptake in tumors differed markedly for both conjugates, which indicates in vivo 
internalization of the nanobody (as was also observed for cetuximab; see figure 1). Tumor 
uptake of 177Lu-αEGFR-αEGFR-αAlb was almost constant at ~12 %ID/g during the period 
48 to 120 h after injection. To test the possibility that in vivo EGFR saturation by nanobody 
had occurred, the following calculation was made to estimate the number of nanobody 
molecules bound per A431 cell in vivo: an uptake of 12 %ID/g means that 120 µg 
nanobody (MW ~50 kDa) had been bound per gram of tumor, which corresponds to ~1.5 x 
1015 nanobody molecules. Assuming that 1 g of tumor contains ~109 tumor cells, this would 
mean that ~1.5 x 106 nanobody molecules had bound per A431 tumor cell in vivo. The 
percentage tumor uptake of 177Lu-cetuximab in the same model and at the same mAb dose 
of 1 mg was higher than for 177Lu-αEGFR-αEGFR-αAlb: ~18 versus ~12 %ID/g. However, 
when performing a similar calculation as above for cetuximab (150 kDa), it appears that 
less molecules of cetuximab had been bound per tumor cell (~0.7 x 106) than of αEGFR-
αEGFR-αAlb.  
Blood kinetics of i.p. injected 177Lu-αEGFR-αEGFR-αAlb appeared slightly faster 
in tumor-bearing mice than in tumor-free mice. While blood levels decreased from 21.1 to 
4.6 %ID/g in tumor-free mice between 24 and 120 h. after injection, in tumor-bearing mice 
a decrease from 16.5 to 2.9 %ID/g was observed (figures 5 and 6). 
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Figure 6. Biodistribution of coinjected 177Lu-αEGFR-αEGFR-αAlb (A) and 125I-αEGFR-αEGFR-αAlb (B) in 
A431 tumor-bearing nude mice up to 5 d after i.p. injection. Total administered antibody dose: 1 mg. Mean 
(%ID/g) ± SD at each time point after injection (n = 3 or 4 animals per time point). 
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Nanobodies can easily be produced as multivalent and/or multispecific single molecule 
formats consisting of ~15 kDa building blocks. In this study, we exploited this flexibility to 
modulate the pharmacokinetics of anti-EGFR nanobodies by introduction of an albumin-
binding unit. As a starting point, a bivalent αEGFR-αEGFR nanobody format was chosen, 
because previous studies had shown that bivalent anti-EGFR nanobodies were more 
effective in competing for EGF binding to EGFR than monovalent nanobodies (12). 
Moreover, this choice enabled direct comparison with the bivalent anti-EGFR mAb 
cetuximab. The αEGFR-αEGFR nanobody showed rapid blood clearance, very high tumor-
to-normal tissue ratios (except for kidney), but moderate levels of tumor uptake (5.0 ± 1.4 
%ID/g at 6 h after injection), which rapidly decreased over time. Although such a nanobody 
format might be ideal for imaging purposes to confirm receptor expression within a short 
time period, it is not suitable for therapy.  
An ideal nanobody format for therapy is a format that is able to block EGFR at 
each individual tumor cell immediately after its administration for a prolonged period. In 
the present study, we show that the aforementioned anti-EGFR nanobody obtained such 
characteristics by introduction of an albumin-binding unit: the αEGFR-αEGFR-αAlb 
showed (a) rapid, high, and selective tumor accumulation when administered at a relatively 
low dose; (b) prolonged residence time in blood and tumor; (c) homogeneous distribution 
throughout the tumor; and (d) apparent saturation of EGFR when administered at a 
relatively high dose. With respect to the latter, by estimation ~1.5x106 αEGFR-αEGFR-
αAlb molecules were found to be bound per A431 tumor cell in vivo on administration of a 
dose of 1 mg (figure 6). This number corresponds very closely with the number of EGFR 
molecules expressed per A431 cell in high-density in vitro cultures (28). Tumor uptake was 
predominantly directed by the αEGFR binding units, because the αTNF-αTNF-αAlb control 
nanobody showed comparable pharmacokinetics but much lower tumor uptake. Some 
contribution of the αAlb unit to tumor targeting, however, cannot be excluded and needs 
further evaluation. Biodistribution and tumor-targeting characteristics were very similar for 
the ~50 kDa αEGFR-αEGFR-αAlb nanobody and the ~150-kDa intact reference mAb 
cetuximab. However, a more homogeneous tumor distribution was found for the nanobody. 
Whether this was related to the smaller size of the nanobody (9), to differences in affinity 
(20, 29), or to other factors needs further investigations. A potential disadvantage of the 
prolonged residence time of nanobodies in blood, is the increased chance for the 
development of immunereactions. However, nanobodies have a high homology with VH 
domains of human antibodies and can be further humanized to decrease their 
immunogenicity. 
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Several strategies have been described in literature to reduce blood clearance of 
targeting molecules. Most of these strategies focus on the enlargement of the targeting 
molecule above the critical size for renal clearance (60-70 kDa) by fusion to other proteins 
like albumin (30) and the Fc portion of an IgG (31), or by glycosylation (32) or pegylation 
(33). The use of bispecific antibodies as described herein, aiming a noncovalent association 
with albumin as a means to improve biodistribution and tumor deposition, was pioneered 
by Dennis et al. from the Genentech labs (17). In an article that was published while our 
article was under preparation, they described the tumor-targeting potential of a bifunctional 
molecule derived from trastuzumab (Herceptin) capable of simultaneous binding of 
albumin and the tumor antigen HER2 (18). This molecule designated AB.Fab4D5 was 
constructed from the F(ab) fragment of trastuzumab by recombinant fusion of a linker and 
an albumin binding peptide to either the COOH terminus of the heavy chain or light chain. 
Before use, AB.Fab4D5 was purified by an albumin affinity column to ensure a properly 
folded albumin-binding peptide. While AB.Fab4D5 showed a much more rapid blood 
clearance than reference mAb trastuzumab, resulting in ~5 times lower blood levels at 2 
days after injection, similar tumor deposition was obtained for both as revealed from 
quantitative imaging studies. As a result, tumor-to-blood ratios were superior for 
AB.Fab4D5, making this agent ideal for tumor imaging. No quantitative data were obtained 
for uptake in other organs. 
  In contrast to AB.Fab4D5, addition of the albumin-binding unit αAlb to single 
chain αEGFR-αEGFR resulted in a blood clearance, which was very similar to the 
clearance of reference intact IgG mAb cetuximab. This might be due to a better 
accessibility and/or higher affinity of the αAlb unit in comparison with the albumin-binding 
peptide of AB.Fab4D5. αEGFR-αEGFR-αAlb showed blood levels of 21.2 ± 2.5 and 11.9 ± 
0.6 %ID/g at 4 and 24 h after injection. Interestingly, Meijs et al. (34) previously assessed 
the pharmacokinetics of radiolabeled mouse serum albumin in mice (34). To this end, 
mouse serum albumin was labeled with the radionuclides 89Zr and 123I. Blood levels of both 
mouse serum albumin conjugates after i.v. injection were ~24 and ~10 %ID/g at 4 and 24 h 
after injection, respectively. The very similar pharmacokinetics of αEGFR-αEGFR-αAlb 
and mouse serum albumin indicates that the αAlb binding unit ensured a very strong 
association between these molecules in vivo. Because the αAlb binding unit also shows 
high affinity for human serum albumin, and human serum albumin was shown to have a 
blood half-life of ~20 days (35), it can be anticipated that αEGFR-αEGFR-αAlb will show a 
much longer half-life in humans.  
 Aforementioned data indicate that simple recombinant fusion of αEGFR and αAlb 
building blocks results in a single molecule format with bifunctional properties, which seem 
more favorable for therapy as far as pharmacokinetics, target binding, and tumor 
penetration are concerned. In addition, preliminary tumor xenograft studies indicated that 
first generation αEGFR-αEGFR-αAlb type nanobodies indeed are effective in delaying the 
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outgrowth of A431-derived solid tumors (12), although to a lesser extent than cetuximab 
(personal communication with dr. R. Roovers). These findings encourage further 
exploration of the nanobody toolbox, especially with respect to the generation of 
multivalent and/or multispecific therapeutic formats. 
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Squamous cell carcinoma of the head and neck arises from the mucosa of the upper 
aerodigestive tract, including the oral cavity, pharynx, and larynx. Squamous cell 
carcinoma accounts for more than 90% of all malignant head and neck tumors, and 
accounts for ~5% of all malignant tumors in Europe and the United States. Worldwide, 
more than half a million new cases of head and neck cancer are diagnosed, and in The 
Netherlands, in 2006 more than 2500 patients developed malignancies in the head and neck, 
whereas more than 800 patients died from this disease. 
Two-thirds of the patients with head and neck cancer are diagnosed with advanced 
stage disease, and their prognosis is poor. During the last three decades, some progress has 
been made in the locoregional treatment of head and neck cancer, but unfortunately this has 
not led to substantial improvement of overall survival. First, because head and neck cancer 
patients frequently develop locoregional recurrences and distant metastases, but also 
because second primary tumors frequently develop. Retreatment is not always possible, due 
to side effects on previously treated healthy tissues. Therefore, more specific and precise 
‘targeted’ locoregional treatment should be developed, eradicating malignant tissue while 
sparing normal tissues. In addition, adjuvant systemic strategies should be developed to 
eradicate occult distant metastases and minimal residual disease. These ‘targeted 
treatments’ are necessary to improve locoregional as well as systemic control and overall 
survival, while sparing normal tissues and keeping patients’ quality of life as best as 
possible. Targeted therapies can be used as monotherapy as well as in combination 
therapies with radiotherapy and chemotherapy, and ideally, these treatments have a 
synergistic effect. The use of multi-targeting instead of mono-targeting strategies should 
have positive effects on treatment efficacy and avoidance of therapy resistance. 
During the last decades, several locoregional treatment options have become 
available aiming definite local tumor eradication, while at the same time preserving organ 
functions, relieving symptoms, and avoiding disease-related complications. Bleomycin-
electroporation therapy is one of these treatment options, designed to be an alternative for 
or an addition to surgery in the treatment of solid tumors. This treatment selectively kills 
cancerous cells and minimizes cosmetic and functional disfigurements. In chapter 2 a 
clinical phase IV study is described with bleomycin-electroporation therapy. Patients 
suffering from malignancies in the head and neck area, who could no longer be treated by 
surgery or radiotherapy, were treated with bleomycin-electroporation therapy. This therapy 
consists of injections of bleomycin directly into the tumor, followed by delivery of 
electrical pulses by a needle-electrode applicator to induce uptake of bleomycin in the 
tumor cells. Twenty-four tumors in fourteen patients were treated with this locoregional 
cancer therapy. Local tumor control for more than two years was reached in 10 of the 24 
tumors (three out of fourteen patients). These three patients were still alive two years after 
treatment. In all cases, functions were preserved successfully, and the treatment provided 
acceptable cosmetic results. Bleomycin-electroporation therapy appeared to be an easy to 
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perform treatment that causes little burden to the patient and is potentially effective in 
patients with tumors in the head and neck area. In addition, the procedure is 
straightforward, and normally takes less than one hour. The treatment can be performed on 
outpatient basis, but in our hospital all treated patients were cared on the ward for a few 
days.  
Despite the challenging starting point of this study (patients who underwent 
extensive therapies before, and who could no longer be treated by surgery or radiotherapy), 
the results with bleomycin-electroporation therapy are encouraging in terms of tissue 
preservation and tumor control. One problem can be the accessibility of the tumors for the 
injection of bleomycin and the insertion of the applicator. For the treatment to be effective 
it is necessary to infiltrate and electroporate the whole tumor area including 0.5 cm margins 
around. Most patients already had been treated with radiotherapy, and this treatment leads 
to DNA damage, not only in the cancer cells, but also in the surrounding normal tissues. 
Because bleomycin leads to similar DNA damage, bleomycin-electroporation therapy 
resulted in delayed wound healing in previously irradiated areas. Furthermore, some 
patients already were suffering from distant metastases at the time of treatment, leading to 
death before reaching the end of study time point. In these cases, palliation was reached, 
but there was no improved survival. Nevertheless, the results of this study were hopeful.  
Bleomycin-electroporation therapy thus far appeared most successful as primary 
therapy in patients with early stage head and neck cancer, with complete remissions in 83% 
of the treated lesions four weeks after treatment (1), but also in advanced  stage disease, this 
treatment led to partial (32%) and complete responses (25%) in 57% of the treated lesions. 
The 30% overall survival rate at one year found in this study was consistent with the overall 
survival rate of patients with advanced stage head and neck squamous cell carcinoma. 
Improved local control of the head and neck tumor site did not influence survival. 
Individual patients demonstrating a positive response to electroporation with bleomycin did 
not have a longer survival period after treatment. However, by controlling local disease, 
their quality of life was much improved (2). The routine treatment strategy for early stage 
oral cavity cancer is surgery, leading to a five-year overall survival of 70-80%. Therefore, 
changing this treatment strategy to bleomycin-electroporation therapy is not indicated. 
Advanced stage disease is treated by surgery and/or radiotherapy with or without 
chemotherapy. In case of local recurrences, second primary tumors, or metastases, 
prognosis is much worse, and standard treatment strategies are not always available. 
Bleomycin-electroporation therapy appeared to be a valuable addition to the standard 
treatments. In our opinion, bleomycin-electroporation therapy is an easy to perform 
treatment that is potentially effective in selected patients with head and neck or skin tumors, 
even in patients with advanced stage disease, with recurrences or distant metastases. An 
enormous advantage of bleomycin-electroporation therapy in comparison to another 
emerging modality for local treatment, photodynamic therapy (3), is the absence of 
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photosensitivity that keeps patients inside for several weeks. Low treatment burden is of 
high importance in the treatment of palliative patients, who have a diminished life 
expectancy. In addition, bleomycin-electroporation therapy is applicable for treatment of 
multiple tumor types, not only squamous cell carcinomas of the mucosa and the skin, but 
also malignant tumors of the salivary glands, basal cell carcinomas, melanomas, 
adenocarcinomas, Merkel cell carcinomas, sarcomas, cutaneous lymphomas, skin 
metastases and primary cutaneous tumors. Also larger tumors with invasion depths up to 
2.5 cm are eligible for this therapy. 
At this moment, there are several groups developing and optimizing 
electroporation systems. The combination with other cytotoxic drugs is under investigation, 
for instance electroporation therapy in combination with systemic cisplatin therapy (4-6). 
Electroporation in combination with simultaneous chemoradiation using cisplatin to 
improve local drug uptake and improve local tumor control, is interesting and needs further 
investigation. 
During the last decades, systemic selective strategies have become more important 
to target minimal residual disease and occult metastases. These adjuvant strategies are 
essential to improve the overall survival of head and neck cancer. Monoclonal antibodies 
(mAbs) or antibody fragments are agents aimed to selectively target tumor cells, for 
selective delivery of toxic payloads or for complete neutralization/blockage of critical 
growth and survival stimulatory pathways. Normal tissues, that are not expressing the 
specific target, should not be affected by these mAbs. The humanized mAb bivatuzumab is 
directed against the CD44v6 antigen that is predominantly expressed on squamous cell 
carcinomas. In previous studies, encouraging progress was obtained with the development 
of bivatuzumab and other anti-CD44v6 mAbs, in CD44v6-directed 
radioimmunoscintigraphy studies prior to radioimmunotherapy (RIT) studies in head and 
neck cancer (7,8). Binding of these mAbs to the target antigen results in internalization of 
the antibody (9). Phase I dose escalation RIT studies showed promising antitumor effects 
with consistent stable disease at higher radioactivity dose levels. Myelotoxicity caused by 
circulating radioimmunoconjugate appeared to be the dose limiting toxicity. In addition, in 
some patients mild oral mucositis was observed (10-12), while these patients had 
experienced severe mucositis during previous external beam radiotherapy. These data 
indicated that cross-reactivity of anti-CD44v6 mAbs with normal mucosa is not a limitation 
for therapeutic application of these mAbs per se. The use of radioimmunoconjugates 
resulted in limitations related to logistics and radiation safety. Omission of radioactivity 
could solve these issues, and therefore, an anti-CD44v6 antibody-drug conjugate was 
developed. Antibody-drug conjugates are particularly attractive, because no bone marrow 
toxicity has to be expected, and therefore perspectives might arise for combined treatment 
with conventional chemotherapeutics. 
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Bivatuzumab mertansine is a tumor-activated prodrug conjugate, which consists of 
the super-toxic anti-microtubule drug mertansine (DM1) covalently linked to bivatuzumab. 
After binding to CD44v6, the complex can be internalized, and the mertansine molecules 
will be released intracellularly by cleavage of the antibody-mertansine disulfide bonds. 
Normal tissues, not expressing the CD44v6 antigen will not be affected by this therapy. In 
chapter 3, a phase I dose escalation study with bivatuzumab mertansine is described. The 
safety, maximum tolerated dose (MTD), and preliminary efficacy of bivatuzumab 
mertansine were assessed, and the pharmacokinetics and immunogenicity were determined 
after three weekly i.v. injections of the conjugate. 
In this study, no toxicity related to free mertansine as a result of deconjugation in 
the circulation was observed, and no evidence was found for the non-specific uptake of 
conjugate by cells not expressing the antigen. The main toxicity of bivatuzumab mertansine 
was directed against the skin, most probably due to CD44v6 expression in this tissue (cross-
reactivity). The majority of skin reactions was reversible; however, one fatal drug-related 
adverse event had occurred. Toxic epidermal necrolysis (TEN) appeared in one patient 
treated at a dose of 140 mg/m2. Toxicity was most probably triggered by the cross-
reactivity of bivatuzumab with skin keratinocytes. There was no evidence for a dose-
toxicity relationship, and it is therefore difficult to predict when severe skin toxicity will 
occur (13). It was decided to discontinue further clinical development of bivatuzumab 
mertansine. 
In parallel studies with single infusion of bivatuzumab mertansine, thirty-one head 
and neck cancer patients had received doses of 25-325 mg/m2. Thirteen patients received a 
second infusion after three weeks. The MTD was reached at 300 mg/m2, with skin toxicity 
being dose limiting. No immune response was induced by the conjugate in any patient. The 
principal toxic effects were maculopapular rashes, focal blister formation and skin 
exfoliation. Three patients had partial responses at doses of 200, 275 and 325 mg/m2 (14-
16). Two patients treated at this latter dose level experienced dose-limiting toxicities, with 
some signs of epidermolysis, but these toxicities appeared to be totally reversible. The 
previous dose level of 300 mg/m2 had been well tolerated. 
In another parallel study with bivatuzumab mertansine in patients with CD44v6-
positive metastatic breast cancer, twenty-four patients were treated at eight different dose 
levels (25-200 mg/m2). Seven of these patients received more than one course of 
bivatuzumab mertansine. Two dose-limiting toxicities occurred: one patient treated with 
125 mg/m2 developed transient grade 4 elevation of liver enzymes; another patient treated 
at 175 mg/m2 experienced grade 3 vomiting. She died from renal failure, which might have 
been caused by deterioration of pre-existing renal insufficiency. The most common 
toxicities were transient and mild skin disorders in 75% of patients. No objective responses 
were observed. Disease stabilization was achieved in 50% of patients independently of dose 
level (17). 
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The patient in the study described in chapter 3 who developed TEN had only 
received two weekly injections of 140 mg/m2. A total of 70 patients have been treated in 
different centers, and a total of five dose-limiting toxicities occurred. TEN is considered to 
be a rare disorder characterized by extensive epidermal death, caused by an idiosyncratic 
drug reaction, without dose-toxicity relationship. The mortality rate of TEN is high, and no 
specific treatment regimen has been described. Because it is unpredictable which patient is 
at risk for developing TEN, the bivatuzumab mertansine conjugate was classified as not 
save, and clinical development was discontinued before reaching overall MTD. 
From this study, it can be concluded that strict tumor-selective expression of the 
particular target antigen is required, when using supertoxic antibody-drug conjugates for 
therapy. The expression of CD44v6 was probably not selective enough to allow safe 
therapy. This may have consequences for the development of other antibody-mertansine 
conjugates like trastuzumab-mertansine (T-DM1), which is currently evaluated in patients 
with advanced HER2-positive breast cancer (18). Overexpression of the receptor tyrosine 
kinase HER2 (erbB2) is correlated with a poor prognosis in breast and ovarian cancer. 
Treatment with the anti-HER2 mAb trastuzumab improves survival in patients with HER2-
positive breast cancer, but it also causes cardiomyopathy (19,20). Anthracycline-
trastuzumab-containing regimens are limited by unacceptably high rates of significant 
cardiotoxicity, particularly upon concurrent administration. Trastuzumab increases the risk 
of anthracycline-induced cardiotoxicity (21). Myocardial HER2-expression may be 
transiently upregulated by a compensatory mechanism following cardiac stress (22). 
Although phase I and II clinical trials with T-DM1 till now did not show cardiac-specific 
toxicity, results from our trial indicate that care should be taken, especially for patients 
treated with anthracyclines in the past (23,24).   
The selective targeting of tumor angiogenesis and neovasculature is another 
appealing therapeutic anti-cancer strategy. Angiogenesis is required for tumor progression 
and metastasis, and the inhibition of this process as well as the eradication of tumor 
vasculature has become an intensive focus of clinical investigation. The mAb fragment 
L19-SIP is directed against the extra-domain B (ED-B) of fibronectin, a marker of 
angiogenesis. Chapter 4 describes the biodistribution of L19-SIP and its potential for RIT 
in nude mice bearing the head and neck cancer xenograft lines FaDu and HNX-OE. L19-
SIP showed high and selective tumor uptake in the two head and neck cancer xenograft 
lines tested, with tumor-to-blood uptake ratios ranging from 4.4 ± 1.8 at 24 h to 21.4 ± 1.8 
at 72 h after injection, for the FaDu line. Tumor-to-nontumor uptake ratios were in general 
at least as high, which is encouraging when taken into account that L19-SIP also binds to 
murine ED-B. RIT with 131I-L19-SIP at MTD level of 74 MBq caused significant tumor 
growth delay and improved survival in both lines. The efficacy was enhanced by 
combination of 131I-L19-SIP RIT with cetuximab, without increase of toxicity. When mice 
with established xenografts were treated with this combination, complete responses without 
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regrowth during the 3-4 months observation period were observed in two out of eight FaDu 
tumors and five out of eight HNX-OE tumors. 
Selective targeting of tumor angiogenesis and neovasculature can be used in nearly 
all solid cancers, since elevated ED-B expression is found in most of these tumors (25,26). 
Recently, a clinical RIT study with 131I-L19-SIP in lymphoma patients showed promising 
results. ED-B expression was found in tumor biopsies from more than 200 Hodgkin and 
non-Hodgkin lymphoma patients of nearly all entities, as well as in biopsies from patients 
with myeloproliferative diseases. In contrast, ED-B expression was nearly absent in normal 
lymph nodes (n = 10) and bone marrow biopsies (n = 9). The extent of ED-B expression in 
lymphoma tissues was positively correlated with grade of malignancy. The in vivo 
accessibility of ED-B for 131I-L19-SIP was confirmed in three lymphoma patients, in whom 
the lymphoma lesions were visualized by SPECT scanning. These patients had failed 
multiple therapies, and presented with relapsed disease as documented by 18FDG PET-CT 
scans. Based on selective uptake into tumor lesions and on adequate bone marrow 
dosimetry, two patients were selected to receive a therapeutic dose of 131I-L19-SIP of 5.55 
GBq (150 mCi), and one patient received a dose of 3.7 GBq (100 mCi). Whole-body and 
SPECT-CT images were obtained 8 to 12 days after administration of this dose to confirm 
specific tumor targeting. In two relapsed Hodgkin lymphoma patients, 131I-L19-SIP RIT 
induced a sustained partial response, qualifying ED-B as a promising target for antibody-
based lymphoma therapies (27). In addition, these achievements justify the development of 
RIT with 131I-L19-SIP in selected patients with solid tumors like head and neck cancer. 
Extensive immunohistochemical evaluation has shown ED-B expression in the majority of 
head and neck tumors, with most abundant expression in the more aggressive ones (28). 
This variability in expression indicates that pretherapy imaging with L19-SIP for the 
assessment of biodistribution and dosimetry is recommended for the selection of RIT 
candidate patients. For high resolution imaging and accurate quantification of L19-SIP 
distribution, PET is a more attractive option than the currently used SPECT procedure 
(29,30). 
Aforementioned encouraging preclinical and clinical data on RIT with 131I-L19-
SIP formed the basis for the development of a pretherapy scouting procedure using 124I-
L19-SIP as the PET-tracer. Molecular imaging of tumor angiogenesis has clinical 
perspectives for lesion detection, patient stratification, new drug development and 
validation, treatment monitoring, and dose optimization (31). Chapter 5 describes the 
development of 124I-L19-SIP immuno-PET, not only for imaging of tumor angiogenesis, 
but also as a scouting procedure prior to clinical 131I-L19-SIP RIT, to confirm selective 
tumor targeting and to enable dosimetry. Imaging of the expression of ED-B of fibronectin 
can be important for cancer diagnosis and monitoring of therapeutic efficacy against cancer.  
As starting point for establishing 124I-L19-SIP immuno-PET, infrastructure and 
procedures were developed for efficient GMP-compliant production of large batches of 124I 
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(> 2 GBq) at high radionuclidic (>99.5%) and radiochemical (>95% as iodide) purity and 
low tellurium (<1 μg/ml) and pyrogen (<5 EU/ml) content. As a result, clinical grade 124I is 
now available for worldwide distribution, not only for immuno-PET applications but also 
for selection of patients with thyroid cancer for 131I therapy (figure 1). 
L19-SIP labeled with 124I demonstrated optimal integrity and immunoreactivity, 
and exhibited the same pharmacokinetic behavior as the corresponding 131I conjugate. 
Biodistribution studies revealed high and selective tumor targeting, resulting in tumor to 
blood ratios ranging from 6.0 at 24 h to 45.9 at 72 h after injection. As a result, high tumor 
to normal tissue ratios were obtained with 124I-L19-SIP, resulting in clear visualization of 
tumors by PET imaging, even when tumors were small (~50 mm3). Immuno-PET with 124I-
L19-SIP appeared qualified for sensitive imaging of tumor neovasculature and for 
predicting 131I-L19-SIP biodistribution. This result paves the way for using 124I-L19-SIP 
immuno-PET in the selection of 131I-L19-SIP RIT candidate patients, on the basis of 
appropriate tumor targeting and dosimetry (personalized therapy). 
Currently, nine mAbs have been approved for cancer therapy, all being intact 
mAbs. Five of the mAbs have been approved for treatment of hematological malignancies: 
rituximab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, and 
tositumomab. Four mAbs consisting of trastuzumab (anti-HER2), cetuximab (anti-EGFR), 
panitumumab (anti-EGFR) and bevacizumab (anti-VEGF) have been approved for therapy 
of solid tumors. One of these mAbs, cetuximab, has been approved for use in head and neck 
cancer. Despite several clinical successes, it is fair to state that the efficacy of current mAbs 
is still quite limited, with benefit for just a portion of patients, while costs of mAb therapy 
are excessive. 
Because cancer cells have the inherent ability to use several pathways for growth 
advantage (e.g. related to proliferation, angiogenesis, invasion and metastasis) selective 
targeting of just one single tumor target might be insufficient for fully effective cancer 
treatment. For example, it has been shown that tumors can become resistant for anti-EGFR 
therapy, and for these tumors the c-Met signaling pathway becomes more important for 
survival (32). These insights have boosted strategies for the simultaneous blockage of 
several critical targets. Studies have been started in which combinations of approved mAbs 
are used, e.g. one mAb directed against EGFR and another mAb directed against VEGF 
(33). Alternatively, some pharmaceutical companies have started the clinical development 
of mAb cocktails. Whereas mAbs are considered to be “expensive medicines”, introduction 
of combination mAb therapy will be even more challenging as far as economic aspects 
concern. 
In this thesis, we introduce the use of nanobodies for inhibition of signal 
transduction pathways, EGFR mediated signaling included (34). Nanobodies are derived 
from a unique antibody format, heavy chain-only antibodies that are present in species from 
the family of Camelidae, including llama, camel, and dromedary. Particularly attractive is 
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the flexibility of drug formatting whereby it is straightforward to generate multivalent 
and/or multi-specific single molecule formats and to produce these formats in a cheap way 
in bacteria or yeast. By doing so, a single “bead chain-like” molecule is obtained consisting 
of several 15 kDa binding units, which can be directed against the same or against different 
targets. Very important for the future perspectives of this modular mAb technology is the 
question whether binding units retain their binding affinity and specificity when placed 
behind each other within such bead chain. In chapter 6 we challenged this question by 
constructing bead chains consisting of anti-EGFR (αEGFR) and/or anti-albumin (αAlb) 
binding units. In vitro binding studies and in vivo biodistribution studies in tumor bearing 
mice were performed to test whether both units retained full functionality. An αEGFR-
αEGFR nanobody showed rapid blood clearance, very high tumor-to-normal tissue ratios 
(except for kidney), but moderate levels of tumor uptake (5.0 ± 1.4 %ID/g at 6 h after 
injection), which rapidly decreased over time. Rapid clearance of this ~35 kDa construct 
was expected, since molecules smaller than 60 to 70 kDa in general are filtered out by the 
kidneys very rapidly. A totally different biodistribution profile was obtained when an αAlb 
binding unit was added to the αEGFR-αEGFR construct. The thus obtained ~50 kDa 
αEGFR-αEGFR-αAlb molecule showed: (a) rapid, high (up to 35.2 ± 7.5 %ID/g), and 
selective tumor accumulation, which was similar to that of the 150 kDa anti-EGFR 
reference mAb cetuximab; (b) prolonged residence time in blood and tumor; (c) 
homogeneous distribution throughout the tumor, more homogeneous than cetuximab, and 
(d) apparent saturation of EGFR when administered at a relatively high dose. These data 
indicate that nanobody technology allows the construction of ligands, which show optimal 
characteristics for EGFR targeting. In addition, the data show that binding units retain their 
binding characteristics when placed within a bead chain. Whereas the presence of αEGFR 
units resulted in selective tumor-targeting of EGFR expressing tumors, the binding of the 
αAlb unit to serum albumin caused extension of half-life in blood, and in fact similar 
pharmacokinetics were found for αEGFR-αEGFR-αAlb and murine serum albumin. These 
findings encourage further exploration of the nanobody toolbox, e.g. for development of 
biparatopic (two different epitopes on the same target antigen) (35) or multi-specific single 
molecule nanobody constructs. With respect to the latter, simultaneous targeting of two or 
more critical tumor targets, e.g. EGFR and VEGF, by one single nanobody molecule 
(αEGFR-αVEGF-αAlb like formats) comes within reach. Until now, nanobody constructs 
with up to 5 binding units can be produced. Whether each of these units will contain full 
binding characteristics has to be demonstrated.  
At this moment, three nanobodies are tested in clinical studies. Two therapeutic 
nanobodies target Von Willebrand Factor, which may reduce the risk of thrombosis in 
patients with acute coronary syndrome and thrombotic thrombocytopenic purpura. The 
third nanobody targets tumor necrosis factor alpha (TNF-α), a key drug target in combating 
inflammation related disorders such as rheumatoid arthritis. Until now, no clinical studies 
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have been started with nanobodies targeting cancer. One of the important questions in these 
clinical trials is whether human-anti-llama antibodies will be formed, since such 
immunological response might hamper efficient targeting. This is particularly true for the 
slow kinetic constructs containing an αAlb unit. 
 
In conclusion: the results from the studies described in this thesis encourage the further 
development of targeted therapies for the locoregional and systemic treatment of head and 
neck cancer. Chemo-electroporation therapy appeared to be a valuable addition in the 
treatment of patients who could no longer be treated by surgery or radiotherapy, and 
combination with systemic therapies is interesting and needs further investigation. The 
selection of target antigens with strict tumor-selective expression needs attention to enable 
the use of antibody-drug conjugates for therapy. Unacceptable toxicities due to cross-
reactivity should be anticipated. The results from the radioimmunotherapy studies for the 
selective targeting of tumor vasculature pave the way for clinical studies. Appropriate 
tumor targeting and dosimetry can be obtained by using immuno-PET prior to 
radioimmunotherapy. The development of next-generation multivalent or multispecific 
antibody-fragments opens new avenues for multi-targeted therapies by blocking several 
critical tumor targets simultaneously. 
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Figure 1. Patient with metastasized thyroid cancer. After extensive vertebral surgery and several treatments 
with 131I, it remained unclear whether vital tumor tissue was still present. 124I-PET-CT clearly shows iodine 
uptake (i.e. vital tumor) at the left side of the vertebra. Therefore, adjuvant high dose 131I therapy is 
recommended for this patient.  
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Samenvatting, discussie en toekomstperspectieven 
 
 
 
    
Hoofd-halskanker omvat voornamelijk tumoren die uitgaan van de slijmvliezen van de 
bovenste lucht- en voedselwegen, met name de mondholte, de keelholte en het 
strottenhoofd. Meer dan 90% van alle maligniteiten in het hoofd-halsgebied betreft een 
plaveiselcelcarcinoom, en deze groep tumoren vormt daarmee ongeveer 5% van alle 
maligniteiten die voorkomen in de westerse wereld. Wereldwijd wordt de diagnose hoofd-
halskanker meer dan een half miljoen keer per jaar gesteld. In Nederland ontwikkelen 
jaarlijks meer dan 2500 mensen deze ziekte, en ruim 800 mensen sterven hieraan. 
Tweederde van de mensen bij wie hoofd-halskanker wordt gediagnosticeerd, heeft 
reeds een vergevorderd stadium van de ziekte, en hun prognose is slecht. In de afgelopen 
drie decennia is een duidelijke vooruitgang geboekt bij de lokale en regionale behandeling 
van hoofd-halskanker, maar helaas heeft dit vooralsnog niet geleid tot een verlenging van 
de overlevingsduur. Dit komt in de eerste plaats omdat deze patiënten regelmatig recidieven 
en metastasen op afstand krijgen, en in de tweede plaats omdat deze patiënten regelmatig 
tweede primaire tumoren ontwikkelen. Behandeling na eerdere uitgebreide behandeling in 
het hoofd-halsgebied is niet altijd mogelijk. Daarom moeten meer specifieke ‘gerichte’ 
therapieën (‘targeted therapies’) ontwikkeld worden voor de locoregionale behandeling van 
tumoren, met als doel maligne weefsel selectief te vernietigen en gelijktijdig gezond 
weefsel te sparen. Daarnaast moeten adjuvante systemische strategieën worden ontwikkeld 
om occulte afstandsmetastasen en kleine achtergebleven tumorresten te vernietigen. Zulke 
‘targeted therapies’ zijn noodzakelijk om zowel de locoregionale als systemische 
behandeling van hoofd-halskanker te verbeteren. Hierbij dient de nadruk te liggen op 
behoud van orgaanfunctie en kwaliteit van leven. Deze ‘targeted therapies’ kunnen ingezet 
worden als monotherapie en als combinatietherapie samen met radiotherapie en 
chemotherapie. Idealiter hebben deze therapieën een synergistisch effect. Het gebruik van 
‘multi-targeting strategieën’ (een tumor aanvallen op meerdere aangrijpingspunten) in 
plaats van ‘mono-targeting strategieën’ zou een positief effect moeten geven op de 
effectiviteit van behandelingen van tumoren en op het voorkomen van therapieresistentie.  
De afgelopen decennia zijn verschillende locoregionale behandelmodaliteiten 
beschikbaar gekomen, die gericht zijn op effectieve vernietiging van tumoren, waarbij 
gelijktijdig het behoud van orgaanfuncties, symptoombestrijding en het vermijden van 
bijwerkingen centraal staan. Bleomycine elektroporatietherapie is één van deze nieuwe 
behandelvormen voor solide tumoren, die ontwikkeld is als alternatief voor chirurgische 
therapieën, of als aanvulling hierop. Deze behandeling leidt tot een selectieve vernietiging 
van kankercellen, waarbij cosmetische en functionele problemen beperkt blijven. In 
hoofdstuk 2 wordt een klinische fase IV studie beschreven met bleomycine 
elektroporatietherapie. Patiënten met maligniteiten uitgaande van het hoofd-halsgebied, die 
niet langer behandeld konden worden middels een operatie of radiotherapie, werden 
behandeld met bleomycine elektroporatietherapie. Bij deze behandeling wordt het 
cytostaticum bleomycine rechtstreeks in de tumor geïnjecteerd, waarna met behulp van 
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naaldelektrodes elektrische pulsen worden toegediend aan de tumor. Deze elektrische 
pulsen zorgen er voor dat de bleomycine beter in de tumorcel komt waar het zijn werking 
heeft. Veertien patiënten met in totaal vierentwintig tumoren ondergingen deze selectieve 
locoregionale behandeling. Bij tien tumoren van drie verschillende patiënten was na twee 
jaar nog steeds sprake van lokale tumorcontrole. In alle gevallen bleven de orgaanfuncties 
bewaard, en werd een esthetisch acceptabel resultaat bereikt. Bleomycine 
elektroporatietherapie bleek een eenvoudig uit te voeren behandeling met weinig nadelige 
effecten voor de patiënt, en is in potentie effectief bij de behandeling van patiënten met 
tumoren in het hoofd-halsgebied. De procedure neemt normaal gesproken minder dan een 
uur in beslag. De behandeling kan in principe poliklinisch plaatsvinden, maar in onze 
kliniek werden alle patiënten enkele dagen opgenomen op de verpleegafdeling.  
Ondanks het feit dat het startpunt van deze studie een flinke uitdaging vormde 
(patiënten die reeds uitgebreide behandelingen ondergaan hadden, en niet meer aanvullend 
behandeld konden worden middels chirurgie of radiotherapie), zijn de resultaten van 
bleomycine elektroporatietherapie bemoedigend in termen van weefselpreservatie en 
tumorcontrole. Een mogelijke beperking bij de toepassing van bleomycine 
elektroporatietherapie is een slechte bereikbaarheid van de tumor voor injectie van 
bleomycine en/of het inbrengen van de applicator. Om effectief te kunnen zijn is het 
noodzakelijk dat de gehele tumor, evenals het ogenschijnlijk normale weefsel binnen een 
marge van 0,5 cm rondom de tumor, behandeld worden. Een andere beperking kan zijn dat 
veel patiënten al radiotherapie ondergaan hebben tijdens eerdere behandelingen, waarbij 
DNA schade in zowel tumorcellen als omringend weefsel is ontstaan. Bleomycine geeft een 
soortgelijke DNA schade. Hoewel normaal, niet-bestraald weefsel deze schade kan 
herstellen (in tegenstelling tot tumorcellen), treedt in eerder bestraalde gebieden regelmatig 
een vertraagde wondgenezing op na bleomycine toediening. Sommige patiënten hadden al 
onbehandelbare afstandsmetastasen op het moment van therapie, en bij deze patiënten werd 
wel palliatie bereikt, maar geen levensverlenging gezien. Toch zijn de resultaten van deze 
studie hoopvol. 
Bleomycine elektroporatietherapie bleek tot dusver het meest effectief als primaire 
behandeling bij patiënten met vroege stadia van hoofd-halskanker. Complete remissie werd 
bereikt bij 83% van de behandelde laesies binnen 4 weken na de behandeling (1). Maar ook 
in verder gevorderde stadia van ziekte leidde deze behandeling tot partiële (32%) en 
complete (25%) responsen bij 57% van de behandelde laesies. Eén jaar na de behandeling 
was nog 30% van de patiënten in leven. Dit getal komt overeen met de getallen die bekend 
zijn voor patiënten met vergevorderde stadia van ziekte. De in deze studie gevonden 
verbeterde lokale controle van hoofd-halstumoren had geen positief effect op de overleving. 
Wel bleek de kwaliteit van leven flink verbeterd door de lokale tumorcontrole (2). De 
huidige standaardbehandeling voor primaire mondholtecarcinomen in een vroeg stadium is 
chirurgie, leidend tot een vijfjaars overall overleving van 70-80%. Derhalve is er geen 
159 
    
harde indicatie om deze behandelstrategie te vervangen door bleomycine 
elektroporatietherapie. Een vergevorderd stadium wordt meestal behandeld met chirurgie 
en/of radiotherapie met of zonder chemotherapie. In geval van het optreden van lokale 
recidieven, tweede primaire tumoren of afstandsmetastasen, is de prognose slechter, en zijn 
standaardbehandelingen niet altijd voorhanden. Bleomycine elektroporatietherapie blijkt 
een waardevolle aanvulling te zijn op de standaardbehandelingen. Wij denken dat 
bleomycine elektroporatietherapie een eenvoudig uit te voeren behandeling is, die 
potentieel effectief is bij geselecteerde groepen van patiënten met tumoren in het hoofd-
halsgebied, zelfs bij patiënten met een vergevorderd stadium van ziekte, met recidieven of 
afstandsmetastasen. Een belangrijk voordeel van bleomycine elektroporatietherapie in 
vergelijking met een andere opkomende selectieve behandelingsmodaliteit, fotodynamische 
therapie (3), is de afwezigheid van fotosensitiviteit, waarbij patiënten enkele weken na 
behandeling rekening moeten houden met zonexpositie. Een behandeling zonder al te veel 
belasting voor de patiënt is met name belangrijk in een palliatieve setting, bij patiënten met 
een beperkte levensverwachting. Daarnaast is bleomycine elektroporatietherapie toepasbaar 
bij meerdere typen van kanker, niet alleen bij plaveiselcelcarcinomen van de slijmvliezen 
en de huid, maar ook bij maligne tumoren van de speekselklieren, basaalcelcarcinomen, 
melanomen, adenocarcinomen, Merkelcelcarcinomen, sarcomen, cutane lymfomen, 
huidmetastasen en overige primaire huidtumoren. Ook grotere tumoren met invasiedieptes 
tot 2,5 cm kunnen behandeld worden met deze therapie.  
Op dit moment zijn meerdere groepen over de hele wereld bezig met het 
optimaliseren van elektroporatiesystemen. Combinaties van elektroporatie met andere 
cytostatica worden momenteel onderzocht, bijvoorbeeld de combinatie met systemische 
cisplatinumtherapie (4-6). Elektroporatie in combinatie met simultane chemoradiatie met 
cisplatinum om de lokale tumoropname te verhogen en zodoende de lokale tumorcontrole 
te verbeteren is een interessant idee, dat verder onderzocht dient te worden. 
De laatste jaren zijn systemische selectieve therapieën steeds belangrijker 
geworden om kleine achtergebleven tumorresten en occulte afstandsmetastasen te 
bestrijden. Deze adjuvante strategieën zijn essentieel om de algehele overleving van hoofd-
halskanker te verbeteren. Monoklonale antilichamen (mAbs) of antilichaamfragmenten zijn 
moleculen die selectief aan tumorcellen kunnen binden, selectief een toxische stof kunnen 
afleveren aan tumoren, of selectief kritische cellulaire processen die essentieel zijn voor 
tumorgroei en overleving kunnen neutraliseren of blokkeren. Normaal weefsel, dat geen 
specifieke bindingsplaats (antigeen) tot expressie brengt, zal niet worden aangevallen door 
deze mAbs. Het gehumaniseerde mAb bivatuzumab is gericht tegen het CD44v6-antigeen, 
dat voornamelijk tot expressie komt op plaveiselcelcarcinomen. In eerdere studies werden 
bemoedigende resultaten geboekt bij de ontwikkeling van bivatuzumab en andere anti-
CD44v6 mAbs, met name in radioimmunoscintigrafiestudies als voorbereiding op 
radioimmunotherapie (RIT) studies bij patiënten met hoofd-halskanker (7,8). Binding van 
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deze mAbs aan het target-antigeen resulteert in internalisatie van het antilichaam (9). De 
fase I dosis escalatie RIT studies lieten veelbelovende anti-tumor effecten zien, met 
consequent stabilisatie van tumorgroei bij hogere dosis radioactiviteit. Beenmergtoxiciteit, 
veroorzaakt door circulerend radioimmunoconjugaat, bleek de dosisbeperkende factor te 
zijn. Daarnaast werd bij slechts enkele patiënten een milde mucositis van de mond gezien 
(10-12). Deze patiënten hadden overigens bij eerdere externe bestraling tijdens 
radiotherapie een zeker zo ernstige mucositis ontwikkeld. Deze data toonden aan dat 
kruisreactiviteit van anti-CD44v6 mAbs met normale mucosa niet direct een beperking 
hoeft te zijn voor therapeutisch toepassing van dergelijke mAbs. Het gebruik van 
radioimmunoconjugaten voor therapie is in het algemeen gecompliceerd in verband met 
logistieke en stralingsveiligheidsaspecten. Daarom werd besloten om de radioactiviteit weg 
te laten, en in plaats daarvan aan het anti-CD44v6 antilichaam een zeer toxische stof te 
koppelen. Dergelijke conjugaten zijn met name interessant omdat ze naar verwachting 
minder beenmergtoxiciteit veroorzaken, en ze daarom wellicht gecombineerd kunnen 
worden met conventionele chemotherapie. Bivatuzumab mertansine is een zogenaamd 
tumor-geactiveerd pro-drug conjugaat, dat bestaat uit het supertoxische anti-microtubuli 
geneesmiddel mertansine (DM1), covalent gebonden aan bivatuzumab. Na binding aan 
CD44v6 wordt het conjugaat geïnternaliseerd, en komen de mertansine moleculen 
intracellulair vrij door verbreking van de disulfide bindingen. Normaal weefsel, dat geen 
CD44v6-expressie vertoont, wordt niet aangevallen door bivatuzumab mertansine. In 
hoofdstuk 3 wordt een klinische fase I dosis escalatiestudie met bivatuzumab mertansine 
beschreven. De veiligheid, maximaal tolerabele dosis (MTD) en eerste anti-tumor effecten 
van bivatuzumab mertansine werden onderzocht, en de farmacokinetiek en immunogeniteit 
werden vastgesteld na drie wekelijkse intraveneuze toedieningen van het conjugaat. 
In deze studie werd geen mertansine toxiciteit gezien ten gevolge van het 
voortijdig vrijkomen van het geneesmiddel in de bloedbaan, en er was geen sprake van 
opname van het conjugaat door cellen zonder expressie van het CD44v6 antigeen. De 
belangrijkste toxiciteit werd gezien in de huid, waarschijnlijk door CD44v6-expressie in dit 
orgaan (kruisreactiviteit). Het grootste gedeelte van de huidreacties ging vanzelf weer over, 
maar er trad ook één fatale bijwerking op die gerelateerd was aan het geïnjecteerde 
antilichaamconjugaat. Een zogenaamde toxische epidermale necrolyse (TEN) trad op bij 
één patiënt die tweemaal een dosis had ontvangen van 140 mg/m2. Het meest waarschijnlijk 
is, dat deze toxiciteit uitgelokt is door kruisreactiviteit in de keratinocyten in de huid. Er 
zijn geen aanwijzingen gevonden voor een relatie tussen de conjugaat dosis en de toxiciteit, 
en daarom is het moeilijk te voorspellen wanneer deze ernstige huidtoxiciteit zal gaan 
optreden (13).  
In een studie die parallel liep aan de hierboven beschreven studie, kregen 
eenendertig patiënten met hoofd-halskanker een éénmalige dosering bivatuzumab 
mertansine toegediend, variërend van 25-325 mg/m2. Dertien van deze patiënten kregen 
161 
    
drie weken later een tweede toediening. De MTD werd vastgesteld op 300 mg/m2, met 
huidtoxiciteit als dosislimiterende factor. Bij geen enkele patiënt werd een immuunrespons 
gericht tegen het toegediende antilichaamconjugaat vastgesteld. De voornaamste toxische 
effecten waren maculo-papuleus exantheem, blaarvorming en schilfering van de huid. Drie 
patiënten toonden een partiële respons bij doses van 200, 275 en 325 mg/m2 (14-16). Twee 
patiënten die behandeld werden op dit laatste dosisniveau ontwikkelden dosislimiterende 
toxiciteiten met tekenen van epidermolyse, maar deze toxiciteiten bleken geheel reversibel 
te zijn. De dosis van 300 mg/m2, die hieraan vooraf ging, werd goed verdragen. 
In een andere parallelle studie met bivatuzumab mertansine bij patiënten met een 
CD44v6-positief, gemetastaseerd mammacarcinoom, werden vierentwintig patiënten 
behandeld op acht verschillende dosis niveaus (25-200 mg/m2). Zeven van hen kregen meer 
dan één toediening van bivatuzumab mertansine. Twee dosislimiterende toxiciteiten traden 
op: één patiënte die behandeld werd met een dosis van 125 mg/m2 ontwikkelde ernstige 
passagère leverenzymstijgingen (graad 4); een andere patiënte die behandeld werd met 175 
mg/m2 ontwikkelde ernstige klachten van braken (graad 3). Zij overleed aan de gevolgen 
van nierfalen, die wellicht veroorzaakt werden door verergering van pre-existente 
nierinsufficiëntie. De meest voorkomende toxiciteit was een passagère en milde 
huidafwijking die optrad bij 75% van de patiënten. Er werden geen objectieve responsen 
waargenomen. Stabilisering van de ziekte werd bereikt bij 50% van de patiënten, 
onafhankelijk van het dosisniveau (17). 
De in hoofdstuk 3 beschreven patiënt die een TEN ontwikkelde, had slechts twee 
wekelijkse giften van 140 mg/m2 ontvangen. In totaal werden 70 patiënten behandeld in 
verschillende centra, waarbij vijf dosislimiterende toxiciteiten optraden. TEN is een 
zeldzame aandoening, die gekenmerkt wordt door uitgebreid afsterven van de epidermis, en 
veroorzaakt wordt door een karakteristieke geneesmiddelreactie, zonder dat er sprake is van 
een dosis-toxiciteitsrelatie. De mortaliteit van TEN is hoog, en er is geen specifieke 
behandeling beschreven. Omdat niet te voorspellen is welke patiënt gevaar loopt een TEN 
te ontwikkelen, werd het bivatuzumab mertansine conjugaat als onveilig geclassificeerd, en 
werd de verdere klinische ontwikkeling gestaakt nog voordat de MTD vastgesteld kon 
worden. 
Uit deze studie kan geconcludeerd worden dat een strikte tumorselectieve 
expressie van het specifieke target-antigeen vereist is, wanneer dergelijke supertoxische 
antilichaamconjugaten gebruikt worden voor therapie. De expressie van CD44v6 was 
blijkbaar niet selectief genoeg. Dit kan consequenties hebben voor de ontwikkeling van 
andere antilichaam-mertansine conjugaten, zoals trastuzumab-mertansine (T-DM1 = 
herceptin-DM1), een conjugaat dat momenteel getest wordt bij patiënten met vergevorderd 
stadium van HER2-positief mammacarcinoom (18). Overexpressie van de receptor tyrosine 
kinase HER2 (erbB2) is gecorreleerd met een slechte prognose bij mamma- en 
ovariumcarcinoom. Behandeling met het anti-HER2 mAb trastuzumab verhoogt de 
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overleving bij patiënten met HER2-positief mammacarcinoom, maar deze behandeling kan 
tevens cardiomyopathie veroorzaken (19,20). Anthracycline-trastuzumab gebaseerde 
behandelingen worden beperkt door een onacceptabel hoge mate van cardiotoxiciteit, met 
name bij gelijktijdige toediening. Trastuzumab verhoogt het risico op anthracycline-
geïnduceerde cardiotoxiciteit (21). Myocardiale HER2-expressie lijkt tijdelijk verhoogd te 
worden als compensatiemechanisme ten gevolge van cardiale stress (22). Hoewel fase I en 
II klinische trials met T-DM1 tot nu toe geen specifieke cardiale toxiciteit laten zien, tonen 
de resultaten van onze studie aan dat voorzichtigheid geboden is, in het bijzonder bij 
patiënten die in het verleden behandeld zijn geweest met anthracyclines (23,24). 
De selectieve aanval op de bloedvaten van tumoren is een volgende interessante 
therapeutische strategie. Bloedvatvorming (angiogenese) is een vereiste voor 
tumorprogressie en metastasering, en het voorkómen van dit proces en de vernietiging van 
tumorbloedvaatjes is een belangrijk aandachtspunt geworden binnen het klinisch 
onderzoek. Het mAb-fragment L19-SIP is gericht tegen het extra-domein B (ED-B) van 
fibronectine, dat verhoogd tot expressie komt in de nabijheid van nieuwgevormde 
bloedvaten. Hoofdstuk 4 beschrijft de biodistributie van L19-SIP en de mogelijkheden 
voor RIT bij naakte muizen, die in beide flanken de humane hoofd-halskanker lijnen FaDu 
of HNX-OE droegen. L19-SIP liet een hoge en selectieve tumoropname zien bij beide 
geteste hoofd-halskanker lijnen. De tumor-bloedopname ratio varieerde van 4.4 ± 1.8 tot 
21.4 ± 1.8, respectievelijk 24 uur en 72 uur na injectie voor de FaDu lijn. De opname ratio 
tussen tumor en normale weefsels was in het algemeen minstens net zo hoog, wat zeer 
bemoedigend is, aangezien L19-SIP in principe ook kan binden aan de ED-B variant van de 
muis. RIT met 131I-L19-SIP op het MTD niveau van 74 MBq leidde tot een significante 
groeivertraging en een verbeterde overleving in beide tumorlijnen. De effectiviteit werd 
verhoogd door 131I-L19-SIP RIT te combineren met het anti-EGFR mAb cetuximab, zonder 
dat er sprake was van een toename in toxiciteit. Wanneer tumor-dragende muizen 
behandeld werden met deze combinatietherapie, werden complete responsen waargenomen 
bij twee van de acht FaDu tumoren en bij vijf van de acht HNX-OE tumoren, zonder dat 
hergroei gedurende de daaropvolgende observatieperiode van 3-4 maanden plaatsvond. 
De selectieve aanval op tumorbloedvaten kan toegepast worden bij bijna alle 
tumortypen, aangezien verhoogde ED-B expressie gevonden wordt in de meeste tumoren 
(25,26). Recent toonde een klinische RIT studie met 131I-L19-SIP bij patiënten met 
lymfomen veelbelovende resultaten. ED-B expressie werd vastgesteld in tumorbiopten van 
meer dan 200 patiënten met Hodgkin en non-Hodgkin lymfomen van bijna alle entiteiten, 
alsook in biopten van patiënten met myeloproliferatieve aandoeningen. Daarentegen was de 
ED-B expressie bijna afwezig in normale lymfeklieren (n = 10) en beenmergbiopten (n = 
9). De mate van ED-B expressie in lymfoomweefsel toonde een positieve correlatie met de 
maligniteitsgraad. De in vivo toegankelijkheid van ED-B voor 131I-L19-SIP werd bevestigd 
bij drie lymfoompatiënten, bij wie de lymfoomhaarden in beeld gebracht konden worden 
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middels SPECT scanning. Bij deze patiënten hadden meerdere voorafgaande therapieën 
niet geleid tot een complete remissie, en zij presenteerden zich met recidieven die 
aangetoond waren middels 18FDG PET-CT scans. Gebaseerd op de selectieve opname in 
tumorlaesies en op acceptabele beenmergdosimetrie, kregen twee patiënten een 
therapeutische dosis 131I-L19-SIP van 5.55 GBq (150 mCi), en één patiënt een dosis van 3.7 
GBq (100 mCi). ‘Whole-body’ en SPECT-CT scans werden 8-12 dagen na toediening van 
het conjugaat gemaakt om de specifieke tumoropname van 131I-L19-SIP te bevestigen. Bij 
twee patiënten met gerecidiveerd Hodgkin lymfoom leidde 131I-L19-SIP RIT tot een 
aanhoudende partiële respons. Op basis van deze resultaten mag ED-B een veelbelovend 
‘target’ voor antilichaamtherapie genoemd worden (27). Daarnaast rechtvaardigen deze 
resultaten de verdere ontwikkeling van RIT met 131I-L19-SIP bij geselecteerde patiënten 
met solide tumoren, zoals hoofd-halskanker. Bij eerder uitgebreid immunohistochemisch 
onderzoek werd ED-B expressie bij het merendeel van de hoofd-halstumoren aangetoond, 
met daarbij de hoogste expressie bij de meest agressieve tumoren (28). Deze variabiliteit in 
expressie duidt er op dat beeldvorming voorafgaand aan therapie met L19-SIP gewenst is, 
om op die manier de meest geschikte kandidaten voor RIT te kunnen selecteren. Voor het 
verkrijgen van hoge resolutie beeldvorming en voor accurate kwantificering van de L19-
SIP distributie, is PET een aantrekkelijkere optie dan de op dit moment veel gebruikte 
SPECT procedure (29,30). 
De eerder genoemde bemoedigende preklinische en klinische resultaten van RIT 
met 131I-L19-SIP vormde de basis voor de ontwikkeling van een pre-therapie ‘scouting’ 
procedure, waarbij de biodistributie van L19-SIP eerst met een PET-camera vastgesteld 
wordt om te kijken of de betreffende patiënt in aanmerking komt voor RIT. Hiertoe wordt 
124I-L19-SIP gebruikt als de PET-tracer. Moleculaire beeldvorming van tumorbloedvaten 
biedt klinische perspectieven voor detectie van laesies en voor patiëntselectie, maar ook 
voor de ontwikkeling en validatie van nieuwe geneesmiddelen, respons-evaluatie, en 
dosisoptimalisatie (31). In hoofdstuk 5 hebben we ons gericht op de ontwikkeling van 124I-
L19-SIP immuno-PET, niet alleen voor beeldvorming van tumorangiogenese, maar ook als 
scouting procedure voorafgaand aan klinische 131I-L19-SIP RIT, om zodoende selectieve 
‘tumortargeting’ te bevestigen en dosimetrie mogelijk te maken. Beeldvorming van ED-B-
expressie kan van belang zijn voor het stellen van de diagnose ‘kanker’ en voor het 
monitoren van de effectiviteit van antikankertherapieën.  
Als uitgangspunt voor de ontwikkeling van 124I-L19-SIP immuno-PET, werden de 
infrastructuur en procedures ontwikkeld voor een efficiënte productie volgens GMP (‘Good 
Manufacturing Practice’) richtlijnen van grote batches 124I (> 2 GBq) met een hoge 
radionuclidische (>99.5%) en radiochemische (>95% als jodide) zuiverheid en een laag 
tellurium- (<1 μg/ml) en pyrogeengehalte (<5 EU/ml). Het resultaat is dat farmaceutische 
kwaliteit 124I beschikbaar is gekomen voor wereldwijde distributie, niet alleen voor 
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immuno-PET toepassingen, maar ook bijvoorbeeld voor de selectie van patiënten met 
schildklierkanker voor 131I-therapie (figuur 1). 
L19-SIP liet na koppeling van 124I een optimale integriteit en immunoreactiviteit 
zien, en vertoonde hetzelfde farmacokinetische gedrag als het overeenkomstige 131I 
conjugaat. Biodistributiestudies toonden hoge en selectieve tumortargeting, resulterend in 
tumor-bloed ratio’s variërend van 6.0 tot 45.9, respectievelijk 24 uur en 72 uur na injectie. 
Het resultaat was ook dat er hoge tumor-normaal weefsel ratio’s werden verkregen met 124I-
L19-SIP, resulterend in duidelijke visualisatie van tumoren middels PET-beeldvorming, 
zelfs wanneer het zeer kleine tumoren betrof (~50 mm3). Immuno-PET met 124I-L19-SIP 
bleek geschikt voor gevoelige beeldvorming van nieuwe tumorbloedvaatjes en voor het 
voorspellen van de 131I-L19-SIP biodistributie. Dit resultaat maakt de weg vrij voor het 
gebruik van 124I-L19-SIP immuno-PET bij de selectie van patiënten, die op basis van 
adequate ‘tumortargeting’ en dosimetrie (gepersonaliseerde therapie), het meest kans op 
baat hebben bij 131I-L19-SIP RIT. 
Op dit moment, zijn negen mAbs goedgekeurd voor de behandeling van kanker, en 
dit zijn allemaal intacte mAbs. Vijf van deze mAbs zijn geregistreerd voor de behandeling 
van hematologische tumoren: rituximab, gemtuzumab ozogamicin, alemtuzumab, 
ibritumomab tiuxetan, en tositumomab. De vier mAbs trastuzumab (anti-HER2), cetuximab 
(anti-EGFR), panitumumab (anti-EGFR) en bevacizumab (anti-VEGF) zijn geregistreerd 
voor de behandeling van solide tumoren. Cetuximab is onder andere geregistreerd voor de 
behandeling van hoofd-halskanker. Ondanks verschillende klinische successen, is het reëel 
om te stellen dat de effectiviteit van de huidige mAbs toch beperkt is, met voordelen voor 
slechts een beperkte groep patiënten, terwijl de kosten van mAb-therapie excessief zijn. 
Omdat kankercellen de eigenschap hebben verschillende groeistimulatieroutes te 
gebruiken voor groei en overleving, proliferatie, angiogenese en invasie en metastasering, 
kan selectieve ‘targeting’ van slechts één enkel ‘tumortarget’ wel eens onvoldoende blijken 
voor het bereiken van een bevredigend therapeutisch resultaat. De resistentie die in tumoren 
kan ontstaan als gevolg van anti-EGFR therapie kan daarbij als voorbeeld dienen. Bij 
dergelijke tumoren wordt de c-Met signaalroute van groter belang voor overleving (32). 
Deze inzichten hebben de aanzet gegeven tot het ontwikkelen van strategieën waarbij 
meerdere kritische tumortargets simultaan geblokkeerd worden. Er zijn o.a. studies gestart 
waarin combinaties van reeds geregistreerde mAbs worden gebruikt, bijvoorbeeld één mAb 
gericht tegen EGFR en een ander mAb gericht tegen VEGF (33). Enkele farmaceutische 
bedrijven zijn zelfs gestart met de klinische ontwikkeling van mAb cocktails. Omdat mAbs 
beschouwd worden als ’dure medicijnen’, vormt de introductie van gecombineerde mAb 
therapie een enorme uitdaging, zeker voor wat betreft de economische aspecten. 
In dit proefschrift introduceren we het gebruik van nanobodies voor de remming 
van signaaltransductieroutes die aanzetten tot tumorgroei en overleving. In eerste instantie 
staat vooral de EGFR gemedieerde route centraal, omdat die een belangrijke rol speelt bij 
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hoofd-halskanker (34). Nanobodies worden verkregen uit een uniek antilichaamformaat, dat 
voorkomt in species van de familie van Camelidae, de kameelachtigen. Deze familie omvat 
lama’s, kamelen en dromedarissen. Terwijl mensen en de meeste andere dieren voor hun 
afweer antilichamen gebruiken die bestaan uit 2 zware en 2 lichte ketens, hebben deze 
dieren tevens antilichamen die uitsluitend uit zware ketens bestaan. Het antigeenbindend 
gedeelte van deze ‘zware keten antilichamen’ wordt nanobody genoemd, en deze 
nanobodies van 15 kDa kunnen uitstekend als bouwstenen gebruikt worden voor de 
ontwikkeling van nieuwe geneesmiddelen. Vooral aantrekkelijk is de flexibiliteit van 
geneesmiddelsamenstelling, waarbij het relatief eenvoudig is om multivalente en/of multi-
specifieke geneesmiddelen samen te stellen, met meerdere bindingsdomeinen binnen één 
molecuul. De productie van deze geneesmiddelen kan op een relatief goedkope manier met 
behulp van bacteriën of gist. Op deze manier kan een enkelvoudig kralensnoerachtig 
molecuul verkregen worden, bestaande uit verschillende 15 kDa bouwstenen, die gericht 
kunnen zijn tegen hetzelfde target of verschillende targets. Van groot belang voor de 
toekomst van deze modulaire mAb technologie is de vraag of deze bouwstenen hun 
bindingsaffiniteit en specificiteit behouden, wanneer ze achter elkaar geplaatst worden 
binnen een dergelijke kralensnoerstructuur. In hoofdstuk 6 zijn we de uitdaging aangegaan 
om deze vraag te beantwoorden, door moleculen te construeren bestaande uit anti-EGFR 
(αEGFR) en/of anti-albumine (αAlb) bouwstenen. In vitro bindingsstudies en in vivo 
biodistributiestudies werden uitgevoerd bij tumordragende muizen om te testen of beide 
bouwstenen hun volledige functionaliteit behouden wanneer ze gekoppeld zijn. Een 
αEGFR-αEGFR nanobody toonde snelle klaring uit het bloed, zeer hoge tumor-normaal 
weefsel ratio’s (behalve voor de nieren), maar slechts een matig niveau van tumoropname 
(5.0 ± 1.4 %ID/g, 6 uur na injectie), dat tevens in de loop van de tijd snel afnam. Snelle 
klaring van dit ~35 kDa construct was te verwachten, aangezien moleculen kleiner dan 60-
70 kDa in het algemeen zeer snel via de nieren uitgescheiden worden. Een totaal andere 
biodistributieprofiel werd gevonden wanneer een αAlb bouwsteen werd toegevoegd aan het 
αEGFR-αEGFR construct. Het op deze manier verkregen ~50 kDa αEGFR-αEGFR-αAlb 
molecuul toonde: (a) snelle, hoge (tot 35.2 ± 7.5 %ID/g), en selectieve tumorophoping, die 
vergelijkbaar was met die van het 150 kDa anti-EGFR referentie-mAb cetuximab; (b) een 
langere verblijftijd in het bloed en in de tumor; (c) homogene verdeling binnen de tumor, 
homogener dan cetuximab, en (d) ogenschijnlijke verzadiging van EGFR wanneer het 
toegediend werd in een relatief hoge dosering. Deze gegevens duiden er op dat met 
nanobodies optimale EGFR-targeting mogelijk is. Daarnaast tonen deze data aan dat de 
afzonderlijke bouwstenen elk hun bindingseigenschappen behouden, zelfs wanneer ze in 
een kralensnoerstructuur gerangschikt zijn. Terwijl de aanwezigheid van αEGFR-units 
resulteerde in selectieve tumortargeting van tumoren met EGFR-expressie, veroorzaakte de 
binding van de αAlb-unit aan serumalbumine een verlenging van de verblijftijd in het 
bloed. Sterker nog, de farmacokinetiek van αEGFR-αEGFR-αAlb bleek precies overeen te 
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komen met die van muize-serumalbumine. Deze resultaten rechtvaardigen de verdere 
toepassing van nanobody technologie, bijvoorbeeld voor de ontwikkeling van 
biparatopische (twee verschillende epitopen op hetzelfde targetantigeen) (35) of multi-
specifieke nanobody-constructen bestaande uit één molecuul. Met betrekking tot dit laatste 
komt de gelijktijdige targeting van twee of meer kritische tumortargets, zoals bijvoorbeeld 
EGFR en VEGF, met één enkel nanobody-molecuul (in dit geval αEGFR-αVEGF-αAlb) 
binnen handbereik. Tot nu toe kunnen nanobody-constructen bestaande uit maximaal vijf 
bouwstenen worden geproduceerd. Of alle units dan nog hun volledige bindingscapaciteit 
behouden, zal moeten worden onderzocht.  
Op dit moment worden drie nanobodies getest in klinische studies. Twee 
therapeutische nanobodies zijn gericht tegen de Von Willebrandfactor, waarbij het risico 
van thrombose bij patiënten met het acuut coronair syndroom en thrombotische 
thrombocytopenische purpura verkleind moet worden. Een derde nanobody is gericht tegen 
de tumor necrosis factor alpha (TNF-α), die een sleutelrol speelt bij ontstekingsgerelateerde 
ziekten als reumatoïde artritis. Op dit moment zijn er nog geen klinische studies gestart met 
nanobodies gericht tegen kanker. Een belangrijke vraag die gesteld kan worden bij 
klinische toepassing is of humane-anti-lama antilichamen gevormd zullen worden. Een 
dergelijke immunologische respons zou een belemmering kunnen vormen voor effectieve 
targeting. Dit is vooral van belang voor de constructen die een αAlb unit bevatten, en 
daardoor een langzame kinetiek vertonen. 
 
Conclusie: de resultaten van de studies beschreven in dit proefschrift bemoedigen een 
verdere ontwikkeling van targeted therapies voor de locoregionale en systemische 
behandeling van hoofd-halskanker. Bleomycine elektroporatietherapie bleek een 
waardevolle aanvulling te zijn op de standaardbehandelingen bij patiënten die niet meer 
behandeld kunnen worden met chirurgie of radiotherapie. De combinatie van elektroporatie 
met systemische chemotherapie is interessant, en zal verder onderzocht moeten worden. 
Verder dient aandacht besteed te worden aan de selectie van target-antigenen met strikt 
tumorselectieve expressie, om therapeutische toepassing van antilichaam-
cytostaticaconjugaten mogelijk te maken. De nadruk zou daarbij moeten liggen op het 
voorkomen van onacceptabele bijwerkingen, die kunnen ontstaan door kruisreactiviteit. De 
resultaten van de radioimmunotherapiestudies voor de selectieve aanval op bloedvaten van 
tumoren maken de weg vrij voor klinische studies. Accurate informatie over tumortargeting 
en dosimetrie kan daarbij verkregen worden door toepassing van moleculaire beeldvorming 
middels immuno-PET, voorafgaand aan radioimmunotherapie. De ontwikkeling van 
nieuwe, multivalente of multi-specifieke antilichaamfragmenten opent nieuwe wegen voor 
het blokkeren van meerdere kritische tumortargets tegelijkertijd. 
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Figuur 1. Patiënt met een gemetastaseerd schildkliercarcinoom. Na uitgebreide chirurgie van de 
wervelkolom en verschillende behandelingen met 131I, was het onduidelijk of er nog vitaal tumorweefsel 
resteerde. 124I-PET-CT toont duidelijk opname van jodium (een indicatie voor vitale tumor) aan de 
linkerkant van de wervel. Op basis van deze bevinding werd een adjuvante hoge dosis 131I therapie 
geadviseerd voor deze patiënt. 
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